1

Curriculum Vitae

Stanley B Kaye

DSc MD FRCP FRCR FRSE FMedSci

Professor of Medical Oncology Royal Marsden NHS Foundation Trust Hospital Sycamore House Downs Road Sutton Surrey SM2 5PT Telephone 020 8661 35389 Fax 020 8642 7979 E-mail stankayermhnhsuk

September 2019

2

Stanley B Kaye DSc MD FRCP FRCR FRSE FMedSci

Date of birth 5th September 1948 (Leeds England) Marital status Married 3 Children 4 Grandchildren Education 1958 - 1965 Roundhay School Leeds 1966 - 1972 Charing Cross Hospital Medical School Present Appointments - Professor of Medical Oncology Royal Marsden Hospital from December 2013 - Senior Research Fellow Biomedical Research Centre Royal Marsden Hospital from December 2013 - Emeritus Professor Institute of Cancer Research London from January 2014 - Research Director RM Partners from 2016 (formerly London Cancer AllianceCancer Vanguard) Qualifications 1969 BSc (Honours) in Biochemistry 2nd Class 21 University of London 1972 MB BS University of London 1975 MRCP (London) 1980 MD University of London 1989 Fellow Royal College of Physicians (London) 1992 Fellow Royal College of Physicians and Surgeons (Glasgow) 1993 Fellow Royal College of Radiologists (London) 1997 Fellow Royal College of Physicians (Edinburgh) 2001 Fellow of Royal Society of Edinburgh 2004 Fellow of the Academy of Medical Sciences 2015 DSc (Hon) University of London 2018 Fellow of the Association of Cancer Physicians (UK) Postgraduate Posts July 1972 ndash March 1977 Junior doctor hospital posts at Charing Cross Hospital Hammersmith Hospital and University College Hospital London April 1977 ndash December 1979 Senior Registrar and CRC Research Fellow

Department of Medical Oncology Charing Cross Hospital London (Professor K Bagshawe Dr E Newlands)

January 1980 ndash December 1980 Acting Staff Specialist in Medical Oncology Ludwig Institute for Cancer Research Royal Prince Alfred Hospital

Sydney Australia January 1981 ndash August 2000 Senior Lecturer then Professor and Head of Department

Department of Medical Oncology University of Glasgow September 2000 ndash July 2011 Cancer Research UK Professor of Medical Oncology

Royal Marsden Hospital and Head of Section of Medicine Institute of Cancer Research August 2011 ndash November 2013 Head of Division of Clinical Studies Institute of Cancer Research December 2013 onwards Professor of Medical Oncology Royal Marsden Hospital a) Administrative Experience CRCCancer Research UK 1980-2007 Member Cancer Research UK Phase I Clinical Trials Committee 1985-1990 Chairman CRC Phase II Clinical Trials Committee 1996-2002 Vice-Chairman CRC Scientific Committee 1997-2002 Chairman CRC Clinical Trials Committee 1998-2001 Member CRC Technology Scientific Advisory Board 2001-2004 Member CRC Ventures Scientific Advisory Board

3

2002-2004 Chairman Cancer Research UK Clinical Trials Committee 2002-2005 Member Cancer Research UK Scientific Executive Board 2004-2007 Vice Chairman CRUK Clinical Trials Advisory amp Awards Committee 2004-2007 Chair Cancer Research UK Clinical and Translational Research Committee 2005-2009 Member CRUK Scientific Strategy Advisory Group 2013-present Chair ad-hoc review of EORTC activities 2013-present Member Imperial College CRUK Cancer Centre Governance Board 2013-present Member ICRRMH CRUK Cance Centre Governance Board 2013-present Deputy Chair West of Scotland CRUK Cancer Centre Governance Board 2013-present Chair CRUK Glasgow Clinical Trials Unit Advisory Board b) EORTCESMO 1980-2001 Member of Chemotherapy Subcommittee of Urology Group 1983-1997 Member of Early Clinical Trials Group 1986-1989 Member of Protocol Review Committee 1987-1988 Secretary of Scientific Audit Committee 1988-1994 Chairman of Scientific Audit Committee 1990-1994 Chairman of Early Clinical Trials Group 1994-1997 Elected Member of the Board of EORTC 1995-2000 Chairman Fellowship and Awards Committee of European Society of Medical Oncology (ESMO) c) MRC 1984-1998 Member of Working Party on Testicular Cancer 1985-1990 Member of Working Party on Bladder Cancer 1987-1990 Chairman of Working Party on Bladder Cancer 1986-1990 Member of Working Party on Osteosarcoma 1986-1994 Member of Cancer Therapy Committee 1990-1998 Member of Gynaecological Cancer Working Party 1998-2002 Member of Oncology Therapy Advisory Committee (OTAC) 1998-2002 Member of Advisory Board (previously Molecular amp Cellular Medicine Board)

d) Scotland 1986-1989 Member of Scottish Breast Cancer Trials Group 1983-2000 Member of Scottish Urology Group 1984-1986 Treasurer of West of Scotland Lung Cancer Group 1984-2000 Member of Cancer AdvisoryClinical Effectiveness Group Geater Glasgow Health Board 1985-1987 Secretary of West of Scotland Oncological Organisation 1987-1990 Chairman West of Scotland Oncological Organization 1986-200 Member of Scottish Gynae Cancer Trials Group (Chairman 1986-1996) 1985-1995 Member of Scottish Melanoma Group 1992-1998 Member of Scottish Cancer Co-ordinating and Advisory Committee 1993-1998 Grant Holder Scottish Cancer Therapy Network 1998-2000 Member of Oncology Board of Academy of Scottish Royal Colleges

e) UKCCCR 1985-1992 Member of Gynaecological Cancer Group 1990-1995 Member of Main Committee 1999-2001 Chairman of Testicular Cancer Group

f) NCRNI 2001-2009 Member of National Cancer Research NetworkInstitute Steering Group

Trust BoardHealth BoardCancer Networks 1997-1999 Non-Executive Director of West Glasgow University Hospitals NHS Trust

4

1999-2000 Non-Executive Director of North Glasgow University Hospitals NHS Trust 1999-2000 Chairman Clinical Governance Committee of North Glasgow University Hosp NHS Trust 2001-2004 Chairman of Gynaecological Cancer Tumour Working Group SW London Cancer Network 2002-2004 Chairman of New Drugs Group SW London Cancer Network 2002-2006 Member of London Networks New Drugs Group 2014-2016 Co-lead for Cancer (Division 1) South London Clinical Research Network 2014-2016 Research Director London Cancer Alliance 2016- present Research Director RM Partners (Cancer Vanguard) Royal Marsden Hospital 2001-2006 Chairman of Drugs amp Therapeutics Advisory Committee 2001-2004 Head of Gynaecology Unit 2001-present Member of Medical Advisory Committee 2004-2012 Head of Drug Development Unit 2006-2012 Chairman of the Genetic Modification Committee 2014- present Member of Biomedical Research Centre Steering Committee 2016-present Chair RM Clinical Trials Unit Steering Committee Institute of Cancer Research 2001 ndash present Member of Joint Research Committee (with RMH) 2001 ndash present Member of Clinical Research Directorate 2002 ndash 2011 Member of Corporate Management Group 2011 ndash present Member of the Executive Strategy Board 2011 ndash 2013 Head Division of Clinical Studies 2014 - present Member of Joint Research Strategy Group Scientific Advisory Boards etc 198895 Advisor on Cancer Services North WalesNorth Lancashire 1993 London Implementation Group Cancer Services Subcommittee 1995 Member of Scientific Advisory Board St Lukes Institute for Cancer Research Dublin 1995 Member of Universities Research Assessment Exercise (RAE) 2001 Committee (Panellist Unit of Assessment 3) and Vice-Chairman Cancer Subpanel (2001) 1997 Member of External Advisory Panel to Committee on Safety of Medicines (CSM) 1997-2000 Member of Scientific Advisory Board Bradford War on Cancer 19971998 Member of ICRF Clinical Review Committee 2000-2002 Member of ICRF Scientific Advisory Board 2001-2004 Member of Prize Committee General Motors Cancer Research Foundation Chairman in 2003 2011 Member of Scientific Advisory Council for

- Institut Curie Paris - Val drsquoHebron Institute Barcelona - National Cancer Institute Napoli - Beatson Institute Glasgow

2014 Member of Prize Committee Szent-Gyorgyi Prize 2014 Member of Scientific Advisory Board Experimental Therapy Centre Singapore and Chair of Novel Agents in Cancer Committee Singapore

In addition over the past 5-10 years I have been a member or chairman of clinicalscientific advisory boards to a number of UK-basedinternational pharmaceutical companies (including Cyclacel Boehringer-Ingelheim PharmaMar Kudos Astex OSI Roche Merck Johnson amp Johnson AstraZeneca GSK amp Astellas) I have also been a memberchairman of 10 data monitoring committees for international clinical

5

trials in cancer I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK CRC MRC Irish Cancer Society ICRF AICR North of England CRC Academy of Medical Sciences and others I am a member or past-member of editorial boards of 21 journals including Clinical Cancer Research and Annals of Oncology and a past editor of British Journal of Cancer (1993-1997) Presentations Lectures and Awards

I have presented clinical and research papers at various Institutions and Societies including the following-

Royal Society of Medicine British Association for Cancer Research American Association for Cancer Research American Society of Clinical Oncology EORTC meetings (various) Clinical Oncology Society of Australia National Cancer Institute Bethesda USA Institute Jules Bordet Brussels Princess Margaret Hospital Toronto British Columbia Cancer Centre Vancouver Peter MacCallum Cancer Institute Melbourne University of Singapore University of Sydney Australia MD Anderson Houston Texas and Madrid Spain as well as Manchester Edinburgh London (Royal Marsden Hammersmith Mount Vernon)

In recent years I have given invited lectures on new drug development drug resistance and ovarian cancer at 1 European Congress Perspectives in Gynecologic Oncology (Chairman) Nice (2006) Barcelona (2007)

Cannes (2008) Nice (2009) Barcelona (2010) Barcelona (2012) Istanbul (2013) Barcelona (2014 2015 2016 amp 2017)

2 Molecular Targeted Therapy in Cancer Teaching Course Krakow (2006) Shanghai (2007) Berlin (2007) Monaco (2008) Prague (2009) Quito (2009) Madrid (2010) Rome (2011) St Petersburg (2012) Sorrento (2013)

3 International Gyn Cancer Workshop Taormina (2006) Bologna (2006) 4 International Gyn Cancer Society meeting Santa Monica (2006) New York (2008) Prague (2010) 5 South Africa Society for Medical Oncology Sandton (2006) 6 NCRI Annual Meeting Birmingham plenary session chair (2006) programme committee chair (2008)

Liverpool (2010) invited plenary lecturer 7 Helene Harris Memorial Trust for Ovarian Cancer Lake Como (2007) Miami (2011) 8 Advanced Oncology Course guest lecturer Institut Jules Bordet Brussels (2007) 9 Ovarian Cancer Action International Conference London (2008) 10 Portuguese Oncology National Congress Madeira (2008) 11 American Society for Clinical Oncology Chicago (2008) Chicago (inv Disc 2011) Chicago (inv Ed

Session 2015) 12 Nordic Society of Gynecologic Oncology Annual Meeting Stockholm (2009) Stockholm (2013) 13 Society of Gynecologic Oncologists of Canada Annual Meeting Toronto (2009) 14 European Gynecologic Oncology Congress Dublin (2009) keynote lecturer Athens (2010) 15 Gynecologic Cancer Intergroup Annual Meeting Orlando 2009 speakerdiscussant Vancouver 2012

speakerdiscussant 16 ECCO15-34th ESMO Multidisciplinary Congress Berlin 2009 invited speaker 17 University of Heidelberg Antiangiogenic therapy strategies in gynecologic oncology ndash from bench to

bedside keynote lecture 2010 18 Investigational Medicine Unit Singapore launch lecture (2010)

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

2

Stanley B Kaye DSc MD FRCP FRCR FRSE FMedSci

Date of birth 5th September 1948 (Leeds England) Marital status Married 3 Children 4 Grandchildren Education 1958 - 1965 Roundhay School Leeds 1966 - 1972 Charing Cross Hospital Medical School Present Appointments - Professor of Medical Oncology Royal Marsden Hospital from December 2013 - Senior Research Fellow Biomedical Research Centre Royal Marsden Hospital from December 2013 - Emeritus Professor Institute of Cancer Research London from January 2014 - Research Director RM Partners from 2016 (formerly London Cancer AllianceCancer Vanguard) Qualifications 1969 BSc (Honours) in Biochemistry 2nd Class 21 University of London 1972 MB BS University of London 1975 MRCP (London) 1980 MD University of London 1989 Fellow Royal College of Physicians (London) 1992 Fellow Royal College of Physicians and Surgeons (Glasgow) 1993 Fellow Royal College of Radiologists (London) 1997 Fellow Royal College of Physicians (Edinburgh) 2001 Fellow of Royal Society of Edinburgh 2004 Fellow of the Academy of Medical Sciences 2015 DSc (Hon) University of London 2018 Fellow of the Association of Cancer Physicians (UK) Postgraduate Posts July 1972 ndash March 1977 Junior doctor hospital posts at Charing Cross Hospital Hammersmith Hospital and University College Hospital London April 1977 ndash December 1979 Senior Registrar and CRC Research Fellow

Department of Medical Oncology Charing Cross Hospital London (Professor K Bagshawe Dr E Newlands)

January 1980 ndash December 1980 Acting Staff Specialist in Medical Oncology Ludwig Institute for Cancer Research Royal Prince Alfred Hospital

Sydney Australia January 1981 ndash August 2000 Senior Lecturer then Professor and Head of Department

Department of Medical Oncology University of Glasgow September 2000 ndash July 2011 Cancer Research UK Professor of Medical Oncology

Royal Marsden Hospital and Head of Section of Medicine Institute of Cancer Research August 2011 ndash November 2013 Head of Division of Clinical Studies Institute of Cancer Research December 2013 onwards Professor of Medical Oncology Royal Marsden Hospital a) Administrative Experience CRCCancer Research UK 1980-2007 Member Cancer Research UK Phase I Clinical Trials Committee 1985-1990 Chairman CRC Phase II Clinical Trials Committee 1996-2002 Vice-Chairman CRC Scientific Committee 1997-2002 Chairman CRC Clinical Trials Committee 1998-2001 Member CRC Technology Scientific Advisory Board 2001-2004 Member CRC Ventures Scientific Advisory Board

3

2002-2004 Chairman Cancer Research UK Clinical Trials Committee 2002-2005 Member Cancer Research UK Scientific Executive Board 2004-2007 Vice Chairman CRUK Clinical Trials Advisory amp Awards Committee 2004-2007 Chair Cancer Research UK Clinical and Translational Research Committee 2005-2009 Member CRUK Scientific Strategy Advisory Group 2013-present Chair ad-hoc review of EORTC activities 2013-present Member Imperial College CRUK Cancer Centre Governance Board 2013-present Member ICRRMH CRUK Cance Centre Governance Board 2013-present Deputy Chair West of Scotland CRUK Cancer Centre Governance Board 2013-present Chair CRUK Glasgow Clinical Trials Unit Advisory Board b) EORTCESMO 1980-2001 Member of Chemotherapy Subcommittee of Urology Group 1983-1997 Member of Early Clinical Trials Group 1986-1989 Member of Protocol Review Committee 1987-1988 Secretary of Scientific Audit Committee 1988-1994 Chairman of Scientific Audit Committee 1990-1994 Chairman of Early Clinical Trials Group 1994-1997 Elected Member of the Board of EORTC 1995-2000 Chairman Fellowship and Awards Committee of European Society of Medical Oncology (ESMO) c) MRC 1984-1998 Member of Working Party on Testicular Cancer 1985-1990 Member of Working Party on Bladder Cancer 1987-1990 Chairman of Working Party on Bladder Cancer 1986-1990 Member of Working Party on Osteosarcoma 1986-1994 Member of Cancer Therapy Committee 1990-1998 Member of Gynaecological Cancer Working Party 1998-2002 Member of Oncology Therapy Advisory Committee (OTAC) 1998-2002 Member of Advisory Board (previously Molecular amp Cellular Medicine Board)

d) Scotland 1986-1989 Member of Scottish Breast Cancer Trials Group 1983-2000 Member of Scottish Urology Group 1984-1986 Treasurer of West of Scotland Lung Cancer Group 1984-2000 Member of Cancer AdvisoryClinical Effectiveness Group Geater Glasgow Health Board 1985-1987 Secretary of West of Scotland Oncological Organisation 1987-1990 Chairman West of Scotland Oncological Organization 1986-200 Member of Scottish Gynae Cancer Trials Group (Chairman 1986-1996) 1985-1995 Member of Scottish Melanoma Group 1992-1998 Member of Scottish Cancer Co-ordinating and Advisory Committee 1993-1998 Grant Holder Scottish Cancer Therapy Network 1998-2000 Member of Oncology Board of Academy of Scottish Royal Colleges

e) UKCCCR 1985-1992 Member of Gynaecological Cancer Group 1990-1995 Member of Main Committee 1999-2001 Chairman of Testicular Cancer Group

f) NCRNI 2001-2009 Member of National Cancer Research NetworkInstitute Steering Group

Trust BoardHealth BoardCancer Networks 1997-1999 Non-Executive Director of West Glasgow University Hospitals NHS Trust

4

1999-2000 Non-Executive Director of North Glasgow University Hospitals NHS Trust 1999-2000 Chairman Clinical Governance Committee of North Glasgow University Hosp NHS Trust 2001-2004 Chairman of Gynaecological Cancer Tumour Working Group SW London Cancer Network 2002-2004 Chairman of New Drugs Group SW London Cancer Network 2002-2006 Member of London Networks New Drugs Group 2014-2016 Co-lead for Cancer (Division 1) South London Clinical Research Network 2014-2016 Research Director London Cancer Alliance 2016- present Research Director RM Partners (Cancer Vanguard) Royal Marsden Hospital 2001-2006 Chairman of Drugs amp Therapeutics Advisory Committee 2001-2004 Head of Gynaecology Unit 2001-present Member of Medical Advisory Committee 2004-2012 Head of Drug Development Unit 2006-2012 Chairman of the Genetic Modification Committee 2014- present Member of Biomedical Research Centre Steering Committee 2016-present Chair RM Clinical Trials Unit Steering Committee Institute of Cancer Research 2001 ndash present Member of Joint Research Committee (with RMH) 2001 ndash present Member of Clinical Research Directorate 2002 ndash 2011 Member of Corporate Management Group 2011 ndash present Member of the Executive Strategy Board 2011 ndash 2013 Head Division of Clinical Studies 2014 - present Member of Joint Research Strategy Group Scientific Advisory Boards etc 198895 Advisor on Cancer Services North WalesNorth Lancashire 1993 London Implementation Group Cancer Services Subcommittee 1995 Member of Scientific Advisory Board St Lukes Institute for Cancer Research Dublin 1995 Member of Universities Research Assessment Exercise (RAE) 2001 Committee (Panellist Unit of Assessment 3) and Vice-Chairman Cancer Subpanel (2001) 1997 Member of External Advisory Panel to Committee on Safety of Medicines (CSM) 1997-2000 Member of Scientific Advisory Board Bradford War on Cancer 19971998 Member of ICRF Clinical Review Committee 2000-2002 Member of ICRF Scientific Advisory Board 2001-2004 Member of Prize Committee General Motors Cancer Research Foundation Chairman in 2003 2011 Member of Scientific Advisory Council for

- Institut Curie Paris - Val drsquoHebron Institute Barcelona - National Cancer Institute Napoli - Beatson Institute Glasgow

2014 Member of Prize Committee Szent-Gyorgyi Prize 2014 Member of Scientific Advisory Board Experimental Therapy Centre Singapore and Chair of Novel Agents in Cancer Committee Singapore

In addition over the past 5-10 years I have been a member or chairman of clinicalscientific advisory boards to a number of UK-basedinternational pharmaceutical companies (including Cyclacel Boehringer-Ingelheim PharmaMar Kudos Astex OSI Roche Merck Johnson amp Johnson AstraZeneca GSK amp Astellas) I have also been a memberchairman of 10 data monitoring committees for international clinical

5

trials in cancer I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK CRC MRC Irish Cancer Society ICRF AICR North of England CRC Academy of Medical Sciences and others I am a member or past-member of editorial boards of 21 journals including Clinical Cancer Research and Annals of Oncology and a past editor of British Journal of Cancer (1993-1997) Presentations Lectures and Awards

I have presented clinical and research papers at various Institutions and Societies including the following-

Royal Society of Medicine British Association for Cancer Research American Association for Cancer Research American Society of Clinical Oncology EORTC meetings (various) Clinical Oncology Society of Australia National Cancer Institute Bethesda USA Institute Jules Bordet Brussels Princess Margaret Hospital Toronto British Columbia Cancer Centre Vancouver Peter MacCallum Cancer Institute Melbourne University of Singapore University of Sydney Australia MD Anderson Houston Texas and Madrid Spain as well as Manchester Edinburgh London (Royal Marsden Hammersmith Mount Vernon)

In recent years I have given invited lectures on new drug development drug resistance and ovarian cancer at 1 European Congress Perspectives in Gynecologic Oncology (Chairman) Nice (2006) Barcelona (2007)

Cannes (2008) Nice (2009) Barcelona (2010) Barcelona (2012) Istanbul (2013) Barcelona (2014 2015 2016 amp 2017)

2 Molecular Targeted Therapy in Cancer Teaching Course Krakow (2006) Shanghai (2007) Berlin (2007) Monaco (2008) Prague (2009) Quito (2009) Madrid (2010) Rome (2011) St Petersburg (2012) Sorrento (2013)

3 International Gyn Cancer Workshop Taormina (2006) Bologna (2006) 4 International Gyn Cancer Society meeting Santa Monica (2006) New York (2008) Prague (2010) 5 South Africa Society for Medical Oncology Sandton (2006) 6 NCRI Annual Meeting Birmingham plenary session chair (2006) programme committee chair (2008)

Liverpool (2010) invited plenary lecturer 7 Helene Harris Memorial Trust for Ovarian Cancer Lake Como (2007) Miami (2011) 8 Advanced Oncology Course guest lecturer Institut Jules Bordet Brussels (2007) 9 Ovarian Cancer Action International Conference London (2008) 10 Portuguese Oncology National Congress Madeira (2008) 11 American Society for Clinical Oncology Chicago (2008) Chicago (inv Disc 2011) Chicago (inv Ed

Session 2015) 12 Nordic Society of Gynecologic Oncology Annual Meeting Stockholm (2009) Stockholm (2013) 13 Society of Gynecologic Oncologists of Canada Annual Meeting Toronto (2009) 14 European Gynecologic Oncology Congress Dublin (2009) keynote lecturer Athens (2010) 15 Gynecologic Cancer Intergroup Annual Meeting Orlando 2009 speakerdiscussant Vancouver 2012

speakerdiscussant 16 ECCO15-34th ESMO Multidisciplinary Congress Berlin 2009 invited speaker 17 University of Heidelberg Antiangiogenic therapy strategies in gynecologic oncology ndash from bench to

bedside keynote lecture 2010 18 Investigational Medicine Unit Singapore launch lecture (2010)

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

3

2002-2004 Chairman Cancer Research UK Clinical Trials Committee 2002-2005 Member Cancer Research UK Scientific Executive Board 2004-2007 Vice Chairman CRUK Clinical Trials Advisory amp Awards Committee 2004-2007 Chair Cancer Research UK Clinical and Translational Research Committee 2005-2009 Member CRUK Scientific Strategy Advisory Group 2013-present Chair ad-hoc review of EORTC activities 2013-present Member Imperial College CRUK Cancer Centre Governance Board 2013-present Member ICRRMH CRUK Cance Centre Governance Board 2013-present Deputy Chair West of Scotland CRUK Cancer Centre Governance Board 2013-present Chair CRUK Glasgow Clinical Trials Unit Advisory Board b) EORTCESMO 1980-2001 Member of Chemotherapy Subcommittee of Urology Group 1983-1997 Member of Early Clinical Trials Group 1986-1989 Member of Protocol Review Committee 1987-1988 Secretary of Scientific Audit Committee 1988-1994 Chairman of Scientific Audit Committee 1990-1994 Chairman of Early Clinical Trials Group 1994-1997 Elected Member of the Board of EORTC 1995-2000 Chairman Fellowship and Awards Committee of European Society of Medical Oncology (ESMO) c) MRC 1984-1998 Member of Working Party on Testicular Cancer 1985-1990 Member of Working Party on Bladder Cancer 1987-1990 Chairman of Working Party on Bladder Cancer 1986-1990 Member of Working Party on Osteosarcoma 1986-1994 Member of Cancer Therapy Committee 1990-1998 Member of Gynaecological Cancer Working Party 1998-2002 Member of Oncology Therapy Advisory Committee (OTAC) 1998-2002 Member of Advisory Board (previously Molecular amp Cellular Medicine Board)

d) Scotland 1986-1989 Member of Scottish Breast Cancer Trials Group 1983-2000 Member of Scottish Urology Group 1984-1986 Treasurer of West of Scotland Lung Cancer Group 1984-2000 Member of Cancer AdvisoryClinical Effectiveness Group Geater Glasgow Health Board 1985-1987 Secretary of West of Scotland Oncological Organisation 1987-1990 Chairman West of Scotland Oncological Organization 1986-200 Member of Scottish Gynae Cancer Trials Group (Chairman 1986-1996) 1985-1995 Member of Scottish Melanoma Group 1992-1998 Member of Scottish Cancer Co-ordinating and Advisory Committee 1993-1998 Grant Holder Scottish Cancer Therapy Network 1998-2000 Member of Oncology Board of Academy of Scottish Royal Colleges

e) UKCCCR 1985-1992 Member of Gynaecological Cancer Group 1990-1995 Member of Main Committee 1999-2001 Chairman of Testicular Cancer Group

f) NCRNI 2001-2009 Member of National Cancer Research NetworkInstitute Steering Group

Trust BoardHealth BoardCancer Networks 1997-1999 Non-Executive Director of West Glasgow University Hospitals NHS Trust

4

1999-2000 Non-Executive Director of North Glasgow University Hospitals NHS Trust 1999-2000 Chairman Clinical Governance Committee of North Glasgow University Hosp NHS Trust 2001-2004 Chairman of Gynaecological Cancer Tumour Working Group SW London Cancer Network 2002-2004 Chairman of New Drugs Group SW London Cancer Network 2002-2006 Member of London Networks New Drugs Group 2014-2016 Co-lead for Cancer (Division 1) South London Clinical Research Network 2014-2016 Research Director London Cancer Alliance 2016- present Research Director RM Partners (Cancer Vanguard) Royal Marsden Hospital 2001-2006 Chairman of Drugs amp Therapeutics Advisory Committee 2001-2004 Head of Gynaecology Unit 2001-present Member of Medical Advisory Committee 2004-2012 Head of Drug Development Unit 2006-2012 Chairman of the Genetic Modification Committee 2014- present Member of Biomedical Research Centre Steering Committee 2016-present Chair RM Clinical Trials Unit Steering Committee Institute of Cancer Research 2001 ndash present Member of Joint Research Committee (with RMH) 2001 ndash present Member of Clinical Research Directorate 2002 ndash 2011 Member of Corporate Management Group 2011 ndash present Member of the Executive Strategy Board 2011 ndash 2013 Head Division of Clinical Studies 2014 - present Member of Joint Research Strategy Group Scientific Advisory Boards etc 198895 Advisor on Cancer Services North WalesNorth Lancashire 1993 London Implementation Group Cancer Services Subcommittee 1995 Member of Scientific Advisory Board St Lukes Institute for Cancer Research Dublin 1995 Member of Universities Research Assessment Exercise (RAE) 2001 Committee (Panellist Unit of Assessment 3) and Vice-Chairman Cancer Subpanel (2001) 1997 Member of External Advisory Panel to Committee on Safety of Medicines (CSM) 1997-2000 Member of Scientific Advisory Board Bradford War on Cancer 19971998 Member of ICRF Clinical Review Committee 2000-2002 Member of ICRF Scientific Advisory Board 2001-2004 Member of Prize Committee General Motors Cancer Research Foundation Chairman in 2003 2011 Member of Scientific Advisory Council for

- Institut Curie Paris - Val drsquoHebron Institute Barcelona - National Cancer Institute Napoli - Beatson Institute Glasgow

2014 Member of Prize Committee Szent-Gyorgyi Prize 2014 Member of Scientific Advisory Board Experimental Therapy Centre Singapore and Chair of Novel Agents in Cancer Committee Singapore

In addition over the past 5-10 years I have been a member or chairman of clinicalscientific advisory boards to a number of UK-basedinternational pharmaceutical companies (including Cyclacel Boehringer-Ingelheim PharmaMar Kudos Astex OSI Roche Merck Johnson amp Johnson AstraZeneca GSK amp Astellas) I have also been a memberchairman of 10 data monitoring committees for international clinical

5

trials in cancer I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK CRC MRC Irish Cancer Society ICRF AICR North of England CRC Academy of Medical Sciences and others I am a member or past-member of editorial boards of 21 journals including Clinical Cancer Research and Annals of Oncology and a past editor of British Journal of Cancer (1993-1997) Presentations Lectures and Awards

I have presented clinical and research papers at various Institutions and Societies including the following-

Royal Society of Medicine British Association for Cancer Research American Association for Cancer Research American Society of Clinical Oncology EORTC meetings (various) Clinical Oncology Society of Australia National Cancer Institute Bethesda USA Institute Jules Bordet Brussels Princess Margaret Hospital Toronto British Columbia Cancer Centre Vancouver Peter MacCallum Cancer Institute Melbourne University of Singapore University of Sydney Australia MD Anderson Houston Texas and Madrid Spain as well as Manchester Edinburgh London (Royal Marsden Hammersmith Mount Vernon)

In recent years I have given invited lectures on new drug development drug resistance and ovarian cancer at 1 European Congress Perspectives in Gynecologic Oncology (Chairman) Nice (2006) Barcelona (2007)

Cannes (2008) Nice (2009) Barcelona (2010) Barcelona (2012) Istanbul (2013) Barcelona (2014 2015 2016 amp 2017)

2 Molecular Targeted Therapy in Cancer Teaching Course Krakow (2006) Shanghai (2007) Berlin (2007) Monaco (2008) Prague (2009) Quito (2009) Madrid (2010) Rome (2011) St Petersburg (2012) Sorrento (2013)

3 International Gyn Cancer Workshop Taormina (2006) Bologna (2006) 4 International Gyn Cancer Society meeting Santa Monica (2006) New York (2008) Prague (2010) 5 South Africa Society for Medical Oncology Sandton (2006) 6 NCRI Annual Meeting Birmingham plenary session chair (2006) programme committee chair (2008)

Liverpool (2010) invited plenary lecturer 7 Helene Harris Memorial Trust for Ovarian Cancer Lake Como (2007) Miami (2011) 8 Advanced Oncology Course guest lecturer Institut Jules Bordet Brussels (2007) 9 Ovarian Cancer Action International Conference London (2008) 10 Portuguese Oncology National Congress Madeira (2008) 11 American Society for Clinical Oncology Chicago (2008) Chicago (inv Disc 2011) Chicago (inv Ed

Session 2015) 12 Nordic Society of Gynecologic Oncology Annual Meeting Stockholm (2009) Stockholm (2013) 13 Society of Gynecologic Oncologists of Canada Annual Meeting Toronto (2009) 14 European Gynecologic Oncology Congress Dublin (2009) keynote lecturer Athens (2010) 15 Gynecologic Cancer Intergroup Annual Meeting Orlando 2009 speakerdiscussant Vancouver 2012

speakerdiscussant 16 ECCO15-34th ESMO Multidisciplinary Congress Berlin 2009 invited speaker 17 University of Heidelberg Antiangiogenic therapy strategies in gynecologic oncology ndash from bench to

bedside keynote lecture 2010 18 Investigational Medicine Unit Singapore launch lecture (2010)

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

4

1999-2000 Non-Executive Director of North Glasgow University Hospitals NHS Trust 1999-2000 Chairman Clinical Governance Committee of North Glasgow University Hosp NHS Trust 2001-2004 Chairman of Gynaecological Cancer Tumour Working Group SW London Cancer Network 2002-2004 Chairman of New Drugs Group SW London Cancer Network 2002-2006 Member of London Networks New Drugs Group 2014-2016 Co-lead for Cancer (Division 1) South London Clinical Research Network 2014-2016 Research Director London Cancer Alliance 2016- present Research Director RM Partners (Cancer Vanguard) Royal Marsden Hospital 2001-2006 Chairman of Drugs amp Therapeutics Advisory Committee 2001-2004 Head of Gynaecology Unit 2001-present Member of Medical Advisory Committee 2004-2012 Head of Drug Development Unit 2006-2012 Chairman of the Genetic Modification Committee 2014- present Member of Biomedical Research Centre Steering Committee 2016-present Chair RM Clinical Trials Unit Steering Committee Institute of Cancer Research 2001 ndash present Member of Joint Research Committee (with RMH) 2001 ndash present Member of Clinical Research Directorate 2002 ndash 2011 Member of Corporate Management Group 2011 ndash present Member of the Executive Strategy Board 2011 ndash 2013 Head Division of Clinical Studies 2014 - present Member of Joint Research Strategy Group Scientific Advisory Boards etc 198895 Advisor on Cancer Services North WalesNorth Lancashire 1993 London Implementation Group Cancer Services Subcommittee 1995 Member of Scientific Advisory Board St Lukes Institute for Cancer Research Dublin 1995 Member of Universities Research Assessment Exercise (RAE) 2001 Committee (Panellist Unit of Assessment 3) and Vice-Chairman Cancer Subpanel (2001) 1997 Member of External Advisory Panel to Committee on Safety of Medicines (CSM) 1997-2000 Member of Scientific Advisory Board Bradford War on Cancer 19971998 Member of ICRF Clinical Review Committee 2000-2002 Member of ICRF Scientific Advisory Board 2001-2004 Member of Prize Committee General Motors Cancer Research Foundation Chairman in 2003 2011 Member of Scientific Advisory Council for

- Institut Curie Paris - Val drsquoHebron Institute Barcelona - National Cancer Institute Napoli - Beatson Institute Glasgow

2014 Member of Prize Committee Szent-Gyorgyi Prize 2014 Member of Scientific Advisory Board Experimental Therapy Centre Singapore and Chair of Novel Agents in Cancer Committee Singapore

In addition over the past 5-10 years I have been a member or chairman of clinicalscientific advisory boards to a number of UK-basedinternational pharmaceutical companies (including Cyclacel Boehringer-Ingelheim PharmaMar Kudos Astex OSI Roche Merck Johnson amp Johnson AstraZeneca GSK amp Astellas) I have also been a memberchairman of 10 data monitoring committees for international clinical

5

trials in cancer I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK CRC MRC Irish Cancer Society ICRF AICR North of England CRC Academy of Medical Sciences and others I am a member or past-member of editorial boards of 21 journals including Clinical Cancer Research and Annals of Oncology and a past editor of British Journal of Cancer (1993-1997) Presentations Lectures and Awards

I have presented clinical and research papers at various Institutions and Societies including the following-

Royal Society of Medicine British Association for Cancer Research American Association for Cancer Research American Society of Clinical Oncology EORTC meetings (various) Clinical Oncology Society of Australia National Cancer Institute Bethesda USA Institute Jules Bordet Brussels Princess Margaret Hospital Toronto British Columbia Cancer Centre Vancouver Peter MacCallum Cancer Institute Melbourne University of Singapore University of Sydney Australia MD Anderson Houston Texas and Madrid Spain as well as Manchester Edinburgh London (Royal Marsden Hammersmith Mount Vernon)

In recent years I have given invited lectures on new drug development drug resistance and ovarian cancer at 1 European Congress Perspectives in Gynecologic Oncology (Chairman) Nice (2006) Barcelona (2007)

Cannes (2008) Nice (2009) Barcelona (2010) Barcelona (2012) Istanbul (2013) Barcelona (2014 2015 2016 amp 2017)

2 Molecular Targeted Therapy in Cancer Teaching Course Krakow (2006) Shanghai (2007) Berlin (2007) Monaco (2008) Prague (2009) Quito (2009) Madrid (2010) Rome (2011) St Petersburg (2012) Sorrento (2013)

3 International Gyn Cancer Workshop Taormina (2006) Bologna (2006) 4 International Gyn Cancer Society meeting Santa Monica (2006) New York (2008) Prague (2010) 5 South Africa Society for Medical Oncology Sandton (2006) 6 NCRI Annual Meeting Birmingham plenary session chair (2006) programme committee chair (2008)

Liverpool (2010) invited plenary lecturer 7 Helene Harris Memorial Trust for Ovarian Cancer Lake Como (2007) Miami (2011) 8 Advanced Oncology Course guest lecturer Institut Jules Bordet Brussels (2007) 9 Ovarian Cancer Action International Conference London (2008) 10 Portuguese Oncology National Congress Madeira (2008) 11 American Society for Clinical Oncology Chicago (2008) Chicago (inv Disc 2011) Chicago (inv Ed

Session 2015) 12 Nordic Society of Gynecologic Oncology Annual Meeting Stockholm (2009) Stockholm (2013) 13 Society of Gynecologic Oncologists of Canada Annual Meeting Toronto (2009) 14 European Gynecologic Oncology Congress Dublin (2009) keynote lecturer Athens (2010) 15 Gynecologic Cancer Intergroup Annual Meeting Orlando 2009 speakerdiscussant Vancouver 2012

speakerdiscussant 16 ECCO15-34th ESMO Multidisciplinary Congress Berlin 2009 invited speaker 17 University of Heidelberg Antiangiogenic therapy strategies in gynecologic oncology ndash from bench to

bedside keynote lecture 2010 18 Investigational Medicine Unit Singapore launch lecture (2010)

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

5

trials in cancer I have acted as Grant Assessor (and Member of Site Visit Committees) for Cancer Research UK CRC MRC Irish Cancer Society ICRF AICR North of England CRC Academy of Medical Sciences and others I am a member or past-member of editorial boards of 21 journals including Clinical Cancer Research and Annals of Oncology and a past editor of British Journal of Cancer (1993-1997) Presentations Lectures and Awards

I have presented clinical and research papers at various Institutions and Societies including the following-

Royal Society of Medicine British Association for Cancer Research American Association for Cancer Research American Society of Clinical Oncology EORTC meetings (various) Clinical Oncology Society of Australia National Cancer Institute Bethesda USA Institute Jules Bordet Brussels Princess Margaret Hospital Toronto British Columbia Cancer Centre Vancouver Peter MacCallum Cancer Institute Melbourne University of Singapore University of Sydney Australia MD Anderson Houston Texas and Madrid Spain as well as Manchester Edinburgh London (Royal Marsden Hammersmith Mount Vernon)

In recent years I have given invited lectures on new drug development drug resistance and ovarian cancer at 1 European Congress Perspectives in Gynecologic Oncology (Chairman) Nice (2006) Barcelona (2007)

Cannes (2008) Nice (2009) Barcelona (2010) Barcelona (2012) Istanbul (2013) Barcelona (2014 2015 2016 amp 2017)

2 Molecular Targeted Therapy in Cancer Teaching Course Krakow (2006) Shanghai (2007) Berlin (2007) Monaco (2008) Prague (2009) Quito (2009) Madrid (2010) Rome (2011) St Petersburg (2012) Sorrento (2013)

3 International Gyn Cancer Workshop Taormina (2006) Bologna (2006) 4 International Gyn Cancer Society meeting Santa Monica (2006) New York (2008) Prague (2010) 5 South Africa Society for Medical Oncology Sandton (2006) 6 NCRI Annual Meeting Birmingham plenary session chair (2006) programme committee chair (2008)

Liverpool (2010) invited plenary lecturer 7 Helene Harris Memorial Trust for Ovarian Cancer Lake Como (2007) Miami (2011) 8 Advanced Oncology Course guest lecturer Institut Jules Bordet Brussels (2007) 9 Ovarian Cancer Action International Conference London (2008) 10 Portuguese Oncology National Congress Madeira (2008) 11 American Society for Clinical Oncology Chicago (2008) Chicago (inv Disc 2011) Chicago (inv Ed

Session 2015) 12 Nordic Society of Gynecologic Oncology Annual Meeting Stockholm (2009) Stockholm (2013) 13 Society of Gynecologic Oncologists of Canada Annual Meeting Toronto (2009) 14 European Gynecologic Oncology Congress Dublin (2009) keynote lecturer Athens (2010) 15 Gynecologic Cancer Intergroup Annual Meeting Orlando 2009 speakerdiscussant Vancouver 2012

speakerdiscussant 16 ECCO15-34th ESMO Multidisciplinary Congress Berlin 2009 invited speaker 17 University of Heidelberg Antiangiogenic therapy strategies in gynecologic oncology ndash from bench to

bedside keynote lecture 2010 18 Investigational Medicine Unit Singapore launch lecture (2010)

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

6

19 ECCO16-36th ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Stockholm (2011) 20 ECCO 17-37 ESMO Multidisciplinary Congress Symposium Chair and Speaker ndash Amsterdam (2013) 21 Greek Annual Medical Oncology Congress Athens (2011) and Ioannina (2016) 22 MD Anderson International Ovarian Cancer Symposium Houston Texas (2011) and Madrid (2013) 23 American Association of Cancer Research Chicago ndash symposium Chair (2012) 24 ESMO Congress Discussant and Invited Speaker Vienna (2012) 25 Translational Research Symposium Sydney (2013) 26 Annual Oncology Congress Hong Kong (2013) 27 International Symposium on Advanced Ovarian Cancer Valencia (2013) (keynote lecture 2015)

I have given award lectures at

ESMO Award Lecture at the European Conference on Clinical Oncology in Paris ndash October 1995

The Bagshawe Lecture at the British Cancer Research Meeting in Leeds ndash July 2001

The Michel Clavel Lecture at the EORTCNCI New Drugs Meeting Frankfurt ndash November 2002

The ESTRO Award Lecture at the European Conference on Clinical Oncology in Barcelona ndash October 2007

The BACR Plenary Lecture at the NCRI Meeting in Liverpool ndash November 2010

The NCRI Meeting in Liverpool ndash November 2016 (Lifetime Achievement Award) Awards

Member of AACR Team Science Award for ICRRMH Cancer Therapeutics and Drug Development - 2012

The Royal Marsden Award for Outstanding Contribution ndash December 2013

Lifetime Achievement Award Quality in Care (QiC) Oncology Awards ndash December 2013

MD Anderson Cancer Centre Madrid Lifetime Foundation Awards ndash February 2014

CRUK Lifetime Achievement Award ndash November 2016 Visiting Professorships

I was awarded the Royal Society of Medicine Foundation Visiting Professorship to USA in 1995 I was awarded the D Bergsagel Visiting Professorship to Toronto Canada in September 1996 I was invited as Visiting Professor to the University of Singapore in 2008 and have ongoing visitor professorships at the University of Glasgow and University of Singapore with active roles in co-ordinating aspects of their research programmes In Singapore I now chair their Novel Agents Committee for Cancer

Postgraduate Supervision (Since 1986)

MD (successfully awarded) 1987 David Kerr 1990 Robert Milroy 1991 James Cassidy 1991 Christopher Bradley 1991 Gordon Wishart 1993 Imogen Stephens 1999 Sheila Stallard 2000 Ian Ganly 2000 Stephen Morley 2002 Simon Crawford 2009 Laura Vidal 2010 Tim Benepal 2011 Stavroula Kyriazi

PhD (successfully awarded)

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

7

2008 Roshan Agarwal 2010 Martin Forster 2010 Debasish Sarker 2011 Richard Baird 2012 David Tan 2013 Tim Yap 2015 Rowan Miller 2016 Emma Kipps I have also acted as PhD examiner in the University of Glasgow Edinburgh London Cambridge Rotterdam and Imperial College London Research Interests

1985 ndash 2000

Having obtained the post of Professor of Medical Oncology in Glasgow in October 1985 I was until August 2000 responsible for the clinical and laboratory activities of the University Department which included a total of approximately 70 members of staff The majority of the research grants were obtained from the Cancer Research Campaign and I was responsible for grants totalling pound1502990 (in year ending March 1999 including all salaries and running costs for 4 programmes)

At the clinical level I had previously been responsible for joint clinics in breast gastrointestinal and lung cancer as well as lymphoma As staff numbers increased my own major interest concentrated on gynaecological cancer testicular cancer and the use of new drugs in Phase I and II trials

In the laboratory one of my long-standing interests is drug resistance Observations which I made in 1979-80 (see publications) indicated that enhanced drug efflux rather than defective drug uptake was a key factor in experimental models and I developed a research group which aimed to assess the importance of P-glycoprotein in this respect Subsequently our attention shifted to cisplatin-resistance as well as other topics in new drug development Approaches to overcome clinical drug resistance coupled to novel therapeutics continued to be an important interest following my move to London

In 1986 we began a major clinical activity with appropriate laboratory pharmacological support in Phase I trials As principal investigators we completed and published over 20 Phase I trials including the first UK trials of docetaxel capecitabine and pemetrexed We established a large referral practice of patients for new drug studies and other examples included a range of new cytotoxic agents an attenuated adenovirus signal transduction inhibitors and novel delivery systems

Between 1988 and 1990 major reorganisation of both the clinical and laboratory services took place In 1988 the Department of Medical Oncology integrated its clinical facilities with those of the newly established Department of Radiation Oncology to form an integrated cancer treatment centre at the Western Infirmary Glasgow under the title the Beatson Oncology Centre

At the beginning of 1990 the laboratories of the CRC Department of Medical Oncology (and of Radiation Oncology) moved to purpose-built laboratories at Garscube adjacent to the Beatson Institute for Cancer Research Glasgow Following the move to Garscube the laboratory research in the Department was directed successively by Professor Paul Workman (1991-93) Professor Allan Balmain (1993-96) and Professor Bob Brown (1996-2007) The commitment by all three to consolidate the link between laboratory and clinic has been a hallmark of the Department

2000 ndash present

In September 2000 I moved from Glasgow to head the Section of Medicine in the Institute of Cancer Research London I was appointed as the Cancer Research UK Professor of Medical Oncology at the Royal Marsden Hospital and a primary objective was to consolidate the links between the Institute and Hospital

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

8

My own clinical interest continued in ovarian cancer (I led the RMH gynae cancer unit from 2001 to 2004) and in Phase I clinical trials New recruits at the Senior Lecturer level were Dr Tim Eisen (covering renal cancer lung cancer and melanoma) in 2001 and Professor Johann de Bono (covering phase I clinical trials and prostate cancer) in 2003 In 2007 Dr Eisen left to take the Chair of Medical Oncology in Cambridge and we appointed Dr Udai Banerji in his place to co-lead a new initiative in translational aspects of Phase I trials The Drug Development Unit overlaps very considerably with the Cancer Research UK Section of Cancer Therapeutics (until 2016 headed by my former colleague Professor Paul Workman) A primary aim was to expand quickly the capacity for new drug development at the RMHICR and in February 2005 we opened a new dedicated clinical facility for Phase I clinical trials (Oak Foundation Drug Development Centre) This is now one of the largest such resources in the world with 16 beds and a staff approaching 100 About 600 patients per year are currently referred for Phase I trials and our current portfolio of studies which incorporate a wide range of molecular targeted approaches numbers 35 to 40

From 2011

In my role as Head of the Division of Clinical Studies I had an additional broader responsibility in bringing together the clinical research in the Royal Marsden Hospital with the laboratory research in the Institute of Cancer Research in the evolving context of presonalised medicine and molecular targeted therapy

The overall strategy was to maximise the interaction between the Institute and Hospital and thereby to consolidate our role as a leading centre for developmental therapeutics We implemented routine molecular characterization of patients entering Phase I trials aiming to optimise the targeted approach with available novel agents Our achievements included the first trials of abiraterone and the oral PARP inhibitor olaparib From 2013 Having retired from the ICR in December 2013 I now have 3 new roles

a) Professor of Medical Oncology and Senior Fellow to the Biomedical Research Centre at the Royal Marsden Hospital ndash continuing to provide advice to the tumour teams on their drug development programmes (previously I co-lead the Cancer Division in the new South London Research Network)

b) Visiting Professor at the University of Singapore ndash advising on their strategy for translational cancer research and mentoring a group of clinical research fellows also Chair of the Novel Agents Committee for Cancer with close links to the Experimental Drug Development Centre

c) Research Director for the Royal Marsden and Partners Cancer Alliance ndash responsible for developing a research strategy for this clinical collaborative network for cancer care covering North West and South West London (population of over 5 million) The focus is on aspects of health services research including variations in delivery of treatment and recently an increasing effort has involved new initiatives in early diagnosis of cancer including colorectal and lung cancer A principal aim is to identify high risk individuals therby enriching screened populations

Current and Recent Grants Held 2006-2011 Cancer Research UK Programme Grant to the Department of Medical Oncology (Principal Investigator) pound185m 2006-2011 Cancer Research UK Joint Phase I clinical core grant (Principal Investigator) pound454m 2007-2012 Experimental Cancer Medicine Centre (Department of HealthCancer Research UK) (Principal Investigator) pound256m

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

9

Publications

Peer-reviewed articlesreviews

1976 - 1982

1 Kaye SB and Ickram H Acute cardiac pain and ECG changes following cytotoxic treatment for metastatic carcinoma Clinical Oncology 2 215 1976

2 Kaye SB and Ross EJ Inappropriate ADH secretion in association with carcinoma of the bladder Postgrad Med J 53 274 1977

3 Kaye SB and Owen M Cardiac arrhythmiarsquos in thalassaemia major Br Med J 1 342 1978

4 Kaye SB Begent RHJ Newlands ES and Bagshawe KD Successful treatment of malignant testicular teratoma with brain metastases Br Med J 1 233 1979

5 Kaye SB Juttner CA Smith IE Barrett A Austin DE Peckham MJ and McElwain TJ Three years experience with ChL VPP (a combination of drugs of low toxicity) for the treatment of Hodgkins disease Br J Cancer 39 168 1979

6 Kaye SB Bagshawe KD McElwain TJ and Peckham MJ Brain metastases in malignant teratoma a review of four years experience and an assessment of the role of tumour markers Br J Cancer 39 217 1979

7 Kaye SB and Richardson VJ Potential of liposomes as drug-Carriers in cancer chemotherapy a review Cancer Chemother Pharmacol 3 81-85 1979

8 Richardson VJ Ryman BE Jewkes RF Jeyasingh K Tattersall MHN Newlands ES and Kaye SB Tissue distribution and tumour localisation of 99M-technetium-labelled liposomes in cancer patients Br J Cancer 40 35-43 1979

9 Fitzharris BM Kaye SB Saverymatta S Newlands ES and McElwain TJ BP16213 as a single agent in advanced testicular tumours Eur J Cancer 16 1193-1199 1980

10 Newlands ES Begent RHJ Kaye SB Rustin GJ and Bagshawe KD Chemotherapy of advanced malignant teratomas Br J Cancer 42 378-391 1980

11 Kaye SB Boden JA and Ryman BE Effect of liposome (phospho-lipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours Eur J Cancer 17 279-289 1980

12 Kaye SB and Boden JA Cross resistance between actinomycin D adriamycin and vincristine in a murine solid tumour in vivo Biochem Pharmacol 29 1081-1084 1980

13 Kaye SB Woods RL Fox RM and Tattersall MHN The treatment of metastatic breast cancer with aminoglutethemide Austr NZ Journal of Med 11 370-374 1981

14 Kaye SB Woods RL Fox RM Coates AS and Tattersall MHN Aminoglutethemide in metastatic breast cancer its use as second-line endocrine therapy Cancer Res (Suppl) 42 3445S-3447S 1982

1983 - 1984

15 Coates A Abraham S Kaye SB Sowerbutts T Frewin S Fox RM and Tattersall MHN On the receiving end - patient perception of the side-effects of cancer chemotherapy Eur J Cancer 19 203-208 1983

16 Coates A Fischer Dillcabeck C McNeil DR Kaye SB Sims K Fox RM Woods RL Milton GW Solomon J and Tattersall MHN On the receiving end II Linear analogue self-assessment in evaluation of aspects of the quality of life of cancer patients receiving therapy Eur J Cancer 19 1633-1638 1983

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

10

17 Stuart-Harris RC Harper PG Parsons CA Kaye SB Mooney CA Gowing NF and Wiltshaw E High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma Cancer Chemother Pharmacol 11 69-72 1983

18 Hutcheon AW Palmer J Soukop M Cunningham D McArdle C Welsh J Stuart F Sangster G Kaye SB Charlton D and Cash H A randomised multi-centre single-blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy Eur J Cancer 19 1647-1650 1983

19 Sangster G Kaye SB Calman KC and Toy JL Cutaneous vasculitis associated with interferon Eur J Cancer 19 1647-1650 1983

20 Welsh J Stuart JF Sangster G Milsted RV Kaye S Cash H Charlton D and Calman K C Oral levonantradol in the control of cancer chemotherapy-induced emesis Cancer Chemother Pharmacol 11 66-67 1983

21 Friedlander M Kaye SB Sullivan A Atkinson K Elliot P Coppleson M Houghton R Solomon J Green D Russell P Hudson CN Langlands AO and Tattersall MHN Cervical carcinoma a drug-responsive tumor experience with combined cisplatin vinblastine and bleomycin therapy Gynaec Oncol 16 275-281 1983

22 Banham S Soukop M Burnett A Stevenson R Cunningham D Tansey P Ahmedzai S Stack B Dorward A Lucie N and Kaye S Treatment of small cell carcinoma of lung with later dosage intensification programmes containing cyclophosphamide and mesna Cancer Treat Rev 10 (Suppl A) 73-77 1983

23 Elliot JA Ahmedzai S Hole D Dorward AJ Stevenson RD Kaye SB Banham SW Stack BHR and Calman KC Vindesine and cisplatin combination chemotherapy compared with vindesine as single agent in the management of non-small cell lung cancer - a randomized study Eur J Cancer 20 1025-1032 1984

24 Sangster G Kaye SB Calman KC and Dalton JF Failure of 2-mercaptoethane sulphonate sodium (Mesna) to protect against ifosfamide nephrotoxicity Eur J Cancer Clinic Oncol 20 435-436 1984

25 Kaye SB Sangster G Hutcheon A Habeshaw T Crossling F Ferguson C McArdle C Smith D George WD and Calman KC Sequential mehtotrexate-5-fluorouracil in advanced breast and colorectal cancer - a Phase II study Cancer Treat Rep 68 547-548 1984

26 Kaye SB McWhinnie D Hart A Deane RF Milsted RV Welsh J Stuart JF Billiaert P and Calman KC The treatment of advanced bladder cancer with methotrexate and cisplatinum - a pharmacokinetic study Eur J Cancer 20 249-252 1984

27 Rustin GJS Kaye SB Williams CJ Newlands ES Bagshawe KD and Toy JL Response of differentiated but not anaplastic teratoma to interferon Br J Cancer 50 611-616 1984

28 Cunningham D Soukop M McArdle CS Carter DC Smyth JF Allan SG Hutcheon AW Calman KC Kaye SB Sangster G and Boyle P Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin C Br J Surg 71 673-676 1984

29 Milsted RV Sangster G Kaye SB Calman K Cordiner J Soutter P Barr W Cunningham D Soukop M Kennedy J and McEwan H The treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide adriamycin and cis-platinum Br J Obst and Gynae 91 927-931 1984

30 Merry S Kaye SB and Freshney RI Cross-resistance to cytotoxic drugs in human glioma cell lines in culture Br J Cancer 50 831-835 1984

31 Samaranayake L Calman KC Ferguson M Kaye SB McFarlane T Main B Welsh J and Willox J The oral carriage of yeasts and coliforms in patients on cytotoxic therapy J Oral Path 13 390-393 1984

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

11

1985

32 Milsted RV Habeshaw T Kaye S Sangster G MacBeth F Campbell-Ferguson J Smith D and Calman KC A randomised trial of tamoxifen versus tamoxifen and aminoglutethimide in post-menopausal women with advanced breast cancer Cancer Chemother Pharmacol 14 272-273 1985

33 Cunningham D Hutcheon A Soukop M Kaye SB Gilchrist NL Forrest GJ McArdle CS and Calder IT A randomised trial comparing intravenous high dose metoclopramide with intramuscular chlorpromazine in the control of nausea and vomiting induced by cytotoxic drugs Br Med J 290 604-605 1985

34 Banham S Dorward A Hutcheon A Ahmedzai S Cunningham D Burnett A Soukop M Lucie N and Kaye S The role of VP16 in the treatment of small cell lung cancer studies of the West of Scotland Lung Cancer Group Seminars in Oncology Vol XII Suppl 2 2-6 1985

35 Maguire J and Kaye SB Psoas abscess unusual complication of effective chemotherapy for teratoma Br Med J 29 1870 1985

36 Kaye SB ten Bokkel-Huinink W van Oosterom A Jones W Sleyfer D Vendrik C and Stoter G EORTC genitourinary group studies in advanced testicular cancer - past and future Aust NZ J Surg 55 239-241 1985

37 Cunningham D Hutcheon A Banham S Dorward A Burnett A Ahmedzai S Tansey P Soukop M Stevenson R Stack B Kaye S and Lucie N High dose cyclophosphamide and VP16 as late dose intensification therapy for small cell carcinoma of lung Cancer Chemother Pharmacol 15 303-306 1985

38 Kaye SB MacFarlane JR McHattie I and Hart AJ Chemotherapy before radiotherapy for T3 bladder cancer - a pilot study Br J Urol 57 434-437 1985

39 Kerr DJ Graham J Blackie R McGovern E Kelman A Cunningham D and Kaye SB Relationship between steady state levels of metoclopramide and control of cis-platinum-induced emesis Br J Clin Pharmacol 20 426-427 1985

40 Lewi HJE Reid R Mucci B Davidson JK Kyle KF MacPherson SG Semple P and Kaye S Malignant Phaeochromocytoma Br J Urol 57 394-398 1985

1986

41 Kaye SB and Davies E Cyclophosphamide adriamycin and cis-platinum for the treatment of advanced granulosa cell tumour using serum estradiol as tumour marker Gynaec Oncol 24 261-264 1986

42 Cunningham D Soukop M Gilchrist N Forrest GJ Carter DC Kaye SB Dobbie JW and Smith M TNO-6 in gastrointestinal cancer with N-acetyl-glucosaminidase as a marker of renal tubular damage Med Oncol Tumour Pharmacol 3 25-28 1986

43 Kerr D Kaye S Graham J Harding S McGrath J Setanoians A Forrest G Cunningham D and Soukop M Phase I and pharmacokinetic trial of LM985 Cancer Res 46 3142-3246 1986

44 Kerr DJ Kerr A Kaye SB and Freshney RI Comparative intracellular uptake of adriamycin and 4-doxydoxorubicin by non-small cell lung cancer cells in culture and its relationship to cell survival Biochem Pharmacol 35 3817-2823 1986

45 Merry S Fetherston CW Kaye SB Freshney RI and Plumb JA Resistance of human glioma to adriamycin in vitro - the role of membrane transport and its circumvention with verapamil Br J Cancer 53 129-135 1986

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

12

46 Dorward AJ Banham SW Hutcheon AW Ahmedzai S Cunningham D Gregor A Soukop M Stack B McKay N and Kaye S Short duration combination chemotherapy in the treatment of small cell lung cancer Thorax 41 688-691 1986

47 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung tumour cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

48 Willox JC McAllister J Sangster G Kaye SB and Calman KC Effects of magnesium supplementation in testicular cancer patients receiving cisplatinum - a randomised trial Br J Cancer 54 19-23 1986

49 Kerr DJ Wheldon TE Kerr AM Freshney RI and Kaye SB The effect of adriamycin and 4deoxydoxorubicin on cell survival of human lung cells grown in monolayer and as spheroids Br J Cancer 54 423-430 1986

50 Cunningham D Jack A McMurdo D Soukop M McArdle C Carter DC and Kaye SB The 6-day subrenal capsule assay is of no value with primary surgical explants from gastric cancer Br J Cancer 54 519-524 1986

51 Cummings J Milsted RAV Cunningham D and Kaye SB Marked interpatient variations in the metabolism of adriamycin to 7-deoxyaglyones metabolites Eur J Cancer 22 991-1001 1986

52 Cunningham D Soukop M Stuart JFB Setanoians A Gilchrist N Forrest G and Kaye SB A clinical and pharmacokinetic Phase I study of 124-triglycidylurazol (TGU) Eur J Cancer 22 1325-1331 1986

53 van Oosterom Allan T Bobo Aldo V Kaye SB Splinter TAW Calciati Alessandro Fossa SD de Pauw M and Sylvester R 4Deoxydoxorubicin in advanced renal cancer A Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group Eur J Cancer 22 1531-1532 1986

54 Kerr DJ Graham J Cummings J Morrison JG Thompson GG Brodie MJ and Kaye SB The effect of verapamil on the pharmaco-kinetics of adriamycin Cancer Chemother Pharmacol 18 239-242 1986

55 Stoter G Sleyfer DTh ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P de Pauw M and Sylvester R High dose versus low dose vinblastine in cisplatin-vinblastine-bleomycin combination chemo-therapy of non-seminomatous testicular cancer A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 4 1199-1206 1986

1987

56 Symonds RP Habeshaw T Kaye SB and Watson ER Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of cervix Clin Radiol 38 273-274 1987

57 Boyle P Kaye SBand Robertson AG Changes in testicular cancer in Scotland Eur J Cancer 23 827-830 1987

58 Kerr DJ and Kaye SB Aspects of cytotoxic drug penetration with particular reference to anthracyclines Cancer Chemother Pharmacol 19 1-6 1987

59 Milroy R Cummings J Kaye SB and Banham SW Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer Cancer Chemother Pharmacol 20 75-77 1987

60 Cummings J Willmott N More I Kerr D Morrison JC and Kaye SB Comparative cardiotoxicity and antitumour activity of doxorubicin and 4deoxydoxorubicin and their relationship to in vivo distribution and metabolism in the target tissues Biochem Pharmacol 36 1521-1526 1987

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

13

61 Kerr DJ Wheldon TE Russell JG Maurer HR Florence AT Freshney RI and Kaye SB The effect of the non ionic surfactant Brij 30 on the cytotoxicity of adriamycin in monolayer and spheroid culture systems Eur J Cancer Clin Oncol 23 1315-1322 1987

62 Kerr DJ Weldon TE Kerr AM and Kaye SB In vitro chemosensitivity testing using the multicellular tumour spheroid model Cancer Drug Deliv 4 124-130 1987

63 Leonard RCF Cornbleet MA Kaye SB Soukop M White G Hutcheon AW Robinson S Kerr ME and Smyth JF Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast J Clin Oncol 5 1056-1063 1987

64 Cummings J Kerr DJ and Kaye SB Metabolism and pharmacokinetics of 4-deoxydoxorubicin in cancer patients Cancer Chemother Pharmacol 20 263-264 1987

65 Stoter G Sylvester R Sleijfer DT ten Bokkel Huinink WW Kaye SB Jones WG van Oosterom AT Vendrik CPJ Spaander P and de Pauw M Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer Results from a European Organization for Research and Treatment of Cancer Multi-institutional Phase III Study Cancer Res 47 2714-2718 1987

66 Beer M Cavalli F Kaye SB Lev L and Clavel M Phase II study carboplatin in advanced or metastatic stomach cancer Eur J Cancer Clin Oncol 23 1665-1567 1987

67 Williams CJ Barley V Blackledge G Hutcheon A Kaye SB Smith D Keen C Webster D Rowland C and Tyrrell C Multicentre study of trilostane a new hormonal agent in advanced post-menopausal breast cancer Cancer Treat Rep 71 1197-1201 1987

68 Kerr DJ Kaye SB Cassidy J Bradley C Rankin EM Adams L Setanoians A Young T Forrest G Soukop M and Clavel M Phase I and pharmacokinetic study of flavone acetic acid Cancer Res 47 6776-6781 1987

69 Merry S Courtney ER Fetherston CA Kaye SB and Freshney RI Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil Br J Cancer 56 401-405 1987

1988

70 Gouyette A Kerr DJ Kaye SB Setanoians A Cassidy J Bradley C Forrest G and Soukop M Flavone acetic acid a non linear pharmacokinetic model Cancer Chemother Pharmacol 22114-119 1988

71 Harding M Kaye SB Soukop M and Ferguson JC A phase II study of sequential methotrexate and 5-Fluorouracil in advanced colorectal carcinoma Med Oncol Tumor Pharmacother 5 239-241 1988

72 Kerr DJ Hynds SA Wheldon TE and Kaye SB Cytotoxicity drug penetration studies in multicellular tumour spheroids Xenobiotica 18 641-648 1988

73 Pledger DR Belfield A Kennedy JH and Kaye SB Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment Eur J Cancer Clin Oncol 24 219-222 1988

74 Boyle P Soukop M Scully C Robertson AG Burns HJG Gillis CR and Kaye SB Improving prognosis of Hodgkins disease in Scotland Eur J Cancer Clin Oncol 24 229-234 1988

75 Cantwell B MacAuley V Harris A Kaye SB Smith IE Milsted R Calvert AH Phase II study of the antifolate CB3717 in advanced breast cancer Eur J Cancer Clin Oncol 24 733-737 1988

76 Graham J Harding M Mill L Kerr DJ Rankin E Calman KC and Kaye SB Results of treatment of non-seminomatous germ cell tumours 122 consecutive cases in the West of Scotland 1981-1985 Br J Cancer 57 182-185 1988

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

14

77 Sessa C Vermorken J Renard J Kaye SB Smith MS Cavalli F and Pinedo H Phase II study of iproplatin in advanced ovarian carcinoma J Clin Oncol 6 98-105 1988

78 Cunningham D Cummings J Blackie RB McTaggart L Banham S Kaye SB and Soukop M The pharmacokinetics of high dose cyclophosphamide and high dose etoposide Med Oncol Tumour Pharmacother 5 117-123 1988

79 Harding M Sangster G Milsted R Kaye SB and Calman KC Adriamycin vincristine and mitomycin C as first and second line therapy for advanced breast carcinoma Med Oncol Tumour Pharmacother 5 125-128 1988

80 Cunningham D Bradley CJ Forrest G Adams L Hutcheon AW Harding M Kerr D Soukop M and Kaye SB A randomised trial of oral nabilone compared to intravenous metoclopramide in the treatment of nausea and vomiting induced by chemotherapy Eur J Cancer Clin Oncol 24 685-689 1988

81 Veale D Carmichael J Cantwell BM Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A Phase I and pharmacokinetic study of Didox a ribonucleotide reductase inhibitor Br J Cancer 58 70-72 1988

82 Smith DB Lind MJ Kaye SB Newlands ES Blackledge GR and Gibson A A negative Phase II trial of methylene dimethane sulphonate in advanced ovarian cancer Br J Cancer 57 576-578 1988

83 Harding MJ Cantwell BM Milsted RV Harris AL and Kaye SB Phase II study of the thymidylate synthetase inhibitor CB3717 in colorectal cancer Br J Cancer 57 628-629 1988

84 Smith MA Merry S Smith JG and Kaye SB Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP 16 Br J Cancer 57 576-578 1988

85 Kerr DJ Harding M Farmer JG Amarin J Blackie RB Harland SJ and Kaye SB Pharmacokinetics of ipoplatinum (CHIP) in patients with normal and impaired renal function and following intraperitoneal administration Med Oncol Tumour Pharmacother 5 153-158 1988

86 Clavel M Monfardini S Gundersen S Kaye SB Siegenthaler P Renard J van Glabbeke M and Pinedo HM Phase II study of Iproplatin (CHIP JM-9) in advanced testicular cancers progressing after prior chemotherapy Eur J Cancer Clin Oncol 24 1345-1348 1988

87 Harding M Kennedy R Mill L MacLean A Duncan I Kennedy J Soukop M and Kaye SB A pilot study of carboplatin (JM8 CBDCA) and chlorambucil in combination of advanced ovarian cancer Br J Cancer 58 640-643 1988

88 Cassidy J Raina V Lewis C Adams L Soukop M Rapeport WG Zussman BD Rankin EM and Kaye SB Pharmacokinetics and anti-emetic efficacy of BRL 43694 a new selective 5HT-3 antagonist Br J Cancer 58 651-654 1988

89 Deans G Bennett-Emslie GB Weir J Smith DC and Kaye SB Cancer support groups - who joins and why Br J Cancer 58 670-4 1988

90 Kerr DJ Rogerson A Morrison GJ Florence AT and Kaye SB Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer spheroid and xenograft Br J Cancer 58 432-436 1988

91 Cummings J Kerr DJ Kaye SB and Smyth JF Optimisation of a reversed-phase high performance liquid chromatography method for the determination of flavone acetic acid and its major human metabolites in plasma and urine J Chromatog 43177-85 1988

92 Kerr DJ Hynds SA Shepherd J Packard CJ Kaye SB Comparative cellular uptake and cytotoxicity of a complex of daunomycin-low density lipoprotein in human squamous lung tumour cell monolayers Biochem Pharmacol 37 3981-3986 1988

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

15

93 Reid A Bennett-Emslie G Adams L Kaye SB What should we tell patients with cancer Scott Med J 33 260 1988

94 Kaye SB Stoter G Sleijfer D Jones W ten Bokkel Huinink W Splinter T van Oosterom A Harris A Bovan E DE Pauw M et al Potential advances in combination chemotherapy for advanced testicular cancer Prog Clin Biol Res 169 461-469 1988

1989

95 Russell J Adam J Wheldon TE and Kaye SB The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma given as spheroids Cancer Chemother Pharmacol 23111-114 1989

96 Cassidy J Duncan R Morrison GJ Srrohalm J Plocava D Kopecek J and Kaye SB Activity of N-(2-Hydroxypropyl)methacrylamide copolymeres containing daunomycin against a rat tumour model Biochem Pharmacol 38 875-879 1989

97 Harding M Docherty V Mackie R Dorward Aand Kaye S Phase II studies of mitozolomide in melanoma lung and ovarian cancer Eur J Cancer Clin Oncol 25 785-788 1989

98 Sessa C Kaye SB Renard J ten Bokkel Huinink W and Cavalli F Phase II study of intravenous menogaril in advanced ovarian carcinoma Eur J Cancer Clin Oncol 25 751-752 1989

99 Cassidy J Kerr DJ Setanoians A Zaharko DS and Kaye SB Could interspecies differences in the protein binding of flavone acid contribute to the failure to predict lack of efficacy in patients Cancer Chemother Pharmacol 23 397-400 1989

100 Merry S Flanigan P Schlick E Freshney RI and Kaye SB Inherent adriamycin resistance in a murine tumour line circumvention with verapamil and norverapamil (Short Communication) Br J Cancer 59 895-897 1989

101 Kerr DJ Maughan T Newlands E Rustin G Bleehen NM Lewis C and Kaye SB Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma Br J Cancer 60 104-106 1989

102 Cassidy J Lewis C Adams L Setanoians A Baysass M Boder GG Rankin EM and Kaye SB Phase I clinical and pharmacokinetic study of LY 195448 Cancer Chemother Pharmacol 24 233-237 1989

103 Plumb JA Milroy R Kaye SB Effects of the pH Dependence of 3-(45-Dimethylthiazol-2-yl)-25-diphenyl-tetrazolium bromide-formazan Absorption of chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 4435-4440 1989

104 Cummings J Double JA Bibby MC Farmer P Evans S Kerr DJ Kaye SB and Smyth JF Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice Cancer Res 49 3587-3593 1989

105 Kerr DJ and Kaye SB Flavone Acetic Acid - Preclinical and Clinical Activity Eur J Cancer Clin Oncol 251271-1272 1989

106 Harding MJ Brown IL MacPherson SG Turner MA and Kaye SB Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours Eur J Cancer Clin Oncol 25 1689-1694 1989

107 Kaye SB and Boyle P The impact of chemotherapy in germ cell tumours Cancer Surveys 8 631-646 1989

108 Symonds RP Burnett RA Habeshaw T Kaye SB Snee MP Watson ER The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix Br J Cancer 59 473-475 1989

1990

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

16

109 Kaye SB Clavel M Dodion P Monfardini S ten Bokkel-Huinink W Renard J van Glabbeke M and Cavalli F Phase II trials with flavone acetic acid (NCS347512 LM975) in patients with advanced carcinoma of the breast colon head and neck and melanoma Invest New Drugs 8 S95-S99 1990

110 Smith MF Lawson AH Kirk D and Kaye SB Low dose methotrexate and doxorubicin in hormone-resistant prostatic cancer Br J Urol 65 513-516 1990

111 Plumb JA Milroy R and Kaye SB The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific Biochem Pharmacol 39 787-792 1990

112 Kerr DJ Slack JA Secrett P Stevens MFG Blackledge GRP Bradley C and Kaye SB Relationship between the pharmacokinetics and toxicity of mitozolomide Cancer Chemother Pharmacol 25 352-354 1990

113 Carmichael J Cantwell BMJ Mannix KA Veale D Elford HL Blackie R Kerr DJ Kaye SB and Harris AL A phase I and pharmacokinetic study of didox administered by 36 hour infusion Br J Cancer 61 447-450 1990

114 Lewis C Lawson N Rankin E Morrison G MacLean AB Cordiner J Cassidy J Kerr DJ Kaye SB Phase I and pharmacokinetic study of intraperitoneal thiotepa in patients with ovarian cancer Cancer Chemother Pharmacol 26 283-287 1990

115 Harding M McAllister J Hulks G Vernon D Monie R Paul J and Kaye SB Neurone specific enolase (NSE) in small cell lung cancer a tumour marker of prognostic significance Br J Cancer 61 605-607 1990

116 Sessa C Cerny T Kaye S Monfardini S Renard J and Cavalli F for the EORTC Early Clinical Trials Group A Phase II study of iproplatin in advanced or metastatic stomach cancer Eur J Cancer 26 61-62 1990

117 Bissett D Kunkeler L Zwanenburg L Paul J Gray C Swan IRC Kerr DJ and Kaye SB Long-term sequelae of treatment for testicular germ cell tumours Br J Cancer 62 655-659 1990

118 Bruntsch U de Mulder HM ten Bokkel Huinink WW Clavel M Drozd A Kaye SB Renard J and van Glabbeke M Phase II Study of Recombinant Human Interferon-y in metastatic renal carcinoma J Biol Response Mod 9 335-338 1990

119 Steward WP Thatcher N and Kaye SB Clinical applications of myeloid colony stimulating factors Cancer Treat Revs 17 77-87 1990

120 Harding M Dall B Crobett R Vallance R and Kaye SB Does lymphangiography have any role in the management of early non-seminomatous germ cell tumours Clinical Radiology 41 392-394 1990

121 Wishart GC Plumb JA Going JJ McNicol AM McArdle CS Tsuruo T and Kaye SB P-glycoprotein expression in primary breast cancer detected by immuno-cytochemistry with two monoclonal antibodies Br J Cancer 62 758-761 1990

122 Geller NL Scher HI Parmar MKB Dalesio O and Kaye SB Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer Semin Oncol 17 628-634 1990

123 Kerr DJ Lewis C ONeil B Lawson N Blackie RG Newell DR Boxall P Cox J Rankin EM Kaye SB The myelotoxicity of carboplatin is influenced by the time of its administration Hematol Oncol 8 59-63 1990

124 Stallard S Morrison JG George WD Kaye SB Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy Cancer Chemother Pharmacol 25 286-290 1990

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

17

125 Jones RD Kerr DJ Harnett AN Rankin EM Ray S and Kaye SB A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer Br J Cancer 62 133-135 1990

1991

126 Lewis CR Fossa SD Mead G ten Bokkel Huinink W Harding MJ Mill L Paul J Jones WG Rodenburg CJ Cantwell B Keizer HJ van Oosterom A Soukop M Splinter T and Kaye SB BOPVIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours Ann Oncol 2 203-211 1991

127 Allan SG Cummings J Evans S Nicolson M Stewart ME Cassidy J Soukop M Kaye SB and Smyth JF Phase I study of the anthrapyrazole biantrazole clinical results and pharmacology Cancer Chemother Pharmacol 28 55-58 1991

128 Junor E Davies J Habeshaw T Kaye S Paul J Rankin E Reed N and Symonds RP Carboplatin-based combination chemotherapy for advanced carcinoma of the cervix (Short Communication) Cancer Chemother Pharmacol 27 484-486 1991

129 Jansen RLH Sylvester R Sleyfer DT ten Bokkel Huinink WW Kaye SB Jones WG Keizer J van Oosterom AT Meyer S Vendrik CPJ De Pauw M and Stoter G for the European Organization for Research on Treatment of Cancer (EORTC GU Group) Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery Eur J Cancer 27 695-698 1991

130 Sessa C Calabresi F Cavalli F Cerny T Skovsgaard T Liati P Sorio R and Kaye SB for the ECTG of the EORTC Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung colon and breast cancers Ann Oncol 2 727-731 1991

131 Schwartsmann G Wanders J Koier IJ Franklin HR Dalesio O Hornstra HW van Glabbeke M Renard J van Oosterom AT Kaye SB and Pinedo HM EORTC New Drug Development Office Coordinating and Monitoring Programme for Phase I and II Trials with New Anticancer Agents Eur J Cancer 27 1162-1168 1991

132 La Vecchia C Levi F Lucchini F Kaye SB and Boyle P Hodgkins disease mortality in Europe Br J Cancer 64 723-734 1991

133 Roberts JT Fossa SD Richards B Kaye SB White EF Robinson MC Uscinska B and Parmar MKB Results of Medical Research Council Phase II Study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder Br J Urol 68 162-168 1991

134 Senan IS and Kaye SB Lung abscess A fatal complication of treatment for testicular teratoma (case report) Clinical Oncology 3 345-347 1991

135 Cassidy J Poole C Sharkie E Steward WP and Kaye SB The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon Eur J Cancer 27 1633-1634 1991

136 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH and Harris AL (on behalf of the CRC Phase III Clinical Trials Committee) Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-1188 1991

137 Bissett D Kerr DJ Cassidy J Meredith P Traugott U and Kaye SB Phase I and pharmacokinetic study of D-verapamil and doxorubicin Br J Cancer 64 1168-1171 1991

138 Wishart GC and Kaye SB Is multidrug resistance relevant in breast cancer Eur J Surg Oncol 17 485-488 1991

139 Senan S Rampling R and Kaye SB Malignant pineal teratomas a report on three patients and the case for crniospinal irradiation following chemotherapy Radiother Oncol 22 209-213 1991

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

18

140 Bindemann S Soukop M and Kaye SB Randomized controlled study of relaxation training Eur J Cancer 27 170-174 1991

141 Habeshaw T Paul J Jones R Stallard S Stewart M Kaye SB Soukop M Symonds RP Reed NS Rankin EM Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer the results of a randomised trial J Clin Oncol 9 295-304 1991

142 Harding M Milsted R Hole D Gordiner J Barr W Soukop M Kennedy J Soutter WP and Kaye S Long-term results of cyclophosphamide adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer Ann Oncol 2 213-233 1991

143 Jones AL Hill AS Soukop M Hutcheon AW Cassidy J Kaye SB Sikora K Carney DN and Cunningham D Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy Lancet 338 483-487 1991

144 Merry S Hamilton TG Flanigan P Freshney RI and Kaye SB Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine Eur J Cancer 27 31-34 1991

145 Gillis CR Hole DJ Still RM Davis J Kaye SB Medical audit cancer registration and survival in ovarian cancer Lancet 337 611-612 1991

146 Kerr DJ Kaye SB Chemoembolism in cancer chemotherapy Crit Rev The Drug Carrier Syst 8 19-37 1991

147 Rubens RD Kaye SB Soukop M Williams CJ Brampton MH Harris AL Phase II trial of didox in advanced breast cancer Br J Cancer 64 1187-188 1991

148 Kaye SB How should nausea be assessed in patients receiving chemotherapy Cancer Treat Rev 18 85-93 1991

1992

149 Cassidy J Lewis CR Kaye SB and Kirk D The changing role of surgery in metastatic non-seminomatous germ cell tumour Br J Cancer 65 127-129 1992

150 Rankin EM Mill L Kaye SB Atkinson R Cassidy L Cordiner J Cruickshank D Davis J Duncan ID Fullerton W Habeshaw T Kennedy J Kennedy R Kitchener H MacLean A Paul J Reed N Sarker T Soukop M Swapp GH and Symonds RP A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 275-281 1992

151 Wishart GC Plumb JA Morrison JG Hamilton TG and Kaye SB Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo Eur J Cancer 28 28-31 1992

152 Foster BJ Newell DR Graham MA Gumbrell LA Jenns KE Kaye SB and Calvert AH Phase I trial of the anthrapyrazole CI-941 prospective evaluation of a pharmacokinetically guided dose escalation scheme Eur J Cancer 28 463-469 1992

153 Cruickshank DJ Paul J Lewis CR McAllister EJ and Kaye SB An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer Br J Cancer 65 597-600 1992

154 Kaye SB Brampton M Harper P Smyth J Kerr DJ Gore M Green JA Gilby E Crawford SM and Rustin GJ on behalf of the CRC Phase II Clinical Trials Committee Phase II trials of fosquidone (GR63178A) in colorectal renal and non-small cell lung cancer Br J Cancer 65 624-625 1992

155 Clavel M Monfardini S Fossa S Smyth J Renard J and Kaye SB 5-Aza-2-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group Ann Oncol 3 339-400 1992

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

19

156 Graham MA Bissett D Setanoians A Hamilton T Kerr DJ Henrar R and Kaye SB Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose escalation scheme J Natl Cancer Inst 84 494-500 1992

157 Kaye SB So what is a clinical oncologist J Royal Coll Phys Ldn 26 314-315 1992

158 Bissett D Graham MA Setanoians A Chadwick GA Wilson P Koier I Henrar R Schwartsmann G Cassidy J Kaye SB Kerr D Phase I and pharmacokinetic study of rhizoxin Cancer Res 52 2894-2898 1992

159 Kaye SB Wanders J Clavel M Verweij J Piccart MJ Smyth JF Huinink WWT Wagener DJT Judson IR Cavalli F Phase II trials of fosquidone (GR63178A) in carcinoma of the breast head and neck ovary and melanoma Ann Oncol 3 406-408 1992

160 Milroy R Plumb JA Batstone P MacLay A Wishart GC Hay FG Candlish W Adamson R Khan MS Banham S Kaye SB Lack of expression of p-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients Anticancer Res 12 193-200 1992

161 Poole CJ Cassidy J Woodroffe C Kaye SB and Cullen MH Is the number of cerebral metastases of distinct prognostic importance in advanced non-seminomatous germ cell tumours Br J Cancer 65 (Suppl 16) 24-33 1992

162 Siegenthaler P Kaye SB Monfardini S and Renard J Phase II trial with flavone acetic acid (NSC 347512 LM 975) in patients with non small cell lung cancer Ann Oncol 3 169-170 1992

163 Fossa SD Harland SJ Kaye SB Raghaven D Russell JM Parmar MKB Uscinska BM Wood R and the MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party) Initial combination chemotherapy with cisplatin methotrexate and vinblastine in locally advanced transitional cell carcinoma - response rate and pitfalls Br J Urol 70 161-168 1992

164 Kaye SB Lewis CR Paul J Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Cassidy J Davis JA Reed NS Crawford SM MacLean A Swapp GA Sarkar TK Kennedy JH and Symonds RP Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer Lancet 340 329-333 1992

165 Read G Stenning SP Cullen MH Parkinson MC Horwich A Kaye SB and Cooke PA Medical Research Council prospective study of surveillance for Stage I testicular teratoma J Clin Oncol 10 1762-1768 1992

166 Barrett A Rampling R and Kaye SB Training for clinical oncology Experience in Glasgow 1987-1992 Clin Oncol 4 381-387 1992

167 Stoter G Akdas A Fossa SD Kaye SB van Groeningen CJ Renard J and van Glabbeke M High dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer A Phase II study Ann Oncol 3 577-578 1992

1993

168 Cassidy J Graham MA ten Bokkel-Huinink W McDaniel C Setanoians A Rankin EM Kerr DJ and Kaye SB Phase I clinical study of LLD-49194agrave1 with retrospective pharmacokinetic investigations in mice and humans Cancer Chemother Pharmacol 31 395-400 1993

169 de Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

170 Cassidy J and Kaye SB An unusual case of haematuria Eur J Cancer 29A 906-907 1993

171 Bissett D Setanoians A Cassidy J Graham MA Chadwick GA Wilson P Kerr DJ Le Bail N and Kaye SB Phase I and pharmacokinetic study of taxotere administered as a 24 hour infusion Cancer Res 53 523-527 1993

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

20

172 Stoter G Sleijfer DTh Kaye SB Jones WG ten Bokkel Huinink WW de Pauw M Sylvester R for the EORTC GU-Group Prognostic factors in metastatic non-seminomatous germ cell tumours An interim analysis of the EORTC GU-Group experience Eur J Urol 23 202-206 1993

173 Harding MJ Paul J Gillis CR and Kaye SB Management of malignant teratoma does referral to a specialist unit matter Lancet 341 999-1002 1993

174 Vermorken JB Gundersen S Clavel M Smyth JF Dodion P and Kaye SB Randomized Phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

175 Schrijvers D Wanders J Dirix L Prove A Vonck I van Oosterom A and Kaye S Coping with toxicities of docetaxel (TaxotereTM) Ann Oncol 4 610-611 1993

176 Aapro M Piguet D Giger K Bauer J Haefliger JM Bremer K Cals L Cattan A Clavel M Czygan P Dearnaley D Kaye SB (Total 32 authors) The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy after 5 days J Cancer Res Clin Oncol 119 555-559 1993

177 De Wit R Kaye SB Roberts JT Stoter G Scott J and Verweij J Oral piritrexim an effective treatment for metastatic urothelial cancer Br J Cancer 67 388-390 1993

178 Vermorken JB Gunderson S Clavel M Smyth JF Dodion P Renard J and Kaye SB Randomised phase II trial of iproplatin and carboplatin in advanced breast cancer Ann Oncol 4 303-306 1993

179 Keith WN Douglas F Wishart GC McCallum HM George WD Kaye SB and Brown R Co-amplification of ERBB2 topoisomerase IIagrave and retinoic acid receptor agrave genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 Eur J Cancer 29A 1469-1475 1993

180 Kaye SB Potential contribution of therapy to cancer mortality reduction Cancer Detection Prevention 17 529-531 1993

181 Brown R Clugston C Burns P Edlin A Vasey P Vojtesek B and Kaye SB Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines Int J Cancer 55 678-684 1993

182 Vermorken JB ten Bokkel Huinink WW Eisenhauer EA Favalli G Belpomme D Conte PF and Kaye SB Carboplatin versus cisplatin Ann Oncol 4 (Suppl 4) S41-S48 1993

1994

183 van der Zee AGJ de Vries EGE Hollema H Kaye SB Brown R and Keith WN Molecular analysis of the topoisomerase II agrave gene and its expression in human ovarian cancer Ann Oncol 5 75-81 1994

184 Verweij J Wanders J Nielsen AL Pavlidis N Calabresi F ten Bokkel Huinink W Bruntsch U Piccart M Franklin H and Kaye SB Phase II studies of Elsamitrucin in breast cancer colorectal cancer non-small cell lung cancer and ovarian cancer Ann Oncol 5 375-376 1994

185 ten Bokkel Huinink WW Prove AM Piccart M Steward W Tursz T Wanders J Franklin H Clavel

M Verweij J Alakl M Baysass M and Kaye SB A phase II trial with Docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer Ann Oncol 5 527-532 1994

186 Catimel G Verweij J Mattijssen V Hanauske A Piccart M Wanders J Franklin H Le Bail N

Clavel M and Kaye SB Docetaxel (Taxotere) An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 533-537 1994

187 Catimel G Vermorken JB Clavel M de Mulder P Judson I Sessa C Piccart M Bruntsch U Verweij J Wanders J Franklin H and Kaye SB A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Ann Oncol 5 543-547 1994

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

21

188 Jodrell DI Oster W Kerr DJ Canney PA Yosef H Steward WP Kaye SB and Cassidy J A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer Eur J Cancer 30A 950-954 1994

189 Sternberg CN ten Bokkel Huinink WW Smyth JF Bruntsch V Dirix LY Pavlidis NA Franklin H Wanders S Le Bail N and Kaye SB Docetaxel (TaxotereTM) a novel taxoid in the treatment of advanced colorectal carcinoma an EORTC Early Clinical Trials Group Study Br J Cancer 70 376-379 1994

190 Sulkes A Smyth J Sessa C Dirix LY Vermorken JB Kaye S Wanders J Franklin H LeBail N and

Verweij J for the EORTC Early Clinical Trials Group Docetaxel (Taxotere) in advanced gastric cancer results of a phase II clinical trial Br J Cancer 70 380-383 1994

191 Cerny T Kaplan S Pavlidis N Schoffski P Epelbaum R van Meerbeek J Wanders J Franklin HR and

Kaye S Docetaxel (Taxotere) is active in non-small-cell lung cancer a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer 70 384-387 1994

192 Bruntsch U Heinrich B Kaye SB de Mulder PHM van Oosertom A Paridaens R Vermorken JB Wanders J Franklin H Baysass M and Verweij J Docetaxel (Taxotere) in advanced renal cell cancer A Phase II trial of the EORTC Early Clinical Trials Group Eur J Cancer 30A 1064-1067 1994

193 Smyth JF Smith IE Sessa C Schoffski P Wanders J Franklin H and Kaye SB on behalf of the Early Clinical Trials Group of the EORTC Activity of Docetaxel (Taxotere) in small cell lung cancer Eur J Cancer 30A 1058-1060 1994

194 Jodrell DI Murray LS Reed NS Canney PA Kaye SB and Cassidy J Bolusinfusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma are sub-optimal dosages being used in the UK Br J Cancer 70 749-752 1994

195 Bleehen NM Calvert AH Lee SM Harper P Kaye SB Judson I and Brampton M A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma Br J Cancer 70 775-777 1994

196 Vasey PA Dunlop DJ and Kaye SB Primary mediastinal germ cell tumour and acute monocytic leukaemia occurring concurrently in a 15-year-old boy Ann Oncol 5 649-652 1994

197 Plumb JA Wishart GC Setanoians A Morrison JG Hamilton T Bicknell SR and Kaye SB Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro toxicity in vivo and growth delay in a solid human tumour xenograft Biochem Pharmacol 47 257- 266 1994

198 McLeod HL Douglas F Oates M Symonds RP Prakash D van der Zee AGJ Kaye SB Brown R and Keith WN Topoisomerase I and II activity in human breast cervix lung and colon cancer Int J Cancer 59 607-611 1994

199 Doherty N Hancock SL Kaye S Coleman CN Shulman L Marquez C Mariscal C Rampling R Senan S and Roemeling RV Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation Int J Radiat Oncol Biol Phys 29 379-382 1994

200 Goedhals L Jordaan JP Kaye SB Armand JP Veenhof CHN Falkson G Soukop M Schneider M Oberling F Bui BN Roche H Adenis L Caty A Blijham GH Deweweire A Coiffier B Sotto JJ Vanheukelom LS Tagonon A Slee PHTJ Kroeks MVAM Ravez P Cupissol D Keizer HJ Brunner K Calvert AH Yernault JC Libert P and Brohee D A dose-finding study of granisetron a novel antiemetic in patients receiving high-dose cisplatin Supportive Care in Cancer 2 177-183 1994

201 Wishart GC Bissett D Paul J Jodrell D Harnett A Habeshaw T Kerr DJ Macham MA Soukop M Leonard RCF Knepil J and Kaye SB Quinidine as a resistance modulator of epirubicin in

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

22

advanced breast cancer - mature results of a placebo-controlled randomized trial J Clin Oncol 12 1771-1777 1994

202 Houghton PJ and Kaye SB Multidrug resistance is not an important factor in therapeutic outcome in human malignancies J NIH Res 6 55-61 1994

1995

203 Murphy D McHardy P Coutts J Mallon EA George WD Kaye SB Brown R and Keith W Nicol Interphase cytogenetic analysis of erbB2 and topoIIagrave co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ Int J Cancer 64 18-26 1995

204 Vasey PA Bissett D Strolin-Benedetti M Poggesi I Breda M Adams L Wilson P Pacciarini MA Kaye SB and Cassidy J Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762) Cancer Res 55 2090-2096 1995

205 Fossa SD Droz JP Stoter G Kaye SB Vermeylen K Sylvester R and the members of the EORTC GU Group Cisplatin vincristine and ifosphamide combination chemotherapy of metastatic seminoma results of EORTC trial 30874 Br J Cancer 71 619-624 1995

206 Bissett D Jodrell D Harnett AN Habeshaw T Kaye SB Evans D Williams M and Canny PA Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support Br J Cancer 71 1279-1282 1995

207 de Wit R Stoter G Sleijfer DTh Kaye SB de Mulder PHM ten Bokkel Huinink WW Spaander PJ de Pauw M and Sylvester R Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 71 1311-1314 1995

208 Piccart MJ Gore M ten Bokkel Huinink W van Oosterom A Verweij J Wanders J Franklin H Baysass M Kaye SB Docetaxel an active new drug for treatment of advanced epithelial ovarian cancer J Natl Cancer Inst 87 676-681 1995

209 Hatton MQF Paul J Harding M MacFarlane G Robertson AG and Kaye SB Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours Eur J Cancer 31A 1487-1491 1995

210 Clarke K Howard GCW Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR Referral patterns within Scotland to specialist oncology centres for patients with testicular germ cell tumours Br J Cancer 72 1300-1302 1995

211 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA and Sharp L on behalf of SRS and SSCRCR A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1303-1306 1995

212 Howard GCW Clarke K Elia MH Hutcheon AW Kaye SB Windsor PM Yosef HMA on behalf of SRS and SSCRCR A Scottish national mortality study assessing cause of death quality and variation in management in patients with testicular non-seminomatous germ cell tumours Br J Cancer 72 1307-1311 1995

213 Monfardini S Sorio R Boes GH Kaye SB and Serraino D Entry and evaluation of elderly patients in EORTC new drug development studies Cancer 76 333-338 1995

214 Kaye SB Piccart M Aapro M Kavanagh J Docetaxel in advanced ovarian cancer Preliminary results from three Phase II trials Eur J Cancer 31A (Suppl 4) S14-S17 1995

215 Kaye SB Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer Semin Oncol 22 SE 30-33 1995

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

23

216 Murphy DS Hoare SF Going JJ Mallon EA George WD Kaye SB Brown R Black DM Keith WN Characterisation of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis J Natl Cancer Inst 87 1694-1704 1995

217 Kerr DJ Rustin GJ Kaye SB Selby P Bleehen NM Harper P and Brampton MH Phase II trials of rhizoxin in advanced ovarian colorectal and renal cancer Br J Cancer 72 1267-1269 1995

218 Harding M Paul J and Kaye SB Does delayed diagnosis or scrotal incision affect outcome for men with non-seminomatous germ cell tumours Br J Urol 76 491-494 1995

219 Anthoney DA Dunlop DJ Connell JM and Kaye SB Colonic adenocarcinoma associated ectopic ACTH secretion A case history Eur J Cancer 31A 2109-2112 1995

220 Kaye SB Clinical drug resistance The role of factors other than P-glycoprotein (Pgp) Am J Med 99 (Suppl 6A) 40S-44S 1995

1996

221 Hanauske AR Catimel G Aamdal S ten Bokkel Huinink W Paridaens R Pavlidis N Kaye SB te Velde A Wanders J Verweij J for the EORTC Early Clinical Trials Group Phase II clinical trials with rhizoxin in breast cancer and melanoma Br J Cancer 73 397-399 1996

222 Kaye SB Ovarian cancer from the laboratory to the clinic Challenges for the future Ann Oncol 7 9-13 1996

223 Lopez RJ Paul J Atkinson R Soukop M Kitchener H Fullerton W Duncan I Kennedy J Davis J MacLean A Cassidy J Pyper E and Kaye SB Prognostic factor analysis for patients with no evidence of disease after initial chemotherapy in advanced epithelial ovarian carcinoma Int J Gynaecol Cancer 6 8-14 1996

224 Hughes MJ Kerr DJ Cassidy J Soukop M McGregor K Blackburn N Yosef H and Kaye SB A

pilot study of combination therapy with interferon--2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours Ann Oncol 7 208-210 1996

225 Cullen MH Stenning SP Parkinson MC Fossa SD Kaye SB Horwich AH Harland SJ Williams MV and Jakes R for the Medical Research Council Testicular Tumor Working Party Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis A Medical Research Council Report J Clin Oncol 14 1106-1113 1996

226 Bissett D Harnett AN Canney PA McMurray A Leake R George WD Paul J and Kaye SB Sequential tamoxifen and megestrol acetate with continuous norethisterone in postmenopausal breast cancer a feasibility study The Breast 5 92-95 1996

227 Monfardini S Sorio R Cavalli F Cerny TH Van Glabbeke M Kaye S Smyth JF Pentostatin (2rsquo-deoxycoformycin dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas Phase II study of the EORTC Early Clinical Trials Group Oncology 53 163-168 1996

228 Hollins GW Thomas S Lanigan DJ Dahar N Jodrell D Kaye SB and Kirk D Retroperitoneal surgery its wider role in the management of malignant teratoma Br J Urol 77 571-576 1996

229 Kaye SB Paul J Cassidy J Lewis CR Duncan ID Gordon HK Kitchener HC Cruickshank DJ Atkinson RJ Soukop M Rankin EM Davis JA Reed NS Crawford SM MacLean A Parkin D Sarkar TK Kennedy J and Symonds RP Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer J Clin Oncol 14 2113-2119 1996

230 Bissett D Kaye SB Baxter G and Moss J Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy Clin Oncol 8 247-249 1996

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

24

1997

231 de Wit R Sylvester R Tsitsa C de Mulder PHM Sleyfer DT ten Bokkel Huinink WW Kaye SB van Oosterom AT Boven E Vermeylen K and Stoter G Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than maker half-life a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432-435 1997

232 Senan S Rampling R Graham MA Wilson P Robin H (Jr) Eckardt N Lawson N McDonald A von Roemeling R Workman P and Kaye SB Phase I and pharmacokinetic study to tirapazamine (SR 4233) administered every three weeks Clin Cancer Res 3 31-38 1997

233 Graham MA Senan S Robin H Jr Eckhardt N Lendrem D Hincks J Greenslade D Rampling R Kaye SB von Roemeling R Workman P Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial Cancer Chemother Pharmacol 40 1-10 1997

234 Duchesne GM Stenning SP Aass N Mead GM Fossa SD Oliver RTD Horwich A Read G Roberts IT Rustin G Cullen MH Kaye SB Harland SJ and Cook PA on behalf of the MRC Testicular Tumour Working Party Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role Eur J Cancer 33 829-835 1997

235 Sternberg CN deMulder P Fossa S Kaye SB Roberts T Pawinsky A Daamen S Lobaplatin in advanced urothelial tract tumors Ann Oncol 8 695-696 1997

236 Mead GM Stenning SP Cook P Fossa SD Horwich A Kaye SB Oliver RTD deMulder PHM deWit R Stoter G Sylvester RJ Bajorin DF Bosl GJ Mazumdar M Nichols CR Amato R Pizzocaro G Droz JP Kramar A Daugaard G CortesFunes H PazAres L Levi JA Colls BM Harvey VJ Coppin C International germ cell consensus classification A prognostic factor-erased staging system for metastatic germ cell cancers J Clin Oncol 15 594-603 1997

237 Horwich A Sleijfer DT Fossa SD Kaye SB Oliver RTD Cullen MH Mead GM de Wit R de Mulder PHM Dearnaley DP Cook PA Sylvester RJ and Stenning SP Randomized trial of bleomycinetoposide and cisplatin compared with bleomycin etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer A multiinstitutional MRCEORTC trial J Clin Oncol 15 1844-1852 1997

238 de Wit R Stoter G Kaye SB Sleijfer DT Jones WG ten Bokkel Huinink WW Rea LA Collette L and Sylvester R Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1837-1843 1997

239 Aamdal S Bruntsch U Kerger J Verweij J ten Bokkel Huinink W Wanders J Rastogi R Franklin HR Kaye SB Zeniplatin in advanced malignant melanoma and renal cancer Phase II studies with unexpected nephrotoxocity Cancer Chemother Pharmacol 40 439-443 1997

240 Fossa SD Oliver RTD Stenning SP Horwich A Wilkinson P Read G Mead GM Roberts JT Rustin G Cullen MH Kaye SB Harland SJ and Cook P Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1380-1387 1997

1998

241 Cassidy J Paul J Soukop M Habeshaw T Reed NS Parkin D Kaye SB Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin Cancer Chemother Pharmacol 41 161-166 1998

242 Ganly I Kaye SB Adenoviral therapy for tumours with non-functional p53 Surgery 161 ii-iii 1998

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

25

243 Bruno R Hille D Riva A Vivier N ten Bokkel Huinink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokineticspharmacodynamics (PKPD) of docetaxel in Phase II studies J Clin Oncol 16 187-196 1998

244 Kaye SB Mead GM Fossa S Cullen M de Wit R Bodrogi I van Groeningen C Sylvester R Collette L Stenning S De Prijck L Lallemand E de Mulder P Intensive induction-sequential chemotherapy with BOPVIP-B compared to treatment with BEPEP for lsquopoor prognosisrsquo metastatic non-seminomatous germ cell tumour A randomized MRCEORTC study J Clin Oncol 16 692-701 1998

245 Fossa SD Kaye SB Mead GM Cullen M de Wit R Bodrogi I van Groeningen CJ de Mulder PHM Stenning S Lallemand E de Prijck L Collette L Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy J Clin Oncol 16 716-724 1998

246 Murray LS Jodrell DI Morrison JG Cook A Kerr DJ Whiting B Kaye SB and Cassidy J The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer Preliminary evidence of a potentially common drug interaction Clin Oncol 10 35-38 1998

247 McDonald AC Vasey PA Adams L Waling J Walling J Woodworth JR Abrahams T McCarthy S Bailey NP Siddiqui N Lind MJ Calvert AH Twelves CJ Cassidy J and Kaye SB A phase I and pharmacokinetic study of LY231514 the multitargeted antifolate Clin Cancer Res 4 605-610 1998

248 Soder AI Going JJ Kaye SB and Keith WN Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization Oncogene 16 979-983 1998

249 Kaye SB Drug development for amyotrophic lateral sclerosis lessons from cancer therapy Int J Clin Practice Suppl 93 6-8 1998

250 Kaye SB New antimetabolites in cancer chemotherapy and their clinical impact Br J Cancer 78 (Suppl 3) 1-7 1998

251 Kaye SB Multidrug resistance clinical relevance in solid tumours and strategies for circumvention Current Opin Oncol 10 (suppl 1) S15-S19 1998

252 Simpson AB Paul J Graham J and Kaye SB Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95 A review of patients with germ cell tumours Br J Cancer 78 1061-1066 1998

253 Mackean M Planting A Twelves C Schellens J Allman D Osterwalder B Reigner B Griffin T Kaye SB and Verweij J Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced andor metastatic cancer J Clin Oncol 16 2977-2985 1998

254 Paz-Ares L Kunka R DeMaria D Cassidy J Alden M Beranek P Kaye SB Littlefield D Reilly D Depee S Wissel P Twelves C and ODwyer PJ A Phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Br J Cancer 78 1329-1336 1998

255 de Wit R Collette L Sylvester R de Mulder RHM Sleijfer DT ten Bokkell Huinink WW Kaye SB van Oosterom AT Boven E and Stoter G Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350-1355 1998

256 Advanced Ovarian Cancer Trialists Group Aabo K Adams M Adnitt P et al (57 authors including Kaye SB) Chemotherapy in advanced ovarian cancer four systematic meta-analyses of individual patients data from 37 randomized trials Br J Cancer 78 1479-1487 1998

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

26

1999

257 Ritchie A Griffiths G Parmar M Fossa SD Selby PJ Cornbleet MA Sibley G Mead GM Kaye SB Owen JR Oliver RTD Smith PH Whelan P Cook PA Fayers PM Cook P Webb J Whitehead J and

Lamont A Interferon- and survival in metastatic renal carcinoma early results of a randomised controlled trial Lancet 353 14-17 1999

258 Kaye SB Perspective cancer care and the new biology J Pathol 187 4-7 1999

259 Vasey PA Kaye SB Morrison R Twelves C Wilson P Duncan R Thomson AH Murray LS Hilditch TE Murray T Burtles S Fraier D Frigerio E Cassidy J on behalf of the CRC Phase IIII Committee Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide co-polymer doxorubicin] first member of a new class of chemotherapeutic agents - drug-polymer conjugates Clin Cancer Res 5 83-94 1999

260 Stroner PL Brewster DH Dewar JA Eremin O Gould A Howard GC and Kaye SB In pursuit of excellence for patients with cancer the Scottish Cancer Therapy Network model Br J Cancer 79 1641-1645 1999

261 Kaye SB Eisenhauer EA and Hamilton TC New non-cytotoxic approaches in ovarian cancer Ann Oncol 10 (Suppl 1) S65-S68 1999

262 Hamilton TC Berek JS and Kaye SB Basic research how much do we know and what are we likely to learn about ovarian cancer in the near future Ann Oncol 10 (Suppl 1) S69-S73 1999

263 Piccart MJ Stuart GCE Cassidy J Bertelsen K Parmar MKB Eisenhauer EA Kaye SB Tropeacute C Swenerton K Harper P and Vermorken JB Intergroup collaboration in ovarian cancer a giant step forward Ann Oncol 10 (Suppl 1) S83-S86 1999

264 Berek JS Bertelsen K du Bois A Brady MF Carmichael J Eisenhauer EA Gore M Grenman S Hamilton TC Hansen SW Harper PG Horvath G Kaye SB Luumlck HJ Lund B McGuire WP Neijt JP Ozols RF Parmar MKB Piccart-Gebhart MJ van Rijswijk R Rosenberg P Rustin GJS Sessa C Thigpen JT Tropeacute C Tuxen MK Vergote I Vermorken JB and Willemse PHB Advanced epithelial ovarian cancer 1998 consensus statements Ann Oncol 10 (Suppl 1) S87-S92 1999

265 Evans TRJ and Kaye SB Retinoids present role and future potential Br J Cancer 80 1-8 1999

266 Stevenson JP DeMaria D Sludden J Kaye SB Paz-Ares L Grochow LB McDonald A Selinger K Wissel P OrsquoDwyer PJ and Twelves C Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion Ann Oncol 10 339-344 1999

267 Anthoney DA and Kaye SB Epithelial ovarian cancer Prescribersrsquo J 39 65-71 1999

268 Evans TRJ and Kaye SB Vaccine therapy for cancer - fact or fiction Q J Med 92 299-307 1999

269 Collette L Sylvester RJ Stenning SP Fossa SD Mead GM de Wit R de Mulder PHM Neymark N Lalleman E and Kaye SB Impact of the treating institution on survival of patients with ldquopoor-prognosisrdquo metastatic nonseminoma J Natl Cancer Inst 91 839-846 1999

270 Fossaring SD Stenning SP Gerl A Horwich A Clark PI Wilkinson PM Jones WG Williams MV Oliver RT Newlands ES Mead GM Cullen MH Kaye SB Rustin GJS and Cooke PA Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1392-1399 1999

271 Vasey PA Paul J Birt A Junor EJ Reed NS Symonds RP Atkinson R Graham J Crawford SM Coleman R Thomas H Davis J Eggleton SPH and Kaye SB for the Scottish Gynaecological Cancer Trials Group Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J Clin Oncol 17 2069-2080 1999

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

27

272 Sarvesvaran J Going JJ Milroy R Kaye SB and Keith WN Is small cell lung cancer the perfect target for anti-telomerase treatment Carcinogenesis 20 1649-1651 1999

273 Kaye SB New drug development its role in reversing drug resistance Br J Cancer 80 (Suppl 1) 116-121 1999

274 Kaye SB (on behalf of the Scottish Gynaecological Cancer Trials Group) Progress in the treatment of ovarian cancer Anti-Cancer Drugs 10 (suppl 1) S29-S32 1999

275 OrsquoNeill VJ Evans TRJ Preston J Moss J Kaye SB A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy Acta Oncol 38 1103-1107 1999

2000

276 Ganly I Soutar DS Brown R and Kaye SB p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br J Cancer 82 392-398 2000

277 Mackay HJ Cameron D Rahilly M Mackean MJ Paul J Kaye SB and Brown R Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival J Clin Oncol 18 87-93 2000

278 Kaye SB Intravenous chemotherapy for ovarian cancer - the state of the art Int J Gynecol Cancer 10 (Suppl 1) 19-25 2000

279 Ganly I and Kaye SB Recurrent squamous cell carcinoma of head and neck overview of current therapy Ann Oncol 11 11-16 2000

280 Ganly I Kirn D Eckhardt SG Rodriguez GI Soutar DS Otto R Robertson AG Park O Gulley ML Heise C von Hoff D and Kaye SB A Phase I study of Onyx-015 an E1B attenuated adenovirus administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 798-806 2000

281 Piccart MJ Bertelsen K James K Cassidy J Mangioni C Simonsen E Stuart G Kaye SB Vergote I Blom R Grimshaw R Atkinson RJ Swenerton KD Trope C Nardi M Kaern J Tumolo S Timmers P Roy J-A Lhoas F Lindvall B Bacon M Birt A Anderson JE Zee B Paul J Baron B and Pecorelli S Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results J Natl Cancer Inst 92 699-708 2000

282 de Bono JS Paul J Simpson A Anthoney A Kirk D Underwood M Graham J and Kaye SB Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) Br J Cancer 83 426-430 2000

283 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L Gore M Ironside J MacDougall RRH Heise C Randlev B Gillenwatter AM Bruso P Kaye SB Hong WK and Kirn DH A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nature Med 6 879-885 2000

284 Eatock MM Schaumltzlein A and Kaye SB Tumour vasculature as a target for anti-cancer therapy Cancer Treat Rev 26 191-204 2000

285 Plumb JA Strathdee G Sludden J Kaye SB and Brown R Reversal of drug resistance in human tumour xenografts by 2lsquo-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res 60 6039-6044 2000

286 Gamucci T Paridaens R Heinrich B Schellens JH Pavlidis N Verweij J Sessa C Kaye SB Roelvink M Wanders J and Hanauske A Activity and toxicity of GI147211 in breast colorectal and non-small-cell lung cancer patients An EORTC-ECSG phase II clinical study Ann Oncol 11 793-797 2000

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

28

287 Ganly I Soutar DS and Kaye SB Current role of gene therapy in head and neck cancer Europ J Surg Oncol 26 338-43 2000

288 Nemunaitis J Ganly Khuri F Arseneau J Kuhn J McCarty T Landers S Maples P Romel L Randlev B Reid T Kaye SB and Kirn D Selective replication and oncolysis in p53 mutant tumors with ONYX-015 an E1B-55kD gene-deleted adenovirus in patients with advanced head and neck cancer A phase II trial Cancer Res 60 6359-6366 2000

2001

289 Vasey PA Atkinson R Coleman R Crawford M Cruickshank K Eggleton P Fleming D Graham J Parkin D Paul J Reed NS and Kaye SB Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Br J Cancer 84 170-178 2001

290 Propper DJ McDonald AC Man A Thavasu P Balkwill F Braybrooke JP Caponigro F Graf P Dutreix C Blackie R Kaye SB Ganesan TS Talbot DC Harris AL and Twelves C Phase I and Pharmacokinetic Study of PKC412 an inhibitor of protein kinase C J Clin Oncol 19 1485-1492 2001

291 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Kuhn J McCarty T Landers S Blackburn A Romel L Randlev B Kaye SB and Kim D Phase II trial of intratumoral administration of ONYX-015 a replication-selective adenovirus in patients with refractory head and neck cancer J Clin Oncol 19 289-298 2001

292 Fizazi K Tjulandin S Salvioni R Germa-Lluch JR Bouzy J Ragan D Bokemeyer C Gerl A Flechon A de Bono JS Stenning S Horwich A Pont J Albers P DeGiorgi U Bower M Bulanov A Pizzocaro G Aparicio J Nichols CR Theodore C Hartmann JT Schmoll HJ Kaye SB Culine S Droz J-P and Mahe C Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumours Prognostic factors and role of post surgery chemotherapy-results from an international study group J Clin Oncol 19 2647-5267 2001

293 Kaye SB on behalf of The Scottish Gynaecological Cancer Trials Group The integration of decetaxel into first-line chemotherapy for ovarian cancer Int J Gynecol Cancer 11 31-33 2001

294 Johnston PG and Kaye SB Capecitabine a novel agent for treatment of solid tumours Anti Cancer Drugs 12 639 ndash 646 2001

295 Pentheroudakis G OrsquoNeill VJ Vasey P and Kaye SB Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours Report of 2 cases Supp Care Cancer 9 554 -557 2001

2002

296 Kolomainen D Larkin JM Badran M ArsquoHern R King M Fisher C Bridges J Blake P Barton D Shepherd J Kaye SB and Gore ME Ovarian cancer metastasising to the brain a late manifestation with increasing incidence J Clin Oncol 20 982-986 2002

297 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Kirn DH OrsquoNeill V Siddiqui N Seiden M and Kaye SB Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus Onyx 015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrentrefractory epithelial ovarian cancer J Clin Oncol 20 1562-1569 2002

298 OrsquoNeill V Kaye SB Reed NS Paul J Davis JA and Vasey PA A dose finding study of carboplatin epirubicin and docetaxel in advanced ovarian cancer Br J Cancer 86 1385-1390 2002

299 Schellens JH Heinrich B Lehnert M Gore ME Kaye SB Dombernowsky P and 14 others Population pharmacokinetics and dynamic analysis of the topoisomerase I inhibitor Iurtotecan in Phase II studies Investig New Drugs 20 82-93 2002

300 Baselga J Rischin D Ranson M Calvert AH Raymond E Kieback D Kaye SB Gianni L Harris A Bjork T Feyereislova A Swaisland H Rojo F and Albanelli J Phase I pharmacokinetic and

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

29

pharmacodynamic trial of ZD 1839 a selective EGFR tyrosine kinase inhibitor in patients with 5 selected solid tumour types J Clin Oncol 20 4292-4302 2002

301 Crown J Dieras V Kaufmann M Kaye SB Leonard R Marty M Misset J-L Osterwalder B Piccart M Assessing the medical need for chemotherapy for metastatic breast cancer after failure of anthracyclines and taxanes Lancet Oncology 3 719-726 2002

302 Vasey PA Roche H Bisset D Terret C Vernillet L Riva A Ramazeilles C Azil N Kaye SB and Twelves CJ Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer Br J Cancer 87 1072-1078 2002

2003

303 Pentheroudakis G de Bono J Kaye SB Simpson A Paul J Brown I Pamenter B Kirk A Vasey P Raby N and Kirk D Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumours Brit J Urol 92 36-42 2003

304 Vasey PA McMahon L Paul J Reed N and Kaye SB A phase II trial of capecitabine (Xelodareg) in recurrent ovarian cancer Br J Cancer 89 1843-1848 2003

305 Twelves C Reck M Anthoney A Gatzemeier U and Kaye S A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies Cancer Chemo Pharmacol 52 277-281 2003

306 Baird RD and Kaye SB Drug resistance reversal - are we getting closer Eur J Cancer 39 2450-2461 2003

307 Piccart MJ Bertelsen K Stuart G Cassidy J Mangioni C Simonsen E James K Kaye S Vergote I Blom R Grimshaw R Atkinson R Swenerton K Trope C Nardi M Kaern J Tumolo S Timmers P Roy JA Lhoas F Lidvall B Bacon M Birt A Andersen J Zee B Paul J Pecorelli S Baron B and McGuire W Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int J Gyn Cancer 13 (Suppl2) 144-148 2003

308 LoRusso P Herbst RS Rischin D Ranson M Calvert H Raymond E Kieback D Kaye S Gianni L Harris A Bjork T Maddox AM Rothenberg ML Small EJ Rubin EH Feyereislova A Heyes A Averbuch SD Ochs J and Baselga J Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral EGFR tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumours Clin Cancer Res 9 2040-2048 2003

309 Kolomainen DF ArsquoHern R Coxon FY Fisher C King DM Blake PR Barton DPJ Shepherd H Kaye S and Gore ME Can patients with relapsed previously untreated stage I epithelial ovarian cancer be successfully treated with salvage therapy J Clin Oncol 21 3113-3118 2003

2004

310 Anthoney DA McKean M Roberts J Hutcheon AW Graham J Jones W Paul J and Kaye SB Bleomycin vincristine cisplatinbleomycin etoposide cisplatin chemotherapy an alternating dose intense regimen with promising results in untreated patients with intermediate or poor prognosis malignant germ cell tumours Br J Cancer 90 601-606 2004

311 Hess V ArsquoHern R Nasiri N King DM Blake PR Barton DPJ Shepherd JH Ind T Bridges J Harrington K Kaye SB and Gore ME Mucinous epithelial ovarian cancer A separate entity requiring specific treatment JClin Oncol 22 1040-1044 2004

312 Harries M Moss C Perren T Gore M Hall G Everard M ArsquoHern R Gibbens I Jenkins A Shah R Cole C Pizzada O and Kaye SB Phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 627-632 2004

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

30

313 Morley S MacDonald G Kirn D Kaye S Brown R and Soutar D The dl1520 virus is found preferentially in tumour tissue after direct intratumoral injection in oral carcinoma Clin Cancer Res 10 4357-4362 2004

314 Gifford G Paul J Vasey PA Kaye SB and Brown R on behalf of the Scottish Gynaecological Clinical Trials Group The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420-4426 2004

315 Vasey P A Jayson G C Gordon A Gabra H Coleman R Atkinson R Parkin D Paul J Hay A and Kaye S B Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer J Natl Cancer Inst 96 1682-1691 2004

316 de Jonge MJA Kaye S Verweij J Brock C Reade S Scurr M van Doorn L Verheij C Loos W Brindley C Mistry P Cooper M and Judson I Phase I and pharmacokinetic study of XR11576 an oral topoisomerase I and II inhibitor administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours Br J Cancer 91 1459-1465 2004

317 Harries M OrsquoDonnell A Scurr M Reade S Cole C Judson I Greystoke A Twelves C and Kaye SB Phase III study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours Br J Cancer 91 1651-1655 2004

2005

318 Kaye SB Management of platinum-sensitive relapsed ovarian cancer with particular reference to the international collaboration in Ovarian Neoplasm-4Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2-2 trial Int J Gynecol Cancer 15 (suppl 3) 1-5 2005

319 Dark GG Calvert AH Grimshaw R Poole C Swenerton K Kaye S Coleman R Jayson G Le T Ellard S Trudeau M Vasey P Hamilton M Cameron T Barrett E Walsh W McIntosh L and Eisenhauer EA Ranodmized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurbotecan in women with relapsed epithelial ovarian cancer A trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 23 1859-1866 2005

320 Dearnaley DP Fossa SD Kaye SB Cullen MH Harland SJ Sokal MP Graham JD Roberts JT Mead GM Williams MV Cook PA and Stenning SP Adjuvant bleomycin vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours a prospective trial (MCR TE17) Br J Cancer 92 2107-2113 2005

321 Banerji U OrsquoDonnell A Scurr M Pacey S Stapleton S Asad Y Simmons L Maloney A Raynaud F Campbell M Walton M Lakhani S Kaye S Workman P and Judson I Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxy-geldanamycin in patients with advanced malignancies J Clin Oncol 23 4152-4161 2005

322 Crawford SC Vasey PA Paul J Hay A Davis JA and Kaye SB on behalf of the Scottish Gynaecological Cancer Trials Group Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 trial J Clin Oncol 23 8802-8811 2005

2006

323 Reed NS Poole CJ Coleman R Parkin D Graham JD Kaye SB Ostrowski J Duncan I Paul J and Hay A A randomised comparison of Treosulfan and Carboplatin in patients with ovarian cancer not suitable for treatment with gt75 mgm2 cisplatin A study by the Scottish Gynaecological Cancer Trials Group (SGCTG) Eur J Cancer 42 179-185 2006

324 Vasey PA Atkinson R Osborne R Parkin D Symonds R Paul J Lewsley L Coleman R Reed NS Kaye S and Rustin GJS SCOTROC 2A carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 62-68 2006

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

31

325 Rothermundt C Hubner R Ahmad T Gibbens I Keyzor C Habeshaw T Kaye S and Gore M Combination chemotherapy with carboplatin capecitabine and Epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer a Phase III trial Br J Cancer 94 74-78 2006

326 Lee CP de Jonge MJA OrsquoDonnell AE Schothorst KL Hanwell J Chick JB Brooimans RA Adams LM Drolet DW de Bono JS Kaye SB Judson IR and Verweij J A Phase I study of a new nucleoside analogue OSI-7836 using two administration schedules in patients with advanced solid malignancy Clin Cancer Res 12 2841-2848 2006

327 Ratain MJ Eisen T Stadler WM Flaherty KT Kaye SB Rosner GL Gore M Seai AA Patnaik A Xiong HQ Rowinsky E Abbruzzese JL Xia C Simantov R Schwartz B and OrsquoDwyer PJ Phase II placebo-controlled randomized discontinuation trials of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505-2512 2006

328 Sain N Krishnan B Ormerod MG De Rienzo A Liu W Kaye SB Workman P and Jackman A Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol Cancer Ther 5 1197-1208 2006

329 Eisen T Ahmad T Flaherty KT Gore M Kaye S Marais R Gibbens I Hackett S James M Schuchter LM Nathanson KL Xia C Simantov R Schwartz B Poulin-Costello M OrsquoDwyer PJ and Ratain MJ Sorafenib in advanced melanoma a Phase II randomized discontinuation trial analysis Br J Cancer 95 581-586 2006

2007

330 Benson C White J de Bono J OrsquoDonnell A Raynaud F Cruickshank C McGrath H Walton M Workman P Kaye S Gianella-Borradori A Judson I Twelves CA Phase I trial of the selective oral cyclin-dependent kinase inhibitor celiciclib (CYC202 R-Roscovitine) administered twice daily for 7 days every 21 days Clin Cancer Res 96 29-37 2007

331 Legge F Eaton D Molife R Judson I de Bono J Ferrandina A and Kaye SB Participation of patients with gynaecological cancer in Phase I clinical trials two years experience in a major cancer centre Gynaecol Oncol 104 551-556 2007

332 England RA deSouza NM and Kaye SB Gliomatosis peritonei MRI appearances and its potential role in follow up Br J Radiol 80 e101-e104 2007

333 Forster M Kaye S Oza A Sklenar I Johri A Zaknoen S and Gore M A Phase Ib and pharmacokinetic trial of Patupilone (EPO906) combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 4178-4184 2007

334 Martin L-A Head JE Pancholi S Salter J Quinn E Detre S Kaye S Howes A Dowsett M and Johnston SRD The farnesyltransferase inhbitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol Cancer Ther 6 2458-2467 2007

335 Harrison ML Gore ME Spriggs D Kaye S Iasanos A Hensley M Aghajanian C and Sabbatini P Duration of second or greater complete clinical remission in ovarian cancer defining a patient cohort for clinical trials Gynaecol Oncol 106 469-475 2007

336 Forster MD Ormerod MG Agarwal R Kaye SB and Jackman AL Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells Cytometry A 71 945-950 2007

337 Plummer R Attard G Pacey S Li L Razak A Perrett R Barrett M Judson I Kaye S Fox NL Halpern W Corey A Calvert H and de Bono J Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer Clin Cancer Res 13 6187-6194 2007

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

32

338 Appleton K Mackay HJ Judson I Plumb JA McCormick C Strathdee G Lee C Barrett S Reade S Jadayel D Tang A Bellenger K Mackay L Setanoians A Schaumltzlein A Twelves C Kaye SB and Brown R Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumours J Clin Oncol 25 4603-4609 2007

339 de Wit R Sleijfer S Kaye SB Horwich A Mead B Sleijfer DT and Stoter G Bleomycin and scuba diving decades of concerns on land but no evidence of harm below the surface Lancet Oncology 8 954-955 2007

340 Krasner CN McMeekin DS Chan S Braly PS Renshaw FG Kaye S Provencher DM Campos A and Gore ME A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 1618-1624 2007

341 Witham J Valenti MR De-Haven-Brandon AK Vidot S Eccles SA Kaye SB and Richardson A The Bcl-2Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin Cancer Res 13 7191-7198 2007

2008

342 Barrett SV Paul J Hay A Vasey PA Kaye SB and Glasspool RM on behalf of the Scottish Gynaecological Cancer Trials Group Does body mass index affect progression-free or overall survival in patients with ovarian cancer Results from SCOTROC 1 trial Ann Oncol 19 898-902 2008

343 Linch M Stavridi F Hook J Barbachano Y Gore M and Kaye SB Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 27-32 2008

344 Witham J Vidot S Kaye SB and Richardson A Transient ectopic expression as a method to detect genes conferring drug resistancerdquo Int J Cancer 122 2641-2645 2008

345 Arkenau H-T Olmos D Ang J-E de Bono J Judson I and Kaye S Clinical outcome and prognostic factors for patients treated within the context of a Phase I study The Royal Marsden Hospital experience Br J Cancer 98 1029-1033 2008

346 Karavasilis V Digue L Arkenau T Eaton D Stapleton S de Bono J Judson I and Kaye S Identification of factors limiting patient recruitment into Phase I trials A study from the Royal Marsden Hospital Eur J Cancer 44 978-982 2008

347 Bishara S Griffin M Cargill A Bali A Gore ME Kaye SB Shepherd JH and Van Trappen PO Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer Eur J Obstet Gynaecol Reprod Biol 138 71-75 2008

348 Vasey PA Gore M Wilson R Rustin G Gabra H Guastalla J-P Pujade-Lauraine E Paul J Carty K and Kaye S on behalf of the Scottish Gynaecological Cancer Trials Group A Phase Ib trial of docetaxel carboplatin and erlotinib in ovarian fallopian tube and primary peritoneal cancers Br J Cancer 98 1774-1780 2008

349 Arkenau H-T Olmos D Ang J-E Barriuso J Karavasilis V Ashley S de Bono J Judson I and Kaye S 90 days mortality rate in patients treated in phase-I trials how should we identify patients who should not be treated Eur J Cancer 44 1536-1540 2008

350 Attard G Reid AHM Yap TA Raynaud F Dowsett M Settatree S Barrett M Parker C Martins V Folkerd E Clark J Cooper CS Kaye SB Dearnaley D Lee G and de Bono J Castration-resistant prostate cancer commonly remains hormone driven evidence from a Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate J Clin Oncol 26 4563-4571 2008

351 de Bono J Kristeleit R Tolcher A Fong P Pacey S Karavasilis V Shaw H Workman P Kaye S Rowinsky E Aherne W Atadja P Scott JW and Patnaik A Phase I pharmacokinetic and

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

33

pharmacodynamic study of LAQ824 a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile I patients with advanced solid tumours Clin Cancer Res 14 6663-6673 2008

352 Tan DSP Rothermundt C Thomas K Bancroft E Eeles R Shanley S Ardern-Jones A Norman A Kaye SB and Gore M The ldquoBRCAnessrdquo syndrome in ovarian cancer a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 12 mutations J Clin Oncol 26 5530-5536 2008

2009

353 Arkenau HT Brunetto AT Barriuso J Olmos D Eaton D de Bono J Judson I and Kaye S Clinical benefit of new targeted agents in Phase I trials in patients with advanced colorectal cancer Oncology 76 151-156 2009

354 Attard G Swennenhuis JF Olmos D Reid AH Vickers E Arsquohern R Levink R Coumans F Moreira J Riisnaes R Oommen NB Hawche G Jameson C Thompson E Sipkema R Carden CP Parker C Dearnaley D Kaye SB Cooper CS Molina A Cox ME Terstappen LW and de Bono JS Characterization of ERG AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2912-2918 2009

355 Arkenau H-T Barriuso J Olmos D Ang J-E de Bono J Judson IR and Kaye SB Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2692-2698 2009

356 Tan DSP Lambros MBK Rayter S Natrajan R Varcheva R Gao A Marchio C Geyer F Savage K Parry S Fenwich K Tamber N Mackay A Dexter T Jameson C McCluggage WG Williams A Graham A Faratian D El-Bahrawy M Paige AJ Gabra H Gore ME Zvelebil M Lord C Kaye SB Ashworth A and Reis-Filho JS PPM1D emerges as a potential therapeutic target in ovarian clear cell carcinomas Clin Cancer Res 15 2269-2280 2009

357 Postel-Vinay S Arkenau H-T Olmos D Ang J Barriuso J Ashley S Banerji U de Bono J Judson I and Kaye S Clinical benefit in Phase-I trials of novel molecularly targeted agents does dose matter Br J Cancer 100 1373-1378 2009

358 Attard G Reid AHM ArsquoHern R Parker C Folkerd E Oomen NB Messiou C Molife LR Meier G Thompson E Olmos D Sinha R Lee G Dowsett M Kaye SB Dearnaley D Kheoh T and Molina A Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 3742-3748 2009

359 Baird RD Kitzen J Clarke PA Planting A Reade S Reid A Welsh L Laacutezaro LL de las Heras B Judson IR Kaye SB Eskens F Workman P de Bono JS and Verweij J Phase I safety pharmacokinetic and pharmacogenomic trial of ES-285 a novel marine cytotoxic agent administered to adult patients with advanced solid tumours Mol Cancer Therapeutics 8 1430-1437 2009

360 Ang JE Shah RN Everard M Keyzor C Coombes I Jenkins A Thomas K ArsquoHern R Jones RL Blake P Gabra H Hall G Gore ME and Kaye SB A feasibility study of sequential doublet chemotherapy comprising carboplatin doxorubicin and carboplatinpaclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma Ann Oncol 20 1787-1793 2009

361 ten Bokkel Huinink W Sufliarsky J Smit W Spanik S Wagnerova M Hirte H Kaye S Johri A and Oza A Safety and efficacy of patupilone in patients with advanced ovarian primary fallopian or primary peritoneal cancer a Phase I open-label dose-escalation study J Clin Oncol 27 3097-3103 2009

362 Fong PC Boss DS Yap TA Tutt A Wu P Mergui-Roelvink M Mortimer P Swaisland H Lau A OrsquoConnor MJ Ashworth A Carmichael J Kaye SB Schellens JHM and de Bono JS Tumor synthetic lethality by targeting PARP in BRCA mutation carriers N Engl J Med 361 123-134 2009

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

34

363 Vergote I Finkler N Del Campo J Lohr A Hunter J Matei D Kavanagh J Vermorken JB Meng L Jones M Brown G and Kaye S The ASSIST-1 Study Group Phase 3 randomized study of canfosfamide (Telcytareg TLK 286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer Eur J Cancer 45 2324-2332 2009

364 Pacey S Ratain MJ Flaherty KT Kaye SB Cupit L Rowinsky EK Xia C OrsquoDwyer PJ and Judson IR Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Invest New Drug epub ahead of print 18 December 2009

2010

365 Carden CP Sarker D Postel-Vinay S Yap TA Attard G Banerji U Garrett MD Thomas GV Workman P Kaye SB and de Bono JS Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development Drug Discov Today 15 88-97 2010

366 Vidot S Witham J Agarwal R Greenhough S Bamrah HS Tigyi GJ Kaye SB and Richardson A Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells Cell Signal 22 926-935 2010

367 Banerji U Camidge DR Verheul HM Agarwal R Sarker D Kaye SB Desar IM Timmer-Bonte JN Eckhardt SG Lewis KD Brown KH Cantarini MV Morris C George SM Smith PD and van Herpen CM The first-in-human study of the hydrogen sulfate (hyd-sulfate) capsule of the MED12 inhibitor AZD6244 (ARRY-142886) A phase I open-label multicentre trial in patients with advanced cancer Clin Cancer Res 16 1613-1623 2010

368 Fong PC Yap TA Boss D Carden CP Mergui-Roelvink M Gourley C De Greve J Lubinski J Shanley S Messiou C ArsquoHern R Tutt A Ashwroth A Stone J Carmichael J Schellens JHM de Bono J and Kaye S Poly(ADP)-ribose polymerase (PARP) inhibition Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2512-2519 2010

369 Gourley C Michie CO Roxburgh P Yap TA Harden S Paul J Ragupathy K Todd R Petty R Reed N Hayward RL Mitchell P Rye T Schellens JHM Lubinski J Carmichael J Kaye SB Macklean M and Ferguson M Increased incidence of visceral metastases in Scottish patients with BRCA12-defective ovarian cancer an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2505-2511 2010

370 Han LY Karavasilis V van Hagen T Nicum S Thomas K Harrison M Papadopoulos P Blake P Barton DP Gore M and Kaye SB Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy Eur J Cancer 46 1359-1364 2010

371 Agarwal R Gourley C Perren TJ Reed N Parkin DE Carty K Rustin GJ Gabra H Paul J Gore ME Kaye SB on behalf of the Scottish Gynecological Cancers Trials Group First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5) A feasibility study and comparative analysis of the SCOTROC series Eur J Cancer 46 2020-2026 2010

372 Monk BJ Herzog TJ Kaye S Krasner CN Vermorken JB Muggia F Pujade-Lauraine E Lisyanskaya AS Makhson AN Rolski J Gorbounova VA Ghatage P Bidzinski M Shen K Ngan HY-S Vergote I Nam J-H Park YC Lebedinsky C and Poveda A Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107-3114 2010

373 Brunetto AT Sarker D Papadatos-Pastos D Fehrmann R Kaye SB Johnston S Allen M de Bono JS and Swanton C A retrospective analysis of clinical outcome of patients with chemo-

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

35

refractory metastatic breast cancer treated in a single institution phase I unit Br J Cancer 10 607-612 2010

374 Brunetto AT Ang JE Olmos D Tan D Barriuso J Arkenau HT Yap TA Molife LR Banerji U de Bono J Judson I and Kaye S A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit unplanned admissions as an early indicator of patient attrition Eur J Cancer 46 2739-2745 2010

375 Bolton KL Tyrer J Song H Ramus SJ Notaridou M Jones C Sher T Gentry-Maharaj A Wozniak E Tsai YY Weidhaas J Paik D Van Den Berg DJ Stram DO Pearce CL Wu AH Brewster W Anton-Culver H Ziogas A Narod SA Levine DA Kaye SB Brown R Paul J Flanagan J Sieh W McGuire V Whittemore AS Campbell I Gore ME Lissowska J Yang HP Medrek K Gronwald J Lubinski J Jakubowska A Le ND Cook LS Kelemen LE Brook-Wilson A Massuger LF Kiemeney LA Aben KK van Altena AM Houlston R Tomlinson I Palmieri RT Moorman PG Schildkraut J Iversen ES Phelan C Vierkant RA Cunningham JM Goode EL Fridley BL Kruger-Kjaer S Blaeker J Hogdall E Hogdall C Gross J Karlan BY Ness RB Edwards RP Odunsi K Moyisch KB Baker JA Modugno F Heikkinenen T Butzow R Nevanlinna H Leminen A Bogdanova N Antonenkova N Doerk T Hillemanns P Duumlrst M Runnebaum I Thompson PJ Carney ME Goodman MT Lurie G Wang-Gohrke S Hein R Chang-Claude J Rossing MA Cushing-Haugen KL Doherty J Chen C Rafnar T Besenbacher S Sulem P Stefansson K Birrer MJ Terry KL Hernandez D Cramer DW Vergote I Amant F Lambrechts D Despierre E Fasching PA Beckmann MW Thiel FC Ekici AB Chen X the Australian Ovarian Cancer Study Group the Australian Cancer Study (Ovarian Cancer) on behalf of the Ovarian Cancer Association Consortium Johnatty SE Webb PM Beesley J Chanock S Garcia-Closas M Sellers T Easton DF Berchuck A Chenevix-Trench G Pharoah PD Gayther SA Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 880-884 2010

376 Jones RL Olmos D Thway K Fisher C Tunariu N Postel-Vinay S Scurr M de Bono J Kaye S and Judson I Clinical benefit of Phase I participation for advanced sarcoma patients Cancer Chemother Pharmacol epub ahead of print 11 November 2010

377 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy correlation of apparent diffusion coefficients with epithelial and stromal densities on histology Cancer Biomarkers 7 201-210 2010

2011

378 Poveda A Vergote I Tjulandin S Kong B Roy M Chan S Filipzyk-Cisarz E Hagberg H Kaye SB Colombo N Lebendinsky C Parekh T Gomez J Park YC Alfaro V and Monk BJ Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomzed trial Ann Oncol 22 39-48 2011

379 Kaye SB Colombo N Monk BJ Tjulandin S Kong B Roy M Chan S Filipczyk-Cisarz E Hagberg H Vergote I Lebedinsky C Parekh T Santabarbara P Park YC Nieto A and Poveda A Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Ann Oncol 22 49-58 2011

380 Rizzo S Hersey JM Mellor P Dai W Santos-Silva A Liber D Luk L Titley I Carden CP Box G Hudson DL Kaye SB and Brown R Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 Mol Cancer Ther 10 325-335 2011

381 Yap TA Olmos D Brunetto AT Tunariu N Barriuso J Riisnaes R Pope L Clark J Futreal A Germuska M Collins D deSouza NM Leach MO Savage RE Waghone C Chai F

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

36

Garney E Schwartz B Kaye SB and de Bono JS Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 1271-1279 2011

382 Postel-Vinay S Gomez-Roca C Molife LR Anghan B Levy A Judson I de Bono J Soria J-C Kaye SB and Paoletti X Phase I trials of molecularly targeted agents should we pay more attention to late toxicities J Clin Oncol 291728-1735 2011

383 Rustin G Reed N Jayson GC Ledermann JA Adams M Perren T Poole C Lind M Persic M Essapen S Gore M Calvert H Stredder C Wagner A Giurescu M and Kaye SB A phase II trial evaluating two schedules of Sagopilone (ZK-EPO) a novel epothilone in patients with platinum-resistant ovarian cancer Ann Oncol 22 2411-2416

384 Pharoah PD Palmieri RT Ramus SJ Gayther SA Andrulis IL Anton-Culver HA Antonenkova N Antoniou AC Bcfr Investigators SG Beattie MS Beckmann M Birrer MJ Bogdanova N Bolton KL Brewster W Brooks-Wilson A Brown R Buumltzow R Caldes T Caligo MA Campbell IG Chang-Claude J Chen A Chenevix-Trench G Cook LS Couch FJ Cramer DW Cunningham JM Despierre E Doherty JA Dork T Durst M Eccles D Ekici AB Embrace Investigators SG Fasching PA de Fazio A Fenstermacher DA Flanagan JM Fridley BL Friedman E Gao B Gemo Study Collaborators SG Gentry-Maharaj A Godwin AK Goode E Goodman MT Gross J Hansen TV Harnett PR Hebon Investigators SG Heikkinen T Hein R Hogdall CK Hogdall EV Iversen E Jakubowska A Johnatty SE Karlan BY Kauff ND Kaye SB KconFab Investigators SG Kelemen LE Kiemeney LA Kjaer SK Lambrechts D Lapolla JP Lazaro C Le ND Leminen A Leunen K Levine DA Lu Y Lundvall L Macgregor S Marees T Massuger L McLaughlin JR Menon U Montagna M Moysich KB Narod S Nathanson KL Nedergaard L Ness RB Nevanlinna HA Nickels S Osorio A Paul J Pearce CL Phelan CM Pike MC Radice P Rossing MA Schildkraut J Sellers TA Singer CF Song H Stram DO Sutphen R Swe-Brca Investigators SG Terry KL Tsai YY van Altena AM Vergote I Vierkant RA Vitonis AF Walsh C Wang-Gohrke S Wappenschmidt B Wu AH Ziogas A Berchuck A and Risch HA The role of KRAS rs61764370 in invasive epithelial ovarian cancer implications for clinical testing Clin Cancer Res 17 3742-3750 2011

385 Tan DSP Iravani M McCluggage WG Lambros MBK Milanezi F Mackay A Gourley C Geyer FC Vatcheva R Millar J Thomas K Natrajan R Savage K Fenwick K Williams A Jameson C El-Bahrawy M Gore ME Gabra H Kaye SB Ashworth A and Reis-Filho JS Genomic analysis revewals the molecular heterogeneity of ovarian clear cell carcinomas Clin Cancer Res 17 1521-1534 2011

386 Olmos D Baird RD Yap TA Massard C Pope L Sandhu SK Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in Phase I oncology trials Clin Cancer Res 17 5188-5196 2011

387 Rudman SM Josephs DH Cambrook H Karagiannis P Gilbert AE Dodev T Hunt J Koers A Montes A Taams L Canevari S Figini M Blower PJ Beavil AJ Nicodemus CF Corrigan C Kaye SB Nestle FO Gould HJ Spicer JF and Karagiannis SN Harnessing engineered antibodies of the IgE class to combat malignancy initial assessment of FcεRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity Clin Exp Allergy 41 1400-1413 2011

388 Ledermann JA Hackshaw A Kaye SB Jayson GC Gabra H McNeish I Earl H Perren T Gore M Persic M Adams M James L Temple G Merger M and Rustin G A randomized phase II

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

37

placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhbitor BIBF 1120 following chemotherapy for relapsed ovarian cancer J Clin Oncol 29 3798-3804 2011

389 Ledermann JA Martin C Carey MS Birrer M Bowtell DD Kaye SB McNeish I Oza A Scambia G Rustin G Stehman FB Gershenson D Thomas G Berns E Casado A Ottevanger N Hilpert F Kim BG Okamoto A Bacon M Mitchener H Stuart GC and on behalf of the Gynecological Cancer InterGroup Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer Int J Gynecol Cancer 21 763-770 2011

390 Suwaki N Vanhecke E Atkins KM Graf M Swabey K Huang P Schraml P Moch H Cassidy A Brewer D Al-Lazikani B Workman P de Bono J Kaye SB Larkin J Gore ME Sawyers CL Nelson P Beer TM Geng H Gao L Quian DZ Alumkal JJ Thomas G and Thomas GV A HIF-regulated VHL-PTP1B-Src signalling axis identifies a therapeutic target in renal cell carcinoma Sci Transl Med 3 85ra47 2011

391 Amankwah EK Wang Q Schildkraut JM Tsai YY Ramus SJ Fridley BL Beesley J Johnatty SE Webb PM Chenevix-Trench G Australian Ovarian Cancer Study Group Dale LC Lambrechts D Amant F Despierre E Vergote I Gayther SA Gentry-Maharaj A Menon U Chang-Claude J Wang-Gohrke S Anton-Culver H Ziogas A Doumlrk T Duumlrst M Antonenkova N Bogdanova N Brown R Flanagan JM Kaye SB Paul J Buumltzow R Nevanlinna H Campbell I Eccles DM Karlan BY Gross J Walsh C Pharoah PD Song H Kruumlger Kjaeligr S Hoslashgdall E Hoslashgdall C Lundvall L Nedergaard L Kiemeney LA Massuger LF van Altena AM Vermeulen SH Le ND Brooks-Wilson A Cook LS Phelan CM Cunningham JM Vachon CM Vierkant RA Iversen ES Berchuck A Goode EL Sellers TA Kelemen LE Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer a report from the ovarian cancer association consortium PLoS One 6 e19642 epub 27 May 2011

392 Poveda A Kaye SB McCormack R Wang S Parekh T Ricci D Lebedinsky CA Tercero JC Zintl P and Monk BJ Circulating tumor cells predict progression free survival and overall survival in patients with relapsedrecurrent advanced ovarian cancer Gynecol Oncol 122 567-572 2012

393 Kyriazi S Nye E Stamp G Collins DJ Kaye SB and deSouza NM Assessing chemotherapy response of metastatic ovarian and primary peritoneal cancer with diffusion-weighted magnetic resonance imaging value of histogram analysis of apparent diffusion coefficients Radiology 261 1 182-192 2011

394 Brunetto A Olmos D Arkenau HT Tan D Yap T de Bono J Barriuso J and Kaye SB Perceptions and referral trends into Phase I oncology trials results of a clinical survey J Oncol epub 27 June 2011 861401

395 Papadatos-Pastos D Dedes KJ de Bono JS and Kaye SB Revisiting the role of anti-oestrogen strategies in ovarian cancer The Oncologist 16 1413-1421 2011

2012

396 Vitfell-Pedersen J Yap TA Moreno V Baird RD Papadatos-Pastos D Tunariu N Khan AZ Barton DPJ de Bono J and Kaye SB The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials European Journal of Gynaecological Oncology 33 2 211-213 2012

397 Kaye SB Lubinski J Matulonis U Ang JE Gourley C Karlan B Amnon A Bell-McGuinn KM Chen L-M Friedlander M Safra T Vergote I Wickens M Lowe ES Carmichael J and Kaufman

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

38

B A Phase II open-label randomized multicentre study to compare the efficacy and safety of olaparib a poly(ADP-ribose) polymerase (PARP) inhibitor and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of Clinical Oncology 30 4 372-379 2012

398 Vidal L Magem M Barlow C Pardo B Florez A Montes A Garcia M Judson I Lebedinsky C Kaye SB Salazar R Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors Investigational New Drugs 30 2 616-628 2012

399 Olmos D ArsquoHern R Marsoni S Tabernero J Gomez-Roca C Verweij J Voest EE Schoffski P Ang J-E Penel N Schellens JH del Conte G Brunetto AT Evans J Wilson R Gallerani E Plummer R Morales R Soria J-C Kaye SB on behalf of the European Drug Development Network (EDDN) Patient selection for oncology Phase I trials ndash a multi-institutional study of prognostic factors Journal of Clinical Oncology 30 996-1004 2012

400 Kolomainen DF Daponte A Barton DP Pennert K Ind TE Bridges JE Shepherd JH Gore ME Kaye SB and Riley J Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC) Gynaecology Oncology 125 31-36 2012

401 Molife LR Alam S Olmos D Puglisi M Shah K Fehrmann R Trani L Tjokrowidjaja A de Bono JS Banerji U and Kaye SB Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents a single centre experience Annals of Oncology 23 1968-1973 2012

402 Olmos D Baird RD Yap T Massard C Pope L Sandhu S Attard G Dukes J Papadatos-Pastos D Grainger P Kaye SB and de Bono JS Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials Clinical Cancer Research 17 15 5188-5196 2012

403 Naing A Aghajanian C Raymond E Olmos D Schwartz G Oelmann E Grinsted L Burke W Taylor R

Kaye SB Kurzrock R and Banerji U Safety tolerability pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma BJC 107 1093-1099 2012

404 Ploquin A Olmos D Lacombe D Hern RA Duhamel ATwelves C Marsoni S Morales-Barrera R Soria

JC Verweij J Voest EE Schoffski P Schellens JH Kramar A Kristeleit RS Arkenau HT Kaye SB and Penel N Prediction of early death among patients enrolled in phase I trials development and validation of a new model based on platelet count and albumin BJC 107 1025-1030 2012

405 Basu B Vitfell-Pedersen Moreno-Garcia V Puglisi M Tjokrowidjaja A Shah K Malvankar S Anghan B

de Bono JS Kaye SB Molife LR and Banerji U Creatinine clearance is associated with toxicity from molecularly tarteted agents in Phase 1 trials Oncology 83 177-182 2012

406 Perkins G Yap TA Pope L Cassidy AM Dukes JP Riisnaes R Masssard C Cassier PA Miranda S Clark J Denhom KA Thway K Gonzales De Castro D Attard G Molife LR Kaye SB Banerji U de Bono JS Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 20127 (11) 2012

407 Moreno Carcia V Thavasu P Blanco Codesido M Molife LR Vitfell Pedersen J Puglisi M Basu B Shah K Iqbal J de Bono JS Kaye SB Banerji U Association of creatinine kinase and kin toxicity in phase I trials of anticancer agents Br J Cancer 107 1797-1800 2012

408 Banerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line

39

chemotherapy for advanced ovarian cancer an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG Annals of Oncology 24 679-687 2012

409 Kaye SB Fehrenbacher L Holloway R Amit A Karlan B Slomovitz B Sabbatini P Fu L Yauch RL Chang I Reddy JC A Phase II Randomized Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission Clinical Cancer Research 18 6509-6518 2012

410 Ang JE Kaye SB Banerji U Tissue-based approaches to study pharmacodynamic endpoints in early

phase oncology clinical trials Current Drug Targets 13 1525-1534 2012

411 Messiou C Orton M Ang JE Collins DJ Morgan VA Mears D Castellano I Papadatos-Pastos D Brunetto A Tunariu N Mann H Tessier J Young H Ghiorghiu D Marley S Kaye SB Debono JS Leach MO Desouza NM Advanced Solid Tumors Treated with Cediranib Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity Radiology 265 (2)426-36 2012

412 Krasner CN Poveda A Herzog TJ Vermorken JB Kaye SB Nieto A Claret PL Park YC Parekh T Monk BJ Patient-reported outcomes in relapsed ovarian cancer results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone Gynecol Oncol 127 (1)161-7 2012

413 Carden CP Stewart A Thavasu P Kipps E Pope L Crespo M Miranda S Attard G Garrett MD Clarke PA Workman P de Bono JS Gore M Kaye SB Banerji U The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer Mol Cancer Ther 11 (7)1609-17 2012

414 Monk BJ Herzog TJ Kaye SB Krasner CN Vermorken JB Muggia FM Pujade-Lauraine E Park YC Parekh TV Poveda AM Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer Overall survival analysisEur J Cancer 48 (15)2361-8 2012

415 Kaye SB Aamdal S Jones R Freyer G Pujade-Lauraine E de Vries EG Barriuso J Sandhu S Tan DS Hartog V Kuenen B Ruijter R Kristensen GB Nyakas M Barrett S Burke W Pietersma D Stuart M Emeribe U Boven E Phase I study of saracatinib (AZD0530) in combination with paclitaxel andor carboplatin in patients with solid tumours British Journal of Cancer 106 (11)1728-34 2012

421 Tunariu N Kaye SB Desouza NM Functional imaging what evidence is there for its utility in clinical trials of targeted therapies British Journal of Cancer 106(4)619-28 2012

2013

422 Bannerjee S Rustin G Paul J Williams C Pledge S Gabra H Skailes G Lamont A Hindley A Goss G Gilby E Hogg M Harper P Kipps E Lewsley LA Hall M Vasey P Kaye SB A multicenter randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG Annals of Oncology 0 1ndash8 2013

423 Kaye SB Poole CJ Dariska-BidzinskaA Gianni L Del Conte G Gorbunova V Novikova E Strauss A Moczko M Mc Nally VA Ross G amp Vergote I A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed platinum-sensitive ovarian cancer Annals of Oncology 24 145-152 2013

424 Yap TA Arkenau HT Camidge DR George S Serkova NJ Gwyther SJ Spratlin JL Lal R Spicer J Desouza NM Leach MO Chick J Poondru S Boinpally R Gedrich R Brock K Stephens A Eckhardt

40

SG Kaye SB Demetri G Scurr M First-in-human phase I trial of two schedules of OSI-930 a novel multikinase inhibitor incorporating translational proof-of-mechanism studies Clinical Cancer Research 19 (4) 909-919 2013

425 Tan D Yap T Hutka M Roxburgh P Ang J Banerjee S Grzybowska E Gourley C Gore M Kaye SB Implications of BRCA1 and BRCA 2 mutations for the efficacy of paclitaxel monitherapy in advanced ovarian cancer European Journal of Cancer 49 1246-1253 2013

426 del Campo M Sessa C Krasner C Vermorken H Colombo N Kaye SB Gore M Zintl P Gomez J Parekh T Park Y McMeekin S Trabectedin as single agent in relapsed advanced ovarian cancer results from a retrospective pooled analysis of three phase II trials Medical Oncology 30 1357-1380 2013

427 Sandhu S Omlin A Hylands L Miranda S Barber LJ Riisnaes R Reid AH Attard G Chen L Kozarewa I Gevensleben H Campbell J Fenwick K Assiotis I Olmos D Yap TA Fong P Tunariu N Koh D Molife R Kaye SB Lord CJ Ashworth A de Bono J PARP inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer Annals of Oncology 24 1416-1418 2013

428 Ang JE Gourley C Bethan Powell C High H Shapira-Frommer R Castonguay V De Greve J Atkinson T Yap TA Sandhu S Banerjee S Chen LM Friedlander M Kaufman B Oza AM Matulonis U Barber LJ Kozarewa I Fenwick K Assiotis I Campbell J Chen L de Bono JS Gore ME Lord CJ Ashworth A and Kaye SB Efficacy of Chemotherapy in BRCA12 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance A Multi-Institutional Study Clinical Cancer Research 19 5485-5493 2013

429 Sandhu S Schelman W Wilding G Moreno V Baird R Miranda S Hylands L Riisnaes R Forster M

Omlin A Kreischer N Thway K Gevensleben H Sun L Loughney J Chatterjee M Toniatti C Carpenter C Iannone R Kaye SB de Bono J Wenham R The PARP inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer a phase 1 dose-escalation trial Lancet Oncology 14 882-892 2013

430 Barber l Sandhu S Che L Campbell J Kozarewa I Fenwick K ASsiotis I Rodrigues D Reis J Moreno

V Mateo J Molife R de Bono J Kaye SB Lord C Ashworth A Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor Journal of Pathology 229 22-429 2013

431 White KL Vierkant RA Fogarty ZC Charbonneau B Block BS Pharoe PDP Chenevix-Trench G Rossing MA Cramer DW Pearce CL Schildkraut JM Menon U Kjaer SK Levine DA Gronwald J Culver HA Whittemore AS Karlan BY Lambrechts D Wentzensen N Kupryjanczyk J Chang-Claude J Bandera EV Hogdall E Heitz F Kaye SB Fasching PA Campbell I Goodman MT Pejovic T Bean Y Lurie G Eccles D Hein A Beckmann MW Ekici AB Paul J Brown R Flanagan JM Harter P du Bois A Schwaab I Hogdall CK Lundvall L Olson SH Orlow I Paddock LE Rudolph A Eilber U Dansonka-Mieszkowska A Rzepecka IK Ziolkowska-Seta I Brinton L Yang H Garcia-Closas M Despierre E Lambrechts S Vergote I Walsh C Lester J Sieh W McGuire V Rothstein JH Ziogas A Lubinski J Cybulski C Menkiszak J Jensen A Gayther SA Ramus SJ Gentry-Maharaj A Berchuck A Wu AH Pike MC Van Denberg D Terry KL Vitonis AF Doherty JA Johnatty SE Defazio A Song H Tyrer J Sellers TA Phelan CM Kalli KR Cunningham JM Fridley BL Goode EL Analysis of over 10000 cases find no association between previously reported candidate polymorphisms and ovarian cancer outcome Cancer Epidemiology Biomerkers and Prevention 22 (5) 987-992 2013

432 Flannagan JM Wilhelm-Banartzi CS Metcalf M Kaye SB Brown R Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients Annals of oncology 24 (11) 2813-2818 2013

2014

41

433 Monk BJ Kaye SB Poveda A Herzog TJ Aracil M Nieto A Badri N Parekh TV Tanovic A Galmarni CM Nibrin is a marker of clinical outcome in patients with advanced seros ovarian cancer treated in the phase III OVA-301 trial Gynaecology Oncology 132 (1) 176-180 2014

434 Fotopoulou C Vergote I Mainwaring P Bidzinski M Vermorken JB Ghamade SA Harnett P Del Prete SA Green JA Spaczynski M Blagden S Gore M Ledermann J Kaye SB Gabra H Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol a sensitizer of platinum cytotoxicity the phase II OVATURE multicentre randomized study Annals of Oncology 25 (1) 160-165 2014

435 Charbonneau B Block MS Bamlet WR Vierkant RA Kalli KR Fogarty Z Rider DN Sellers TA Tworoger SS Poole E Risch HA Salvesen HB Kiemeney LA Baglietto L Giles GG Severi G Trabert B Wentzensen N Chenevix-Trench G Whittemore AS Sieh W Chang-Claude J Bandera EV Orlow I Terry K Goodman MT Thompson PJ Cook LS Rossing MA Ness R B Narod SA Kupryjanczyk J Lu KR Butzow R Dork T Pejovic T Campbell I Le ND Bunker CH Bogdanova N Runnebaum IB Eccles D Paul J Wu ANH Gayther SA Hogdall E Heitz F Kaye SB Karlan BY Anton-Culver H Gronwald J Hogdall CK Lambrechts D Fasching PA Menon U Schildkraut J Pearce CL Levine DA Kjaer S K Cramer D Flanagan JM Phelan CM Brown R Massuger Lfag Song HL Doherty JA Krakstad C Liang D Odunsi K BerchuckA Jensen A Lubinski J Nevanlinna H Bean YT Lurie G Ziogas A Walsh C Despierre E Brinton L Hein A Rudolph A Dansonka-Mieszkowska A Olson SH Harter P Tyrer J Vitonis AF Brooks-Wilson A Aben KK Pike MC Ramus S J Wik E Cybulski C Lin J Sucheston L Edwards R McGuire V Lester J du Bois A Lundvall L Wang-Gohrke S et al Risk of Ovarian Cancer and the NF-kappa B Pathway Genetic Association with IL1A and TNFSF10 CANCER RESEARCH 74 (3) 852-861 2014

436 Glasspool RM Brown R Gore ME Rustin GJS Mc Neish IA Wilson RH Pledge S Paul J Mackean M Hall GD Gabra H Halford SER Walker J Appleton K Ullah R and Kaye SB A randomised Phase I trial of the DNA-hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent partially platinum-resistant ovarian cancer BJC 110 1923-1929 2014

437 Postel-Viney S Collette L Paoletti X Rizzo E Massard C Olmos D Fowst C Levy B Mancini P Lacombe D Ivy P Syemour L Le Tourneau C Siu LL Kaye SB Verweij J and Soria J-C Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents ndash Dose limiting toxicity and toxicity of targeted therapies a European organisation for research and treatment of cancer-led study EJC 50 2040-2049 2014

438 Jones RL Kim ES Nava-Parada P Alam S Johnson FM Stephens AW Simantov R Poondru S Gedrich R Lippman SM Kaye SB and Carden CP Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-960 in patients with advanced solid tumours CCR 21 1-8 2014

439 Moreno Garcia V Olmos D Gomez-Roca C Cassier PA Morales-Barrera R Del Conte G Gallerani E Brunetto AT Schoffski P Marsoni S Schellens JH Penel N Voest E Evans J Plummer R Wilson RH Soria JC Tabernero J Verweij J Kaye SB Dose-response relationship in phase I clinical trials a European Drug Development Network (EDDN) Collaboration Study CCR 20 5663-5671 2014

440 McNeish IA Ledermann J Webber L James L Kaye SB Hall M Hall G Clamp A Earl H Banerjee S Kristeleit R Raja F Feeney A Lawrence C Dawson-Athey L Persic M Khan I A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-reistant ovarian fallopian tube or primary peritoneal cancer Ann Onc 25 1988-1995 2014

42

441 Paoletti X Le Tourneaeu C Verweij J Siu LL Seymour L Postel-Vinay S Collette L Rizzo E Ivy P Olmos D Massard C Lacombe D Kaye SB Soria JC Defining dose-limitng toxicity for phase I trials of molecularly targeted agents results of a DLT-TARGETT international survey Eur J Cancer 50 2050-2056 2014

442 Cassier PA Polivka V Judson I Soria JC Penel N MarsoniS Verweij J Schellens JH Morales-Barrera R Schoffski P Voest EE Gomez-Roca C Evans TR Plummer R Gallerani E Kaye SB Olmos D Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials a subset analysis of a European Phase I database Ann Oncol 25 1222-1228 2014

443 Khan K Ang JE Starling N Sclafani F Shah K Judson I Molife R Banerji U de Bono JS Cunningham D Kaye SB Phase I trials in patient with relapsed advanced upper gastrointestinal carcinomas experience in a specialist unit Gastric Cancer 17 621-629 2014

2015

444 Debashis Sarker Joo Ern Ang Richard Baird Rebecca Kristeleit Krunal Shah Victor Moreno Paul Clarke Michelle Garrett Florence I Raynaud Gallia Levy Joseph A Ware Kathryn Mazina Ray Lin Jenny Wu Jill Fredrickson Jill M Spoerke Mark R Lackner Hartmut Koeppen Yibing Yan Lori Friedman Kaye SB Mika Derynck Paul Workman and Johann S de Bono First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors Clin Can Res 21 77-86 2015

445 Kumar R Guena E Michalarea V Guardascione M Naumann U Lorente D Kaye SB de Bono JS The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials BJC 112 1157-1165 2015

446 Rafii S Roda D Guena E Jiminez B Rihawi K Capelan M Yap T Molife R Kaye SB de Bono JS Banerji U Higher rist of infections with P13K-AKT-mTOR pathway inhibitors in patients with advanced solid tumours on Phase I clinical trials Clin Can Res 21 1869-1876 2015

447 Guena E Roda D Rafii S Jimenez B Capelan M Rihawi K Montemurro F Yap TA Kaye SB de Bono JS Molife LR and Banerji U Complications of hyperglycaemia with P13K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials BJC 113 1541-1547 2015

2016

448 Khan KH Yap TA Ring A Molife LR Bodla S Thomas K Zivi A Smith A Judson I Banerji U de Bono JS and Kaye SB Phase I trial outcomes in older patients with advanced solid tumours BJC 114 262-268 2016

449 Mateo J Olmos D Dumez H Poondru S Samberg NL Barr S Van Tournout JM Jie F Sandhu S Tan DS Moreno V LoRusso PM Kaye SB Shoffski P A first-in-man dose-finding study of the mTORC 1mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies BJC 114 889-896 2016

450 Ledermann JA Embleton AC Raja F Perren TJ Jayson GC Rustin GJS Kaye SB Hirte H Eisenhauer E

Vaughan M Friedlander M Gonzalez-Martin A Stark D Clark E Farrelly L Swart AM Cook A Kaplan RS and Parmar MKB Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6) a randomized double-blind placebo-controlled phase 3 trial The Lancet 387 1066 ndash 1074 2016

451 Mateo J V Moreno V Gupta A Kaye SB Dean E Middleton MR M Friedlander M Gourley C

Plummer R Rustin G Sessa C Leunen K Ledermann JA Swaisland S Fielding A Bannister W Nicum

43

S Molife LR An adaptive study to determine the optimal dose of the tablet folumulation of the PARP inhibitor olaparib Targeted Oncology 11 401-415 2016

452 Kaye SB Progress in the treatment of ovarian cancer lessons from homologous recombination

deficiency ndash the first 10 years Ann Oncol 27 Suppl 1 i1-i13

453 Moschetta M George A Kaye SB and Banerjee S BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer Annal of Onc 27 1449-1455 2016

454 Ang JE Pandher R Ang JC Asad YJ Henley AT Valenti M Box G de Haven Brandon A Baird RD

Friedman L Derynck M Vanhaesebroeck B Eccles SA Kaye SB Workman P de Bono JS and Raynaud FI Plasma metabolomic changes following P13K inhibition as pharmacodynamic biomarkers preclinical discovery to Phase I trial evaluation Mol Cancer Ther 15 1412-1424 2016

455 Matulonis UA Penson RT Domchek SM Kaufman B Shapira-Frommer R Audeh MW Kaye SB

Molife LF Gelmon KA Robertson JD Mann H Ho TW and Coleman RL Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a Germline BRCA12 mutation a multistudy analysis of respone rates and safety Ann Onc 27 1013-1019 2016

456 Monk BJ Lorusso D Italiano A Kaye SB Aracil M Tanovic A DrsquoIncalci M Trabectadin as a chemotherapy option for patients with BRCA deficiency Cancer Treatment Reviews 50 175-182 2016

457 Heath OM van Beekhuizen HJ Nama V Kolomainen D Nobbenhuis MA Ind TE Sohaib SA Lofts FL

Heenan S Gore M Banerjee S Kaye SB and Barton DP Venous thromboembolism at time of diagnosis of ovarian cancer Survival differs in symptomatic and asymptomatic cases Thromb Res 137 30-35 2016

458 Dolly SO Kalaitzaki E Puglisi M Stimpson S Hanwell J Serano S Stapleton S Ansari T Peckitt C

Kaye SB lopez J Yap T van der Graaf W de Bono J Banerji U A study of motivations and expectations of patient seen in phase 1 oncology clinics Cancer 122 3501-3508 2016

2017 459 George A Kristeleit R Rafii S Michie CO Bowen R Michalarea V van Hagen T Wong M Rallis G

Molife LR Lopez J Banerji U Banerjee SN Gore ME de Bono JS Kaye SB amp Yap T Clinica factors of response in patient with advanced ovarian cancer participating in early phase clinical trials Europe J Canc 76 52-59 2017

460 de Bono J Ramanathan RK Mina L Chugh R Glaspy J Rafii S Kaye SB Sachdev J Heymach J Smith DC Henshaw JW Herriott A Patterson M Curtin NJ Averett Byers L and Wainberg ZA Phase 1 Does-escalation two-part trial of the PARP inhibitor Talazparib in patient with advanced Germline BRCA 12 mutations and selected sporadic cancers Cancer Discovery 7(6) 620-629 2017

461 Lrsquoheureux S Zhongwu L Dougherty BA Runswick S Hodgson D Timms KM Lanchbury JS Kaye SB Gourley C Bowtell DDL Kohn EC Scott CL Matulonis UA Panzarella T Karakasis K Burnier JV Gilks B OrsquoConnor MJ Robertson JD Ledermann J Barrett JC Ho TW and Oza AM Long-term responders on olaparib maintenance in high-grade serous ovarian cancer clinical and molecular characterization CCR 23(15) 4086-4094 2017

462 Rafii S Gourley C Kumar R Guena E Ang JE Chen LM Shapira-Frommer R Friedlander M Matulonis

U De Greve J Oza AM Banerjee S Molife LR Gore ME Kaye SB and Yap TA Baseline clinical

44

predictors of antitumour reponse to the PARP inhibitor olaparib in Germline BRCA 12 mutated patients with advanced ovarian cancer Oncotarget 8 47154-47160 2017

463 Ang JE Pal A Asad YJ Henley AT Valenti M Box G de Haven Brandon A Revell V Skene DJ Venturi

M Rueger R Meresse V Eccles SA de Bono JS Kaye SB Workman P Banerji U and Raynaud FI Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655 pharmacodynamic and predictive potential in metastatic menaoma Mol Cancer Ther 10 2315-2323 2017

464 Capelan M Roda D Guena E Rihawi K Bodla S Kaye SB Bhosle J Banerji U OrsquoBrien M de Bono JS

Popat S Yap TA Phase I clinical trials in patient with advanced non-small cell lung cancer treated within a Drug Development Unit What have we learnt Lung Cancer 111 6-11 2017

465 Perez-Lopez R Roda D Jiminez B Brown J Mateo J Carreira S Lopez J Banerji U Molife LR Koh DM

Kaye SB de Bono JS Tunariu N Yap TA High frequency of radiological differential responses with poly (ADP-Ribose) polymerase (PARP) inhibitor therapy Oncotarget 68 (61) 104430-104443 2017

466 Dolly SO Migali C Tunariu N Della-Pepa C Khakoo S Hazell S de Bono JS Kaye SB and Banerjee S

Indolent peritoneal mesothelioma P13K-m TOR inhibitors as a novel therapeutic strategy ESMO Open 2017 122 (1) e000101

2018 467 Sundar R Custodio A Petruckvich Chenard-Poirier M Ameratunga M Collins D Lim J Kaye SB

Tunariu N Banerji U de Bono J Lopez JS Clinical outcome of patients with advanced biliary tract cancer in a dedicated Phase I Unit Clinical Oncology 30 (3) 185-191 2018

468 Ameratunga M Chenard-Poirier M Moreno Cadilejo I Pedregal M Lui A Dolling D Aversa C Ingles

Garces A Ang JE Banerji U Kaye SB Gan Hui Doger B Moreno V de Bono J and Lopez J Neutrophil-lymphocyte ration kinetics in patients with advanced solid tumours on phase I trials of PD-1PD-L1 inhibitors Euro J Cancer 89 56-63 2018

469 McVeigh TP Sundar R Diamantis N Kaye SB Banerji U Lopez J de Bono J van der Graaf WTA George AJ The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials Eur J Cancer 95 20-29 2018

2019 470 Moss CA Cojocaru E Hanwell J Ward S Xu W van Zyl M OrsquoLeary L de Bono J Banerji U Kaye SB

Minchom A George A Lopez J McVeigh TP Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics Eur J Cancer 114 97ndash106 2019

471 Mateo J Lord CJ Serra V Tutt A Balmana J Castroviejo-Bermejo M Cruz C Oaknin A Kaye SB and de Bono JS A decade of clinical development of PARP inhibitors in perspective Annals of Oncology 0 1-11 2019

Book Chapters

1 Patterson DLH Kaye SB and Owen M Cardiac arrhythmias in thalassaemia major an evaluation of chronic therapy using ambulatory cardiac monitoring In International Symposium and Ambulatory Monitoring ed F D Stott and E B Raferty p37 Academic Press London 1978

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

41

433 Monk BJ Kaye SB Poveda A Herzog TJ Aracil M Nieto A Badri N Parekh TV Tanovic A Galmarni CM Nibrin is a marker of clinical outcome in patients with advanced seros ovarian cancer treated in the phase III OVA-301 trial Gynaecology Oncology 132 (1) 176-180 2014

434 Fotopoulou C Vergote I Mainwaring P Bidzinski M Vermorken JB Ghamade SA Harnett P Del Prete SA Green JA Spaczynski M Blagden S Gore M Ledermann J Kaye SB Gabra H Weekly AUC2 carboplatin in acquired platinum resistant ovarian cancer with or without oral phenoxodiol a sensitizer of platinum cytotoxicity the phase II OVATURE multicentre randomized study Annals of Oncology 25 (1) 160-165 2014

435 Charbonneau B Block MS Bamlet WR Vierkant RA Kalli KR Fogarty Z Rider DN Sellers TA Tworoger SS Poole E Risch HA Salvesen HB Kiemeney LA Baglietto L Giles GG Severi G Trabert B Wentzensen N Chenevix-Trench G Whittemore AS Sieh W Chang-Claude J Bandera EV Orlow I Terry K Goodman MT Thompson PJ Cook LS Rossing MA Ness R B Narod SA Kupryjanczyk J Lu KR Butzow R Dork T Pejovic T Campbell I Le ND Bunker CH Bogdanova N Runnebaum IB Eccles D Paul J Wu ANH Gayther SA Hogdall E Heitz F Kaye SB Karlan BY Anton-Culver H Gronwald J Hogdall CK Lambrechts D Fasching PA Menon U Schildkraut J Pearce CL Levine DA Kjaer S K Cramer D Flanagan JM Phelan CM Brown R Massuger Lfag Song HL Doherty JA Krakstad C Liang D Odunsi K BerchuckA Jensen A Lubinski J Nevanlinna H Bean YT Lurie G Ziogas A Walsh C Despierre E Brinton L Hein A Rudolph A Dansonka-Mieszkowska A Olson SH Harter P Tyrer J Vitonis AF Brooks-Wilson A Aben KK Pike MC Ramus S J Wik E Cybulski C Lin J Sucheston L Edwards R McGuire V Lester J du Bois A Lundvall L Wang-Gohrke S et al Risk of Ovarian Cancer and the NF-kappa B Pathway Genetic Association with IL1A and TNFSF10 CANCER RESEARCH 74 (3) 852-861 2014

436 Glasspool RM Brown R Gore ME Rustin GJS Mc Neish IA Wilson RH Pledge S Paul J Mackean M Hall GD Gabra H Halford SER Walker J Appleton K Ullah R and Kaye SB A randomised Phase I trial of the DNA-hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent partially platinum-resistant ovarian cancer BJC 110 1923-1929 2014

437 Postel-Viney S Collette L Paoletti X Rizzo E Massard C Olmos D Fowst C Levy B Mancini P Lacombe D Ivy P Syemour L Le Tourneau C Siu LL Kaye SB Verweij J and Soria J-C Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents ndash Dose limiting toxicity and toxicity of targeted therapies a European organisation for research and treatment of cancer-led study EJC 50 2040-2049 2014

438 Jones RL Kim ES Nava-Parada P Alam S Johnson FM Stephens AW Simantov R Poondru S Gedrich R Lippman SM Kaye SB and Carden CP Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-960 in patients with advanced solid tumours CCR 21 1-8 2014

439 Moreno Garcia V Olmos D Gomez-Roca C Cassier PA Morales-Barrera R Del Conte G Gallerani E Brunetto AT Schoffski P Marsoni S Schellens JH Penel N Voest E Evans J Plummer R Wilson RH Soria JC Tabernero J Verweij J Kaye SB Dose-response relationship in phase I clinical trials a European Drug Development Network (EDDN) Collaboration Study CCR 20 5663-5671 2014

440 McNeish IA Ledermann J Webber L James L Kaye SB Hall M Hall G Clamp A Earl H Banerjee S Kristeleit R Raja F Feeney A Lawrence C Dawson-Athey L Persic M Khan I A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-reistant ovarian fallopian tube or primary peritoneal cancer Ann Onc 25 1988-1995 2014

42

441 Paoletti X Le Tourneaeu C Verweij J Siu LL Seymour L Postel-Vinay S Collette L Rizzo E Ivy P Olmos D Massard C Lacombe D Kaye SB Soria JC Defining dose-limitng toxicity for phase I trials of molecularly targeted agents results of a DLT-TARGETT international survey Eur J Cancer 50 2050-2056 2014

442 Cassier PA Polivka V Judson I Soria JC Penel N MarsoniS Verweij J Schellens JH Morales-Barrera R Schoffski P Voest EE Gomez-Roca C Evans TR Plummer R Gallerani E Kaye SB Olmos D Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials a subset analysis of a European Phase I database Ann Oncol 25 1222-1228 2014

443 Khan K Ang JE Starling N Sclafani F Shah K Judson I Molife R Banerji U de Bono JS Cunningham D Kaye SB Phase I trials in patient with relapsed advanced upper gastrointestinal carcinomas experience in a specialist unit Gastric Cancer 17 621-629 2014

2015

444 Debashis Sarker Joo Ern Ang Richard Baird Rebecca Kristeleit Krunal Shah Victor Moreno Paul Clarke Michelle Garrett Florence I Raynaud Gallia Levy Joseph A Ware Kathryn Mazina Ray Lin Jenny Wu Jill Fredrickson Jill M Spoerke Mark R Lackner Hartmut Koeppen Yibing Yan Lori Friedman Kaye SB Mika Derynck Paul Workman and Johann S de Bono First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors Clin Can Res 21 77-86 2015

445 Kumar R Guena E Michalarea V Guardascione M Naumann U Lorente D Kaye SB de Bono JS The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials BJC 112 1157-1165 2015

446 Rafii S Roda D Guena E Jiminez B Rihawi K Capelan M Yap T Molife R Kaye SB de Bono JS Banerji U Higher rist of infections with P13K-AKT-mTOR pathway inhibitors in patients with advanced solid tumours on Phase I clinical trials Clin Can Res 21 1869-1876 2015

447 Guena E Roda D Rafii S Jimenez B Capelan M Rihawi K Montemurro F Yap TA Kaye SB de Bono JS Molife LR and Banerji U Complications of hyperglycaemia with P13K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials BJC 113 1541-1547 2015

2016

448 Khan KH Yap TA Ring A Molife LR Bodla S Thomas K Zivi A Smith A Judson I Banerji U de Bono JS and Kaye SB Phase I trial outcomes in older patients with advanced solid tumours BJC 114 262-268 2016

449 Mateo J Olmos D Dumez H Poondru S Samberg NL Barr S Van Tournout JM Jie F Sandhu S Tan DS Moreno V LoRusso PM Kaye SB Shoffski P A first-in-man dose-finding study of the mTORC 1mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies BJC 114 889-896 2016

450 Ledermann JA Embleton AC Raja F Perren TJ Jayson GC Rustin GJS Kaye SB Hirte H Eisenhauer E

Vaughan M Friedlander M Gonzalez-Martin A Stark D Clark E Farrelly L Swart AM Cook A Kaplan RS and Parmar MKB Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6) a randomized double-blind placebo-controlled phase 3 trial The Lancet 387 1066 ndash 1074 2016

451 Mateo J V Moreno V Gupta A Kaye SB Dean E Middleton MR M Friedlander M Gourley C

Plummer R Rustin G Sessa C Leunen K Ledermann JA Swaisland S Fielding A Bannister W Nicum

43

S Molife LR An adaptive study to determine the optimal dose of the tablet folumulation of the PARP inhibitor olaparib Targeted Oncology 11 401-415 2016

452 Kaye SB Progress in the treatment of ovarian cancer lessons from homologous recombination

deficiency ndash the first 10 years Ann Oncol 27 Suppl 1 i1-i13

453 Moschetta M George A Kaye SB and Banerjee S BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer Annal of Onc 27 1449-1455 2016

454 Ang JE Pandher R Ang JC Asad YJ Henley AT Valenti M Box G de Haven Brandon A Baird RD

Friedman L Derynck M Vanhaesebroeck B Eccles SA Kaye SB Workman P de Bono JS and Raynaud FI Plasma metabolomic changes following P13K inhibition as pharmacodynamic biomarkers preclinical discovery to Phase I trial evaluation Mol Cancer Ther 15 1412-1424 2016

455 Matulonis UA Penson RT Domchek SM Kaufman B Shapira-Frommer R Audeh MW Kaye SB

Molife LF Gelmon KA Robertson JD Mann H Ho TW and Coleman RL Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a Germline BRCA12 mutation a multistudy analysis of respone rates and safety Ann Onc 27 1013-1019 2016

456 Monk BJ Lorusso D Italiano A Kaye SB Aracil M Tanovic A DrsquoIncalci M Trabectadin as a chemotherapy option for patients with BRCA deficiency Cancer Treatment Reviews 50 175-182 2016

457 Heath OM van Beekhuizen HJ Nama V Kolomainen D Nobbenhuis MA Ind TE Sohaib SA Lofts FL

Heenan S Gore M Banerjee S Kaye SB and Barton DP Venous thromboembolism at time of diagnosis of ovarian cancer Survival differs in symptomatic and asymptomatic cases Thromb Res 137 30-35 2016

458 Dolly SO Kalaitzaki E Puglisi M Stimpson S Hanwell J Serano S Stapleton S Ansari T Peckitt C

Kaye SB lopez J Yap T van der Graaf W de Bono J Banerji U A study of motivations and expectations of patient seen in phase 1 oncology clinics Cancer 122 3501-3508 2016

2017 459 George A Kristeleit R Rafii S Michie CO Bowen R Michalarea V van Hagen T Wong M Rallis G

Molife LR Lopez J Banerji U Banerjee SN Gore ME de Bono JS Kaye SB amp Yap T Clinica factors of response in patient with advanced ovarian cancer participating in early phase clinical trials Europe J Canc 76 52-59 2017

460 de Bono J Ramanathan RK Mina L Chugh R Glaspy J Rafii S Kaye SB Sachdev J Heymach J Smith DC Henshaw JW Herriott A Patterson M Curtin NJ Averett Byers L and Wainberg ZA Phase 1 Does-escalation two-part trial of the PARP inhibitor Talazparib in patient with advanced Germline BRCA 12 mutations and selected sporadic cancers Cancer Discovery 7(6) 620-629 2017

461 Lrsquoheureux S Zhongwu L Dougherty BA Runswick S Hodgson D Timms KM Lanchbury JS Kaye SB Gourley C Bowtell DDL Kohn EC Scott CL Matulonis UA Panzarella T Karakasis K Burnier JV Gilks B OrsquoConnor MJ Robertson JD Ledermann J Barrett JC Ho TW and Oza AM Long-term responders on olaparib maintenance in high-grade serous ovarian cancer clinical and molecular characterization CCR 23(15) 4086-4094 2017

462 Rafii S Gourley C Kumar R Guena E Ang JE Chen LM Shapira-Frommer R Friedlander M Matulonis

U De Greve J Oza AM Banerjee S Molife LR Gore ME Kaye SB and Yap TA Baseline clinical

44

predictors of antitumour reponse to the PARP inhibitor olaparib in Germline BRCA 12 mutated patients with advanced ovarian cancer Oncotarget 8 47154-47160 2017

463 Ang JE Pal A Asad YJ Henley AT Valenti M Box G de Haven Brandon A Revell V Skene DJ Venturi

M Rueger R Meresse V Eccles SA de Bono JS Kaye SB Workman P Banerji U and Raynaud FI Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655 pharmacodynamic and predictive potential in metastatic menaoma Mol Cancer Ther 10 2315-2323 2017

464 Capelan M Roda D Guena E Rihawi K Bodla S Kaye SB Bhosle J Banerji U OrsquoBrien M de Bono JS

Popat S Yap TA Phase I clinical trials in patient with advanced non-small cell lung cancer treated within a Drug Development Unit What have we learnt Lung Cancer 111 6-11 2017

465 Perez-Lopez R Roda D Jiminez B Brown J Mateo J Carreira S Lopez J Banerji U Molife LR Koh DM

Kaye SB de Bono JS Tunariu N Yap TA High frequency of radiological differential responses with poly (ADP-Ribose) polymerase (PARP) inhibitor therapy Oncotarget 68 (61) 104430-104443 2017

466 Dolly SO Migali C Tunariu N Della-Pepa C Khakoo S Hazell S de Bono JS Kaye SB and Banerjee S

Indolent peritoneal mesothelioma P13K-m TOR inhibitors as a novel therapeutic strategy ESMO Open 2017 122 (1) e000101

2018 467 Sundar R Custodio A Petruckvich Chenard-Poirier M Ameratunga M Collins D Lim J Kaye SB

Tunariu N Banerji U de Bono J Lopez JS Clinical outcome of patients with advanced biliary tract cancer in a dedicated Phase I Unit Clinical Oncology 30 (3) 185-191 2018

468 Ameratunga M Chenard-Poirier M Moreno Cadilejo I Pedregal M Lui A Dolling D Aversa C Ingles

Garces A Ang JE Banerji U Kaye SB Gan Hui Doger B Moreno V de Bono J and Lopez J Neutrophil-lymphocyte ration kinetics in patients with advanced solid tumours on phase I trials of PD-1PD-L1 inhibitors Euro J Cancer 89 56-63 2018

469 McVeigh TP Sundar R Diamantis N Kaye SB Banerji U Lopez J de Bono J van der Graaf WTA George AJ The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials Eur J Cancer 95 20-29 2018

2019 470 Moss CA Cojocaru E Hanwell J Ward S Xu W van Zyl M OrsquoLeary L de Bono J Banerji U Kaye SB

Minchom A George A Lopez J McVeigh TP Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics Eur J Cancer 114 97ndash106 2019

471 Mateo J Lord CJ Serra V Tutt A Balmana J Castroviejo-Bermejo M Cruz C Oaknin A Kaye SB and de Bono JS A decade of clinical development of PARP inhibitors in perspective Annals of Oncology 0 1-11 2019

Book Chapters

1 Patterson DLH Kaye SB and Owen M Cardiac arrhythmias in thalassaemia major an evaluation of chronic therapy using ambulatory cardiac monitoring In International Symposium and Ambulatory Monitoring ed F D Stott and E B Raferty p37 Academic Press London 1978

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

42

441 Paoletti X Le Tourneaeu C Verweij J Siu LL Seymour L Postel-Vinay S Collette L Rizzo E Ivy P Olmos D Massard C Lacombe D Kaye SB Soria JC Defining dose-limitng toxicity for phase I trials of molecularly targeted agents results of a DLT-TARGETT international survey Eur J Cancer 50 2050-2056 2014

442 Cassier PA Polivka V Judson I Soria JC Penel N MarsoniS Verweij J Schellens JH Morales-Barrera R Schoffski P Voest EE Gomez-Roca C Evans TR Plummer R Gallerani E Kaye SB Olmos D Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials a subset analysis of a European Phase I database Ann Oncol 25 1222-1228 2014

443 Khan K Ang JE Starling N Sclafani F Shah K Judson I Molife R Banerji U de Bono JS Cunningham D Kaye SB Phase I trials in patient with relapsed advanced upper gastrointestinal carcinomas experience in a specialist unit Gastric Cancer 17 621-629 2014

2015

444 Debashis Sarker Joo Ern Ang Richard Baird Rebecca Kristeleit Krunal Shah Victor Moreno Paul Clarke Michelle Garrett Florence I Raynaud Gallia Levy Joseph A Ware Kathryn Mazina Ray Lin Jenny Wu Jill Fredrickson Jill M Spoerke Mark R Lackner Hartmut Koeppen Yibing Yan Lori Friedman Kaye SB Mika Derynck Paul Workman and Johann S de Bono First-in-human Phase I study of Pictilisib (GDC-0941) a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in patients with advanced solid tumors Clin Can Res 21 77-86 2015

445 Kumar R Guena E Michalarea V Guardascione M Naumann U Lorente D Kaye SB de Bono JS The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials BJC 112 1157-1165 2015

446 Rafii S Roda D Guena E Jiminez B Rihawi K Capelan M Yap T Molife R Kaye SB de Bono JS Banerji U Higher rist of infections with P13K-AKT-mTOR pathway inhibitors in patients with advanced solid tumours on Phase I clinical trials Clin Can Res 21 1869-1876 2015

447 Guena E Roda D Rafii S Jimenez B Capelan M Rihawi K Montemurro F Yap TA Kaye SB de Bono JS Molife LR and Banerji U Complications of hyperglycaemia with P13K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials BJC 113 1541-1547 2015

2016

448 Khan KH Yap TA Ring A Molife LR Bodla S Thomas K Zivi A Smith A Judson I Banerji U de Bono JS and Kaye SB Phase I trial outcomes in older patients with advanced solid tumours BJC 114 262-268 2016

449 Mateo J Olmos D Dumez H Poondru S Samberg NL Barr S Van Tournout JM Jie F Sandhu S Tan DS Moreno V LoRusso PM Kaye SB Shoffski P A first-in-man dose-finding study of the mTORC 1mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies BJC 114 889-896 2016

450 Ledermann JA Embleton AC Raja F Perren TJ Jayson GC Rustin GJS Kaye SB Hirte H Eisenhauer E

Vaughan M Friedlander M Gonzalez-Martin A Stark D Clark E Farrelly L Swart AM Cook A Kaplan RS and Parmar MKB Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6) a randomized double-blind placebo-controlled phase 3 trial The Lancet 387 1066 ndash 1074 2016

451 Mateo J V Moreno V Gupta A Kaye SB Dean E Middleton MR M Friedlander M Gourley C

Plummer R Rustin G Sessa C Leunen K Ledermann JA Swaisland S Fielding A Bannister W Nicum

43

S Molife LR An adaptive study to determine the optimal dose of the tablet folumulation of the PARP inhibitor olaparib Targeted Oncology 11 401-415 2016

452 Kaye SB Progress in the treatment of ovarian cancer lessons from homologous recombination

deficiency ndash the first 10 years Ann Oncol 27 Suppl 1 i1-i13

453 Moschetta M George A Kaye SB and Banerjee S BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer Annal of Onc 27 1449-1455 2016

454 Ang JE Pandher R Ang JC Asad YJ Henley AT Valenti M Box G de Haven Brandon A Baird RD

Friedman L Derynck M Vanhaesebroeck B Eccles SA Kaye SB Workman P de Bono JS and Raynaud FI Plasma metabolomic changes following P13K inhibition as pharmacodynamic biomarkers preclinical discovery to Phase I trial evaluation Mol Cancer Ther 15 1412-1424 2016

455 Matulonis UA Penson RT Domchek SM Kaufman B Shapira-Frommer R Audeh MW Kaye SB

Molife LF Gelmon KA Robertson JD Mann H Ho TW and Coleman RL Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a Germline BRCA12 mutation a multistudy analysis of respone rates and safety Ann Onc 27 1013-1019 2016

456 Monk BJ Lorusso D Italiano A Kaye SB Aracil M Tanovic A DrsquoIncalci M Trabectadin as a chemotherapy option for patients with BRCA deficiency Cancer Treatment Reviews 50 175-182 2016

457 Heath OM van Beekhuizen HJ Nama V Kolomainen D Nobbenhuis MA Ind TE Sohaib SA Lofts FL

Heenan S Gore M Banerjee S Kaye SB and Barton DP Venous thromboembolism at time of diagnosis of ovarian cancer Survival differs in symptomatic and asymptomatic cases Thromb Res 137 30-35 2016

458 Dolly SO Kalaitzaki E Puglisi M Stimpson S Hanwell J Serano S Stapleton S Ansari T Peckitt C

Kaye SB lopez J Yap T van der Graaf W de Bono J Banerji U A study of motivations and expectations of patient seen in phase 1 oncology clinics Cancer 122 3501-3508 2016

2017 459 George A Kristeleit R Rafii S Michie CO Bowen R Michalarea V van Hagen T Wong M Rallis G

Molife LR Lopez J Banerji U Banerjee SN Gore ME de Bono JS Kaye SB amp Yap T Clinica factors of response in patient with advanced ovarian cancer participating in early phase clinical trials Europe J Canc 76 52-59 2017

460 de Bono J Ramanathan RK Mina L Chugh R Glaspy J Rafii S Kaye SB Sachdev J Heymach J Smith DC Henshaw JW Herriott A Patterson M Curtin NJ Averett Byers L and Wainberg ZA Phase 1 Does-escalation two-part trial of the PARP inhibitor Talazparib in patient with advanced Germline BRCA 12 mutations and selected sporadic cancers Cancer Discovery 7(6) 620-629 2017

461 Lrsquoheureux S Zhongwu L Dougherty BA Runswick S Hodgson D Timms KM Lanchbury JS Kaye SB Gourley C Bowtell DDL Kohn EC Scott CL Matulonis UA Panzarella T Karakasis K Burnier JV Gilks B OrsquoConnor MJ Robertson JD Ledermann J Barrett JC Ho TW and Oza AM Long-term responders on olaparib maintenance in high-grade serous ovarian cancer clinical and molecular characterization CCR 23(15) 4086-4094 2017

462 Rafii S Gourley C Kumar R Guena E Ang JE Chen LM Shapira-Frommer R Friedlander M Matulonis

U De Greve J Oza AM Banerjee S Molife LR Gore ME Kaye SB and Yap TA Baseline clinical

44

predictors of antitumour reponse to the PARP inhibitor olaparib in Germline BRCA 12 mutated patients with advanced ovarian cancer Oncotarget 8 47154-47160 2017

463 Ang JE Pal A Asad YJ Henley AT Valenti M Box G de Haven Brandon A Revell V Skene DJ Venturi

M Rueger R Meresse V Eccles SA de Bono JS Kaye SB Workman P Banerji U and Raynaud FI Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655 pharmacodynamic and predictive potential in metastatic menaoma Mol Cancer Ther 10 2315-2323 2017

464 Capelan M Roda D Guena E Rihawi K Bodla S Kaye SB Bhosle J Banerji U OrsquoBrien M de Bono JS

Popat S Yap TA Phase I clinical trials in patient with advanced non-small cell lung cancer treated within a Drug Development Unit What have we learnt Lung Cancer 111 6-11 2017

465 Perez-Lopez R Roda D Jiminez B Brown J Mateo J Carreira S Lopez J Banerji U Molife LR Koh DM

Kaye SB de Bono JS Tunariu N Yap TA High frequency of radiological differential responses with poly (ADP-Ribose) polymerase (PARP) inhibitor therapy Oncotarget 68 (61) 104430-104443 2017

466 Dolly SO Migali C Tunariu N Della-Pepa C Khakoo S Hazell S de Bono JS Kaye SB and Banerjee S

Indolent peritoneal mesothelioma P13K-m TOR inhibitors as a novel therapeutic strategy ESMO Open 2017 122 (1) e000101

2018 467 Sundar R Custodio A Petruckvich Chenard-Poirier M Ameratunga M Collins D Lim J Kaye SB

Tunariu N Banerji U de Bono J Lopez JS Clinical outcome of patients with advanced biliary tract cancer in a dedicated Phase I Unit Clinical Oncology 30 (3) 185-191 2018

468 Ameratunga M Chenard-Poirier M Moreno Cadilejo I Pedregal M Lui A Dolling D Aversa C Ingles

Garces A Ang JE Banerji U Kaye SB Gan Hui Doger B Moreno V de Bono J and Lopez J Neutrophil-lymphocyte ration kinetics in patients with advanced solid tumours on phase I trials of PD-1PD-L1 inhibitors Euro J Cancer 89 56-63 2018

469 McVeigh TP Sundar R Diamantis N Kaye SB Banerji U Lopez J de Bono J van der Graaf WTA George AJ The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials Eur J Cancer 95 20-29 2018

2019 470 Moss CA Cojocaru E Hanwell J Ward S Xu W van Zyl M OrsquoLeary L de Bono J Banerji U Kaye SB

Minchom A George A Lopez J McVeigh TP Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics Eur J Cancer 114 97ndash106 2019

471 Mateo J Lord CJ Serra V Tutt A Balmana J Castroviejo-Bermejo M Cruz C Oaknin A Kaye SB and de Bono JS A decade of clinical development of PARP inhibitors in perspective Annals of Oncology 0 1-11 2019

Book Chapters

1 Patterson DLH Kaye SB and Owen M Cardiac arrhythmias in thalassaemia major an evaluation of chronic therapy using ambulatory cardiac monitoring In International Symposium and Ambulatory Monitoring ed F D Stott and E B Raferty p37 Academic Press London 1978

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

43

S Molife LR An adaptive study to determine the optimal dose of the tablet folumulation of the PARP inhibitor olaparib Targeted Oncology 11 401-415 2016

452 Kaye SB Progress in the treatment of ovarian cancer lessons from homologous recombination

deficiency ndash the first 10 years Ann Oncol 27 Suppl 1 i1-i13

453 Moschetta M George A Kaye SB and Banerjee S BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer Annal of Onc 27 1449-1455 2016

454 Ang JE Pandher R Ang JC Asad YJ Henley AT Valenti M Box G de Haven Brandon A Baird RD

Friedman L Derynck M Vanhaesebroeck B Eccles SA Kaye SB Workman P de Bono JS and Raynaud FI Plasma metabolomic changes following P13K inhibition as pharmacodynamic biomarkers preclinical discovery to Phase I trial evaluation Mol Cancer Ther 15 1412-1424 2016

455 Matulonis UA Penson RT Domchek SM Kaufman B Shapira-Frommer R Audeh MW Kaye SB

Molife LF Gelmon KA Robertson JD Mann H Ho TW and Coleman RL Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a Germline BRCA12 mutation a multistudy analysis of respone rates and safety Ann Onc 27 1013-1019 2016

456 Monk BJ Lorusso D Italiano A Kaye SB Aracil M Tanovic A DrsquoIncalci M Trabectadin as a chemotherapy option for patients with BRCA deficiency Cancer Treatment Reviews 50 175-182 2016

457 Heath OM van Beekhuizen HJ Nama V Kolomainen D Nobbenhuis MA Ind TE Sohaib SA Lofts FL

Heenan S Gore M Banerjee S Kaye SB and Barton DP Venous thromboembolism at time of diagnosis of ovarian cancer Survival differs in symptomatic and asymptomatic cases Thromb Res 137 30-35 2016

458 Dolly SO Kalaitzaki E Puglisi M Stimpson S Hanwell J Serano S Stapleton S Ansari T Peckitt C

Kaye SB lopez J Yap T van der Graaf W de Bono J Banerji U A study of motivations and expectations of patient seen in phase 1 oncology clinics Cancer 122 3501-3508 2016

2017 459 George A Kristeleit R Rafii S Michie CO Bowen R Michalarea V van Hagen T Wong M Rallis G

Molife LR Lopez J Banerji U Banerjee SN Gore ME de Bono JS Kaye SB amp Yap T Clinica factors of response in patient with advanced ovarian cancer participating in early phase clinical trials Europe J Canc 76 52-59 2017

460 de Bono J Ramanathan RK Mina L Chugh R Glaspy J Rafii S Kaye SB Sachdev J Heymach J Smith DC Henshaw JW Herriott A Patterson M Curtin NJ Averett Byers L and Wainberg ZA Phase 1 Does-escalation two-part trial of the PARP inhibitor Talazparib in patient with advanced Germline BRCA 12 mutations and selected sporadic cancers Cancer Discovery 7(6) 620-629 2017

461 Lrsquoheureux S Zhongwu L Dougherty BA Runswick S Hodgson D Timms KM Lanchbury JS Kaye SB Gourley C Bowtell DDL Kohn EC Scott CL Matulonis UA Panzarella T Karakasis K Burnier JV Gilks B OrsquoConnor MJ Robertson JD Ledermann J Barrett JC Ho TW and Oza AM Long-term responders on olaparib maintenance in high-grade serous ovarian cancer clinical and molecular characterization CCR 23(15) 4086-4094 2017

462 Rafii S Gourley C Kumar R Guena E Ang JE Chen LM Shapira-Frommer R Friedlander M Matulonis

U De Greve J Oza AM Banerjee S Molife LR Gore ME Kaye SB and Yap TA Baseline clinical

44

predictors of antitumour reponse to the PARP inhibitor olaparib in Germline BRCA 12 mutated patients with advanced ovarian cancer Oncotarget 8 47154-47160 2017

463 Ang JE Pal A Asad YJ Henley AT Valenti M Box G de Haven Brandon A Revell V Skene DJ Venturi

M Rueger R Meresse V Eccles SA de Bono JS Kaye SB Workman P Banerji U and Raynaud FI Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655 pharmacodynamic and predictive potential in metastatic menaoma Mol Cancer Ther 10 2315-2323 2017

464 Capelan M Roda D Guena E Rihawi K Bodla S Kaye SB Bhosle J Banerji U OrsquoBrien M de Bono JS

Popat S Yap TA Phase I clinical trials in patient with advanced non-small cell lung cancer treated within a Drug Development Unit What have we learnt Lung Cancer 111 6-11 2017

465 Perez-Lopez R Roda D Jiminez B Brown J Mateo J Carreira S Lopez J Banerji U Molife LR Koh DM

Kaye SB de Bono JS Tunariu N Yap TA High frequency of radiological differential responses with poly (ADP-Ribose) polymerase (PARP) inhibitor therapy Oncotarget 68 (61) 104430-104443 2017

466 Dolly SO Migali C Tunariu N Della-Pepa C Khakoo S Hazell S de Bono JS Kaye SB and Banerjee S

Indolent peritoneal mesothelioma P13K-m TOR inhibitors as a novel therapeutic strategy ESMO Open 2017 122 (1) e000101

2018 467 Sundar R Custodio A Petruckvich Chenard-Poirier M Ameratunga M Collins D Lim J Kaye SB

Tunariu N Banerji U de Bono J Lopez JS Clinical outcome of patients with advanced biliary tract cancer in a dedicated Phase I Unit Clinical Oncology 30 (3) 185-191 2018

468 Ameratunga M Chenard-Poirier M Moreno Cadilejo I Pedregal M Lui A Dolling D Aversa C Ingles

Garces A Ang JE Banerji U Kaye SB Gan Hui Doger B Moreno V de Bono J and Lopez J Neutrophil-lymphocyte ration kinetics in patients with advanced solid tumours on phase I trials of PD-1PD-L1 inhibitors Euro J Cancer 89 56-63 2018

469 McVeigh TP Sundar R Diamantis N Kaye SB Banerji U Lopez J de Bono J van der Graaf WTA George AJ The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials Eur J Cancer 95 20-29 2018

2019 470 Moss CA Cojocaru E Hanwell J Ward S Xu W van Zyl M OrsquoLeary L de Bono J Banerji U Kaye SB

Minchom A George A Lopez J McVeigh TP Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics Eur J Cancer 114 97ndash106 2019

471 Mateo J Lord CJ Serra V Tutt A Balmana J Castroviejo-Bermejo M Cruz C Oaknin A Kaye SB and de Bono JS A decade of clinical development of PARP inhibitors in perspective Annals of Oncology 0 1-11 2019

Book Chapters

1 Patterson DLH Kaye SB and Owen M Cardiac arrhythmias in thalassaemia major an evaluation of chronic therapy using ambulatory cardiac monitoring In International Symposium and Ambulatory Monitoring ed F D Stott and E B Raferty p37 Academic Press London 1978

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

44

predictors of antitumour reponse to the PARP inhibitor olaparib in Germline BRCA 12 mutated patients with advanced ovarian cancer Oncotarget 8 47154-47160 2017

463 Ang JE Pal A Asad YJ Henley AT Valenti M Box G de Haven Brandon A Revell V Skene DJ Venturi

M Rueger R Meresse V Eccles SA de Bono JS Kaye SB Workman P Banerji U and Raynaud FI Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655 pharmacodynamic and predictive potential in metastatic menaoma Mol Cancer Ther 10 2315-2323 2017

464 Capelan M Roda D Guena E Rihawi K Bodla S Kaye SB Bhosle J Banerji U OrsquoBrien M de Bono JS

Popat S Yap TA Phase I clinical trials in patient with advanced non-small cell lung cancer treated within a Drug Development Unit What have we learnt Lung Cancer 111 6-11 2017

465 Perez-Lopez R Roda D Jiminez B Brown J Mateo J Carreira S Lopez J Banerji U Molife LR Koh DM

Kaye SB de Bono JS Tunariu N Yap TA High frequency of radiological differential responses with poly (ADP-Ribose) polymerase (PARP) inhibitor therapy Oncotarget 68 (61) 104430-104443 2017

466 Dolly SO Migali C Tunariu N Della-Pepa C Khakoo S Hazell S de Bono JS Kaye SB and Banerjee S

Indolent peritoneal mesothelioma P13K-m TOR inhibitors as a novel therapeutic strategy ESMO Open 2017 122 (1) e000101

2018 467 Sundar R Custodio A Petruckvich Chenard-Poirier M Ameratunga M Collins D Lim J Kaye SB

Tunariu N Banerji U de Bono J Lopez JS Clinical outcome of patients with advanced biliary tract cancer in a dedicated Phase I Unit Clinical Oncology 30 (3) 185-191 2018

468 Ameratunga M Chenard-Poirier M Moreno Cadilejo I Pedregal M Lui A Dolling D Aversa C Ingles

Garces A Ang JE Banerji U Kaye SB Gan Hui Doger B Moreno V de Bono J and Lopez J Neutrophil-lymphocyte ration kinetics in patients with advanced solid tumours on phase I trials of PD-1PD-L1 inhibitors Euro J Cancer 89 56-63 2018

469 McVeigh TP Sundar R Diamantis N Kaye SB Banerji U Lopez J de Bono J van der Graaf WTA George AJ The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in Phase I clinical trials Eur J Cancer 95 20-29 2018

2019 470 Moss CA Cojocaru E Hanwell J Ward S Xu W van Zyl M OrsquoLeary L de Bono J Banerji U Kaye SB

Minchom A George A Lopez J McVeigh TP Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics Eur J Cancer 114 97ndash106 2019

471 Mateo J Lord CJ Serra V Tutt A Balmana J Castroviejo-Bermejo M Cruz C Oaknin A Kaye SB and de Bono JS A decade of clinical development of PARP inhibitors in perspective Annals of Oncology 0 1-11 2019

Book Chapters

1 Patterson DLH Kaye SB and Owen M Cardiac arrhythmias in thalassaemia major an evaluation of chronic therapy using ambulatory cardiac monitoring In International Symposium and Ambulatory Monitoring ed F D Stott and E B Raferty p37 Academic Press London 1978

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

45

2 Kaye SB and Bagshawe KD Chemical markers in spinal fluid for tumours of the central nervous system (CNS) In CNS complications of malignant disease ed H E M Kay and J M A Whitehouse 306-324 Macmillan London 1979

3 Kaye SB Liposomes as carriers of antimetabolites In Nucleosides and Cancer Treatment ed Tattersall M H N and Fox R M pp428-436 Academic Press 1981

4 Kaye SB Liposomes and other cytotoxic drug carriers Proceedings of 13th Int Congress of Chemotherapy 11 23127-34 Verlag H Egermann 1983

5 Stoter G Sleyfer D ten Bokkel-Huinink W van Oosterom A Jones W and Kaye SB Current status of EORTC protocols of disseminated testicular non-seminomatous cancer In Controlled Clinical Trials in urologic Oncology ed by Denis L Murphy G Prout G and Schroder F Raven Press New York 23-28 1984

6 Banham S Soukop M Ahmedzai S Burnett A Cunningham D Dorward A Hutcheon A Lucie N Kaye S Stevenson R and Tansey T Late dose intensification chemotherapy in small cell lung cancer In Autologous Bone Marrow Transplantation and Solid Tumours ed by McVie JG Dalesio O and Smith IE Raven Press New York 105-116 1984

7 Kaye SB Improved curability of advanced germ cell tumours carrying the worst prognosis In Germ Cell Tumours II ed by Jones W Anderson C and Ward HM Pergamon Press Oxford 363-369 1986

8 Kaye SB McDougall H Symonds RP and Tolley D The management of bladder cancer in Scotland In The Management of Bladder Cancer ed Raghaven D Series ed MJ Peckham Edward Arnold London 1987

9 Bindemann S Milsted R Welsh J Habeshaw T Kaye SB and Calman K Enhancement of quality of life with relaxation therapy in cancer patients attending a chemotherapy unit In Psychological Aspects of Cancer ed Watson M and Pettingale K Pergamon Press 1987

10 Harding Mand Kaye SB Prognostic significance of response to therapy ed B Stoll Martinus Nijhoff 65-78 1987

11 Leake RE Cowan SK Kaye SB and Kennedy JH Steroid receptors and prognosis In Ovarian Cancer - the way ahead eds Sharp F and Soutter WP RCOG London pp85-91 1987

12 Kaye SB MacLean A Cordiner J Kennedy J Soukop M Kennedy R and Duncan I Chemotherapy for advanced ovarian cancer - single agent versus combination chemotherapy In Ovarian Cancer - The Way Ahead eds Sharp F and Souter WP RCOG 323328 1987

13 Kaye SB Potential advances in chemotherapy for metastatic testicular cancer In Progress and Controversies in Urological Cancer Alan Liss 1987

14 Rankin EM and Kaye SB Principles of chemotherapy In The Treatment of Cancer (2nd edition) ed Halnan K and Sikora K Chapman amp Hall pp 127-146 1988

15 Merry S Cunningham D Courntey ER Hamilton T Kaye SB and Freshney RI Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft In Human Tumour Xenografts in Anticancer Drug Development eds Winograd B Peckham MJ and Pinedo HM ESO Monographs Series Springer-Verlag 1988

16 Kaye SB and Rankin EM (Eds) Medical Complications of Malignant Disease In Ballieres Clinical Oncology - International practice and Research Vol 2No 2 1988

17 Kaye SB Single agent chemotherapy In Ovarian Cancer biological and therapeutic challenges pp 299-308 eds Sharp F Mason W and Leake R Chapman amp Hall - London 1989

18 Kaye SB Testis Cancer In Surgical Oncology Current Concepts and Practice ed C McArdle pp204-217 Butterworths 1990

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

46

19 Rankin EM and Kaye SB Principles of Chemotherapy in Treatment of Cancer eds Sikora K and Halman K Chapman and Hall London 1990

20 Lewis CR Kaye SB and Calman KC Principles of chemotherapy In Cancer in the Elderly eds Caird FL and Brewin TB pp 49-56 Wright 1990

21 Kaye SB Aggressive Therapy for Advanced Disease In EORTC Genitourinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 229-234 1990 Wiley-Liss Inc

22 Stoter G Bosl GJ Droz JP Fossa SD Freedman LS Geller NL Horwich A Jones WG Kaye SB Mead GM Oosterom R Rodenburg CJ Scheulen ME Stenning S Sylvester R Vogelzang NJ Prognostic Factors in Metastatic Germ Cell Tumors In EORTC Genitoruinary Group Monograph 7 Prostate Cancer and Testicular Cancer Eds Newling DWW and Jones WG pages 313-319 1990 Wiley-Liss Inc

23 Plumb JA Kaye SB The Cell Membrane and Drug Resistance In Genes and cancer Eds Carney D and Sikora K pages 211-217 1990 J Wiley amp Sons

24 Kaye SB The multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens) In Endocrine Therapy of Breast Cancer V (ESO Monographs) Goldhirsch A (Ed) Springer-Verlag Heidelberg pp 35-44 1992

25 Kaye SB Workman P Graham MA Cassidy J and Jodrell D Pharmacokinetics and early clinical studies of selected new drugs Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 371-396 1993

26 Graham MA Kaye SB New approaches in preclinical and clinical pharmacokinetics Cancer Surveys 17 Pharmacokinetics and Cancer Chemotherapy eds Workman P and Graham MA Cold Spring Harbor Press 27-50 1993

27 Cassidy J Kaye SB New drugs in clinical development in Europe New Drug Therapy In HematolOncology Clinics of North America eds Muggia F Speyer J Saunders WB Vol 8 289-303 1994

28 Paz-Ares L and Kaye SB Schedule intensive treatment for testicular germ cell tumours Germ Cell Tumors III Eds Jones W Harnden P Appleyard I (Pergaman Oxford) pages 261-270 1994

29 Kirk D and Kaye SB Retroperitoneal surgery Management strategies in malignant teratoma In Advances in the Biosciences - Germ Cell Tumours III vol 91 eds Jones WG Harnden P Appleyard I Pergamon page 333 1994

30 Steward WP Cassidy J Kaye SB Principles of chemotherapy In Treatment of Cancer Third edition (Sikora K Ed) London Chapman amp Hall) 1995

31 Kerr DJ and Kaye SB New and miscellaneous anticancer drugs future developments in drug design In Oxford Textbook of Oncology Eds Peckham Pinedo and Veronesi Oxford University Press pp 578-585 1995

32 Piccart MJ Rustin GJS Gore ME ten Bokkel Huinink W van Oosterom A van der Burg M Nelstrop A Selleslags J Te Velde A Wanders J and Kaye SB (on behalf of the EORTC Early Clinical Trials Group) Docetaxel in platinum-pretreated patients In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R Berek J (Chapman amp Hall Medical London) pp 153-163 1996

33 Kaye SB Causes of clinical drug resistance In Ovarian Cancer 4 Eds Sharp F Blackett T Leake R and Berek J Chapman amp Hall pp 215-220 1996

34 Vasey P Kaye SB and Thigpen JT Importance of dose-intensity in ovarian cancer In Ovarian Cancer Controversies in Management Eds Gershenson DM McGuire WP Churchill Livingstone New York pp 139-167 1998

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

47

35 Simpson AB Graham J Paul J and Kaye SB Fatal bleomycin toxicity in germ cell tumour patients a review of five years experience in the West of Scoltand In Germ Cell Tumours IV Eds Jones WG Appleyard I Harnden P Joffe JK John Libbey amp Co Ltd pp 417-418 1998

36 Kaye SB Overview - New drug strategies in ovarian cancer In Ovarian Cancer 5 Eds Sharp F Blackett T Berek J Bast R ISIS Medical Media Oxford pp 355-362 1998

37 Vasey P and Kaye SB Management of Stage IV Ovarian Cancer In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 67-80 Martin Dunitz 2001

38 Ten Bokkel Heinink WW and Kaye SB Early relapse (within six months) drug resistance In Clinical Management of Ovarian Cancer Eds Ledermann J Hoskins W Kaye SB and Vergote I pp 159-164 Martin Dunitz 2001

39 Kaye SB Chemotherapy for testicular cancer present standards and future advances In Renal Bladder Prostate and Testicular Cancer - An Update pp 29-33 Eds Kurth K Mickisch G and Schroder F Parthenon Publishing Group 2001

40 Kaye SB and Workman P Signal transduction pathway targeting In Cancer Handbook vol 2 Chap 96 p1497 - 1505 Ed Alison M Nature Publishing Group 2001

41 Workman P and Kaye S B Translating basic cancer research into new cancer therapeutics Trends Mol Med 8 (suppl) S27-31 2002

42 Shah R and Kaye SB Natural products In Handbook of Anticancer Drug Development Chapter 2 pp 13-23 Eds Budman DR Calvert AH Rowinsky EK Lippincott Williams amp Wilkins Philadelphia 2003

43 Kaye S B First line chemotherapy in ovarian cancer In Key Advances in the Clinical Management of ovarian cancer Ed Ghaem-Maghami S Orton K and Soutter P pp 33-38 Royal Soc Med Press Ltd 2003

44 Baird R and Kaye SB Drug resistance a problem and possible solutions In Cancer Therapy Molecular Targets in Tumor-Host Interactions Chapter 15 pp 315-361 Ed Weber GF Horizon Biosciences Wymondham 2005

45 Collins I Molife R Workman P and Kaye SB Rational drug design of small molecule anticancer agents preclinical discovery In The Cancer Handbook 2nd edition pp 1199-1215 Ed Alison MR pub John Wiley amp Sons Chichester 2007

46 Molife R Collins I Workman P and Kaye SB Rational drug design early clinical development In The Cancer Handbook 2nd edition pp 1216-1241 Ed Alison MR pub John Wiley amp Sons Chichester 2007

47 Yap TA Sarker D Kaye SB and de Bono JS Functional imaging clinical applications in molecular targeted therapy In Imaging in Oncology 3rd Edition ed Husband JE and Reznek RH chapter 62 pp 1388-1405 Informa Healthcare chapter 61 pp 1366-1383 2009

48 Carden CP Kipps E and Kaye SB Prognostic factors in epithelial ovarian cancer In 100 Key Questions on Ovarian Cancer ed Poveda A pub Permanyer Publications Barcelona pp 23-35 2010

49 Nicum S and Kaye SB Epithelial ovarian cancer In Oxford Desk Reference Oncology eds Ajithkumar T Barrett A Hatcher H and Cook N Oxford University Press New York Chapter 47 pp 346-354 2011

50 Yap TA Kaye S Ashworth A and Tutt A Tumour-specific synthetic lethality targeting BRCA dysfunction in ovarian cancer In Emerging Therapeutic Targets in Ovarian Cancer ed SB Kaye R Brown H Gabra and M Gore Springer Science New York chapter 6 pp 109-132 2011

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

48

51 Drew Y Tap TA and Kaye SB The future of PARP inhibitors in the treatment of cancer In Gynaecological Cancers Biology and Therapeutics ed Kehoe S Edmondson RJ Gore M and McNeish IA RCOG Press London chapter 7 pp 83-95 2011

BooksMonographs 1 Medical Complications of Malignant Disease Ed SB Kaye and EM Rankin (Balliere Tindall) 1989

2 New Antimetabolites in Cancer Chemotherapy and their Clinical Impact Guest Editor SBKaye Br J Cancer 78 (Suppl 3) 1998

3 Clinical Management of Ovarian Cancer Eds J Ledermann W Hoskins I Vergote and SB Kaye (Martin Dunitz) 2001

4 A Trends Guide to Cancer Therapeutics Ed P Workman and SB Kaye A supplement to Trends in Molecular Medicine (vol 8 no 4) Elsevier

Science 2002 5 Textbook of Medical Oncology Ed F Cavalli H Hansen SB Kaye (Martin Dunitz) 1996 2000 (2nd Edition) and 2004 (3rd Edition) Ed

F Cavalli SB Kaye HH Hansen JO Ormitage and MJ Piccart-Gebhart 2009 (4th Edition) Informa Healthcare UK Ltd

6 Emerging Therapeutic Targets in Ovarian Cancer Ed SB Kaye R Brown H Gabra and M Gore Springer Science New York 2011 ISBN 978-1-4419-

7215-6 eISBN 978-1-4419-7216-3

Letters published

1 Kaye SB Shaw KM and Ross EJ Bromocriptine and hypertension Lancet 1176 I 1976

2 Kaye SB and Boden JA Lactate dehydrogenase virus and the response to chemotherapy of solid murine tumours Cancer Treat Rep 64 1161-2 1980

3 Kaye SB Nuclear medicine in the 1980s the challenge of clinical oncology Newsletter of Australian and New Zealand Soc of Nuclear Medicine 11 19 1980

4 Calvert AH Horwich A Newlands ES Begent R Rustin GJ Kaye SB Carboplatin or cisplatin (letter) Lancet 2(8610) 577-578 1988

5 Lewis CR Jardine A Rankin EM and Kaye SB Autonomic neuropathy following treatment with flavone acetic acid (letter) Eur J Cancer Clin Oncol 25(3) 573-574 1989

6 Boyle P Maisonneuve P and Kaye SB Therapy for testicular cancer in Central and Eastern Europe (Letter) Lancet 28 335(8696) 1033 1990

7 Senan S Paul J Thomson N and Kaye SB Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity Eur J Cancer 28A 2084 1992

8 Bissett D and Kaye SB Myocardial infarction after chemotherapy for testicular teratoma Ann Oncol 4 432 1993

9 Monfardini S Sorio R and Kaye SB Should elderly patients be entered in dose-escalation studies Ann Oncol 5 964-966 1994

10 Crawford SC Paul J Kaye SB Vasey PA Davis JA and Hay A Aggressive surgery and ovarian cancer ndash reply J Clin Oncol 24 2396-2397 2006

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

49

11 Molife R Fong P Scurr M Judson I Kaye S and de Bono J HDAC inhibitors and cardiac safety Clin Cancer Res 13 1068 2007

12 Banerji U de Bono J Judson I Kaye S and Workman P Biomarkers in early clinical trials the committed and the skeptics Clin Cancer Res 14 2512 2008

13 Olmos D Arkenau HT Ang JE de Bono JS Judson I and Kaye SB Reply Clinical outcome and prognostic factors for patients treated within a Phase I study the Royal Marsden Hospital experience Br J Cancer 99 1365 2008

14 Yap TA Kaye SB and de Bono JS Inhibition of Poly (ADP-Ribose) Polymerase in BRCA-mutation carriers N Engl J Med 361 17 1707-1708 2009

15 Yap TA de Bono J Kaye SB Tutt A Ashworth A Schellens JH Reply to J Veeck et al J Clin Oncol epub ahead of print 2 August 2010

Invited reviewseditorials

1 Kaye SB The chemotherapy of advanced carcinoma of the cervix Oncology Conspectus (Lundbeck) 7 1981

2 Kaye SB Liposomes - problems and promise as selective drug carriers Cancer Treat Rev 8 27-50 1981

3 Kaye SB Intensive chemotherapy for solid tumours - current clinical applications Cancer Chemother Pharmacol 9 127-133 1982

4 Kaye SB Pneumocystis pneumonia (editorial) Br Med J 286 ef499-500 1983

5 Kaye SB Whither lung cancer treatment in 1983 (editorial) Scot Med J 28 215-217 1983

6 Kaye SB and Merry S Tumour cell resistance to anthracyclines - a review Cancer Chemother Pharmacol 14 96-103 1985

7 Kaye SB Cummings J and Kerr D How much does liver disease affect the pharmacokinetics of adriamycin Eur J Cancer 21 No 8 893-895 1985

8 Plumb J and Kaye SB Cytotoxic drug resistance and the cell membrane Cancer Topics 1986

9 Rankin E and Kaye SB Metabolic complications of malignancy Medicine International 39 1637-1639 1987

10 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

11 Kaye SB The multidrug resistance phenotype (Guest Editorial) Br J Cancer 58 691-694 1988

12 Kaye SB Prevention of vomiting due to cytotoxic drugs Prescribers Journal 28 144-151 1988

13 Kaye SB Multidrug resistance in cancer (Editorial) Lancet 21075 1989

14 Kerr DJ and Kaye SB Multidrug resistance in haematological malignancies Hematology Reviews 4 61-64 1990

15 Kaye SB Reversal of multidrug resistance Cancer Treat Rev 17 (Supplement A) 37-43 1990

16 Kaye SB Steward WP Hodgkins disease the role of haematopoietic growth factors Consultant Series The role of haematopoietic growth factors Ed L Denis 1990

17 Kaye SB New Drug Development Eur J Cancer 27 377-380 1991

18 Kaye SB Kerr DJ Multidrug resistance clinical relevance in haematological malignancies Blood Rev 5 38-41 1991

19 Bissett D Kaye SB and Kerr DJ Can primary osteosarcoma act as a third space after high-dose methotrexate Eur J Cancer 27 1060 1991

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

50

20 Workman P Kaye SB and Schwartsmann G Laboratory and Phase I studies of new cancer drugs Curr Opin Oncol 4 1065-72 1992

21 Fox BW and Kaye SB Current results with rhizoxin the evaluation of a clinical and a basic scientist Ann Oncol 3 707-709 1992

22 Kaye SB Chemotherapy of ovarian cancer Eur J Cancer 29A 632-635 1993

23 Kaye SB P-glycoprotein (P-gp) and drug resistance - time for reappraisal Br J Cancer 67 641-643 1993

24 Bissett D and Kaye SB Taxol and taxotere - Current status and future prospects Eur J Cancer 29A 1228-1231 1993

25 Kaye SB Antiemetic therapy - Where do we go from here Ann Oncol 4 443-445 1993

26 Kaye SB and van Houwelingen HC What have we learnt from meta-analyses in ovarian cancer Ann Oncol 4 (Suppl 4) S79-S82 1993

27 Kaye SB Multidrug resistance clinical relevance and potential circumvention - a personal view ESMO 19th Congress 141-144 1994

28 Kaye SB Modern chemotherapy in solid tumours Quarterly Journal of Medicine 87 319-322 1994

29 Kaye SB Gemcitabine Current status of Phase I and II trials J Clin Oncol 12(S) 1527-1531 1994

30 Hughes MJ Kaye SB Should we still advocate referral to specialist centres for teratoma Eur J Cancer 31A 291-292 1995

31 Kaye SB Taxoids Eur J Cancer 31A 824-826 1995

32 Caponigro F French RC and Kaye SB Protein kinase C a worthwhile target for anticancer drugs Anti-Cancer Drugs 8 26-33 1997

33 Kaye SB Multidrug resistance in breast cancer - is the jury in yet J Natl Cancer Inst 89 902-903 1997

34 OrsquoNeill VJ Kaye SB Clinical multi-drug resistance Is our understanding sufficient to permit attempts at circumvention South Amer J Cancer 1 102-108 1997

35 Vasey PA and Kaye SB Combined inhibition of topoisomerases I and II - is this a worthwhilefeasible strategy Br J Cancer 76 1395-1397 1997

36 Kaye SB Piccart M Aapro M Francis P and Kavanagh J Phase II trials of docetaxel (Taxoterereg) in advanced ovarian cancer - an updated overview Eur J Cancer 33 2167-2170 1997

37 Adams M Calvert AH Carmichael J Clark PI Coleman RE Earl HM Gallagher CJ Ganesan TS Gore ME Graham JD Harper PG Jayson GC Kaye SB Ledermann JA Osborne RJ Perren TJ Poole CJ Radford JA Rustin GJS Slevin ML Smyth JF Thomas H Wilkinson PM Chemotherapy for ovarian cancer - a consensus statement on standard practice Br J Cancer 78 1404-1406 1998

38 Anthoney DA Kaye SB Treatment of poor prognosis metastatic germ-cell tumours Much heat but as yet little light Ann Oncol 10 255-258 1999

39 Kaye SB Future directions for the management of ovarian cancer Eur J Cancer 37 S19-S23 2001

40 Johnston SRD Kaye SB Caelyx treatment for relapsing ovarian cancer Hospital Medicine 62 611-622 2001

41 Harries M and Kaye SB Recent advances in the treatment of epithelial ovarian cancer In Expert Opinion Investigational Drugs 10 1715-1724 2001

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

51

42 Kaye S B Combination chemotherapy for ovarian cancer - lessons not yet learned Current Oncology Reports 4 185-186 2002

43 Kaye S B First line chemotherapy for ovarian cancer - the controversy continues Brit J Cancer 87 813-4 2002

44 Swannie H and Kaye S B Protein kinase C inhibitors Current Oncology Reports 4 37-46 2002

45 Kaye S B and Vasey P Docetaxel in ovarian cancer Phase III perspectives and future developments Seminars in Oncology 2002 3 (Suppl 12) 22-27 2002

46 Moss C and Kaye SB Progress and continuing controversies in ovarian cancer Eur J Cancer 38 1701-1707 2002

47 Kaye SB Gershensen D Hung MC and Seiden M Discussion (ovarian cancer) molecular therapeutics and pharmacogenomics Gynae Oncol 88 593-596 2003

48 Agarwal R and Kaye SB Ovarian cancer strategies for overcoming resistance to chemotherapy Nature Reviews Cancer 7 502-16 2003

49 Kaye SB Chemotherapy for ovarian cancer yesterday today and tomorrow (editorial) Br J Cancer 89 (suppl 3) S1-S2 2003

50 Kaye SB Chemotherapy for recurrent ovarian cancer Lancet 361 2094-2095 2003

52 Vidal L Attard G Kaye S and de Bono J Reversing resistance to targeted therapy J Chemother 16 suppl 4 101-106 2004

53 Jackman AL Kaye S and Workman P The combination of cytotoxic and molecularly targeted therapies ndash can it be done Drug Discovery Today Therapeutic Strategies 1 445-454 2004

54 Kaye SB Proteasome inhibitionpotential benefits in the treatment of cancer Eur J Cancer Suppl 2 no 6 7-11 2004

55 Benson C Kaye S Workman P Garrett M Walton M and de Bono J Clinical anticancer drug development targeting the cyclin-dependent kinases Br J Cancer 92 7-12 2005

56 Agarwal R and Kaye SB Editorial Prognostic factors in ovarian cancer how close are we to a complete picture Ann Oncol 16 4-6 2005

57 Blagden SP and Kaye SB Docetaxel in the management of ovarian cancer Expert Rev Anticancer Ther 5 203-214 2005

58 Richardson A and Kaye SB Drug resistance in ovarian cancer the emerging importance of gene transcription and spatio-temporal regulation of resistance Drug Resist Update 8 311-321 2005

59 du Bois A Quinn M Thigpen T Vermorken J Avall-Lundqvist E Bookman M Bowtell D Brady M Cadado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Genman S Guastalla JP Harper P Hogberg T Kaye SB Kitchener H Kristensen G Mannel R Meier W Miller B Neijt JP Oza A Ozols R Parmar M Pecorelli S Pfisterer J Poveda A Provencher D Pujade-Lauraine E Randall M Rochon J Rustin G Sagae S Stehman F Stuart G Trimble E Vasey P Vergote I Verheijen R and Wagner U 2004 Consensus statements on the management of ovarian cancer final document of the 3rd International Gynecologic Cancer Intergroup Ovaran Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 (suppl 8) viii7-viii12 2005

60 Stuart G Avall-Lundqvist E Du Bois A Bookman M Bowtell D Brady M Casado A Cervantes A Eisenhauer E Friedlaender M Fujiwara K Grenman S Guastalla JP Harper P Hogberg T Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Oza A Ozols R Parmar M Pfisterer J Poveda A Provencher D Pujade-Lauraine E Quinn M Randall M Rochon J Rustin G Sagae S Stehman F Trimble E Thigpen T Vasey P Vergote I Verheijen R Vermorken J and Wagner U 3rd International Ovarian Cancer Consensus Conference outstanding issues for future consideration Ann Oncol 16 (suppl 8) viii36-viii38 2005

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

52

61 Thigpen T Stuart G du Bois A Friedlander M Fujiwara K Guastalla JP Kaye S Kitchener H Kristensen G Mannel R Meier W Miller B Poveda A Provencher D Stehman F Vergote I Clinical trials in ovarian carcinoma requirements for standard approaches and regimens Ann Oncol 16 (suppl 8) viii13-viii19 2005

62 Larkin J and Kaye SB Carcinoma of the ovary MIMS Advances Ovarian Cancer issue 7 December 2005 pp 6-8

63 Attard G Greystoke A Kaye SB and de Bono J Update on tubulin-binding agents Path Biol 54 72-84 2006

64 Balkwill FR Ashworth A Bast RC Berek JS Boyd J Disis ML Gabra H Gore ME Hamilton TC Jacobs IJ Kaye SB Kohn EC Mills GB and Urban ND 10th Biennial Helene Harris Memorial Trust Meeting Cancer Res 66 2904-2906 2006

65 Agarwal R Linch M and Kaye SB Novel therapeutic agents in ovarian cancer Eur J Surg Oncol 32 875-886 2006

66 Larkin JMG and Kaye SB Epothilones in the treatment of cancer Expert Opin Investig Drugs 15 691-702 2006

67 Agarwal R and Kaye SB Expression profiling and individualisation of treatment for ovarian cancer Curr Opin Pharmacol 6 345-349 2006

68 Kaye S Which drugs for which patients Future Oncol 2 317-319 2006

69 Vidal L Yap TA White CL Twigger KM Hingorani M Agrawal V Kaye SB Harrington KJ and de Bono JS Reovirus and other oncolytic viruses for the targeted treatment of cancer Targ Oncol 1 130-150 2006

70 Tan D Agarwal R and Kaye SB Mechanisms of transcoelomic metastasis in ovarian cancer Lancet Oncol 7 925-934 2006

71 Tan D and Kaye S Clear cell carcinoma of the ovary a continuing enigma J Clin Pathol 60 355-360 2007

72 Ang J-E and Kaye SB Molecular targeted therapies in the treatment of ovarian cancer Advances in Gene Molecular and Cell Therapy 1 68-79 2007

73 Larkin JMG and Kaye SB Epothilones other potential clinical applications Ann Oncol 18 (suppl 5) v28-v34 2007

74 Kaye SB Bevacizumab for the treatment of epithelial ovarian cancer will this be its finest hour Editorial J Clin Oncol 25 5150-5152 2007

75 Kaye SB New drugs for ovarian cancer Clin Adv Hematol Oncol 6 91-93 2008

76 Kaye SB Breast cancer and ovarian cancer State of the art treatment approaches Eur J Cancer suppl 6 1 2008 Editorial

77 Kaye SB Management of partially platinum-sensitive relapsed ovarian cancer Eur J Cancer suppl 6 16-21 2008

78 Jones R Karavasilis V and Kaye SB Paclitaxel in the management of ovarian cancer Expert Rev Obstet Gynaecol in press (accepted February 2008)

79 Tan D Ang J-E and Kaye SB Ovarian cancer ndash can we reverse drug resistance Adv Exp Med Biol 622 153-167 2008

80 Kaye SB Reversal of drug resistance in ovarian cancer ndash where do we go from here Editorial J Clin Oncol 26 2616-2618 2008

81 Richardson A and Kaye SB Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy Curr Mol Pharmacol 1(3) 244-254

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

53

82 Carden C Banerji U Kaye S Workman P and de Bono J From darkness to light with biomarkers in early clinical trials of cancer drugs Clin Pharm Therap 85 131-133 2009

83 Yap TA Carden CD and Kaye SB Beyond Chemotherapy targeted therapies in ovarian cancer Nature Rev Cancer 9 167-181 2009

84 Graham JS Kaye SB and Brown R The promises and pitfalls of epigenetic therapies in solid tumours Eur J Cancer 45 1129-1136 2009

85 Tan DA Thomas GV Garrett MD Banerji U de Bono JS Kaye SB and Workman P Biomarker-driven early clinical trials in oncology A paradigm shift in drug development Cancer J 15 406-420 2009

86 Kaye SB Should routine CA125 screening be discontinued ASCO News amp Forum January 2010 10

87 Han L Kipps E and Kaye SB Current treatment and clinical trials in ovarian cancer Expert Opin Invest Drugs 19 1-14 2010

88 Kyriazi S Kaye SB and deSouza N Imaging ovarian cancer and peritoneal metastases ndash current and emerging techniques Nature Rev Clin Oncol 7 381-393 2010

89 Powell C Mikropoulos C Kaye SB Nutting CM Bhide SA Newbold K and Harrington KJ Preclinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 566-575 2010

90 Carden C Yap T and Kaye SB PARP inhibition targeting the Achillesrsquo heel of DNA repair to treat germline and sporadic ovarian cancers Curr Opin Oncol 22 473-480 2010

91 Banerjee S Kaye SB and Ashworth A Making the best of PARP inhibitors in ovarian cancer Nature Rev Clin Oncol 7 508-519 2010

92 Baird R Tan D and Kaye SB Weekly paclitaxel in the treatment of ovarian cancer Nature Rev Clin Oncol 7 575-582 2010

93 Trimble EL Birrer MJ Hoskins WJ Marth C Petryshyn R Quinn M Thomas GM Kitchener HC Gynecological Cancer IntergroupNational Cancer Institute Writing Committee Aghajanian C Alberts DS Armstrong D Brown J Coleman RL Colombo N Eisenhauer E Friedlander M Fujiwara K Hunsberger S Kaye SB Ledermann JA Lee S Look K Mannel R McNeish IA Minasian L Oza A Paul J Poveda A Pujade-Oauraine E Schoenfeldt M Swart AM von Gruenigen V Wenzel L (2010) Current academic clinical trials in ovarian cancer Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting May 2009 Int J Gynecol Cancer 20 1290-1298 2010

94 Forster MD Dedes KJ Sandhu S Frentzas S Kristeleit R Ashworth A Poole CJ Weigelt B Kaye SB and Molife LR Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 302-306 2011

95 Vaughan S Coward JI Bast RC Jr Berchuck A Berek JS Brenton JD Coukos G Crum CC Drapkin R Etemadmoghadam D Friedlander M Gabra H Kaye SB Lord CJ Lengyel E Levine DA McNeish IA Menon U Mills GB Nephew KP Oza AM Sood AK Stroncah EA Walczak H Bowtell DD and Balkwill FR Rethinking ovarian cancer recommendations for improving outcomes Nat Rev Cancer 11 719-725 2011

95 Banerjee S and Kaye SB PARP Inhibitors in BRCA gene-mutated ovarian cancer and beyond Curr Oncol Rep 13 442-449 2011

96 Banerjee S and Kaye SB The role of targeted therapy in ovarian cancer Eur J Cancer 47 suppl 3 S116-130 2011

97 Banerjee S Kaye SB Progression-free survival versus overall survival in ovarian cancer where are we now Curr Oncol Rep 14 (6) 483-5 2012

54

98 Moreno Garcia V Basu B Molife LR Kaye SB Combining antiangiogenics to overcome resistance rationale and clinical experienceClin Cancer Res (14) 3750-61 2012

99 Banerjee S Kaye SB (2013) New Strategies in the Treatment of Ovarian Cancer Current Clinical Perspectives and Future Potential Clin Can Res 19 (5) 961-968 2013

100 Banerjee S Kaye SB Gynecological cancer First-line bevacizumab for ovarian cancer--new standard of care Nat Rev Clin Oncol 4 194-6 2012

102 Hall M Gourley C McNeish I Ledermann J Gore M Jayson G Perren T Rustin G and Kaye SB Targeted anti-vascular therapies for ovarian cancer current evidence BJC 108 (2) 250-258 2013

103 Kipps E Tan D Kaye SB Meeting the challenge of ascites in ovarian cancer new avenues for therapy and research Nature Review Cancer 13 273-282 2013

104 Tan D Miller R Kaye SB New perspectives on molecular targeted therapy in ovarian clear cell

carcinoma BJC 108 1557-1559 2013 105 Attard G Kaye SB Identifying prognostic signatures in the blood of ovarian cancer patients Gyn Onc

128 1-2 2013 106 Lopez j Banerjee S Kaye SB New Development in the treatment of ovarian cancer ndash future

perspectives Annals of Oncology 24 69-76 2013 107 Wilson M Collyar D Chingos DT Friedlander M Ho T Karakasis K Kaye SB Parmar MKB Sydes MR

Tannock I and Oza AM Outcomes and enpoints in cancer trials bridging the divide Lancet Onc 16 e43-e52 2015

108 Syrios J Banerjee S Kaye SB Advanced epithelial ovarian cancer from standard chemotherapy to

promising molecular pathway targets ndash where are we now Anticancer Research 34 2069-2077 2014 109 Tan DS amp Kaye SB Chemotherapy for patients with BRCA 1 and BRCA-2 mutated ovarian cancer

same or different Am Soc Clin Onc Educ Book 35 114-121 2015 110 Brown J Kaye SB and Yap TA PARP inhibitors the race is on BJC 114 713-715 2016

111 Kaye SB Progress in the treatment of ocarian cancer ndash lessons from homologous recombination

deficiency ndash the first 10 years Annals of Oncology 27 1-3 2016

112 George A Kaye SB Banerjee S Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer Nature Reviews Clinical Oncology 14 284-296 2017